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(57) ABSTRACT 
The present invention provides compositions for inhibiting 
proteases, methods for synthesizing the compositions, and 
methods of using the disclosed protease inhibitors. Aspects 
of the invention include aza-peptide epoxide compositions 
that inhibit proteases, for example cysteine proteases, either 
in vivo or in vitro. The disclosed compounds, pharmaceu-
tically acceptable salts, pharmaceutically acceptable deriva-
tives, prodrugs, or combinations thereof can be used to treat 
disease or pathological conditions related to the activity of 
proteases associated with a specific disease or condition. 
Such treatable conditions include viral infections, stroke, 
neurodegenerative disease, and inflammatory disease, 
among others. 
50 Claims, No Drawings 
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AZA-PEPTIDE EPOXIDES 
CROSS-REFERENCED TO RELATED 
APPLICATIONS 
This application claims benefit of U.S. Provisional Patent 
Application No. 60/394,221 filed on Jul. 5, 2002, U.S. 
Provisional Patent Application No. 60/394,023, filed on Jul. 
10 
5, 2002, and U.S. Provisional Patent Application No. 
60/394,024 filed on Jul. 5, 2002, all of which are incorpo-
rated by reference in their entirety. 
2 
E-64 
NH/ ----< 0 
~ ~ W ~H 
H1N N~~N ,.· ··• (OH 
H M H H'' '''1 
0 
Once the E-64 structure was elucidated, the research 
groups of Katunuma, Barrett, and others discovered E-64's 
inhibitory potency toward a large number of other cysteine 
proteases. E-64 inhibits papain, ficin, bromelain, cathepsin 
BACKGROUND OF THE INVENTION 15 B, H, F, K, L, 0, S, V, X, calpain, calpain II, cruzain, and 
other cysteine proteases. Cathepsin J and streptococcal cys-
teine protease are slowly inhibited by E-64. 
1. Field of the Invention Unlike many other microbial inhibitors, E-64 is a potent 
and specific irreversible inhibitor of cysteine proteases, and 
This invention relates generally to protease inhibitors and 
applications thereof, more specifically to peptide inhibitors 
of cysteine proteases, even more specifically to aza-peptide 
epoxides, methods of their use, and methods of their pro-
duction. 
20 is used as a diagnostic reagent for identification of cysteine 
proteases. The compound E-64 does not inhibit serine pro-
teases, aspartic proteases, or metalloproteases. However, not 
all cysteine proteases are inhibited by E-64. Examples of 
non-inhibited cysteine proteases are legumain and caspases. 
2. Related Art 
Protease inhibitors are important therapeutics in the treat-
ment of a variety of disease conditions including viral 
25 Caspases and legumain are members of the CD clan of 
cysteine proteases, while papain, cathepsins, and calpains 
are members of clan CA. The following table lists those 
enzymes which are inactivated by E-64 and those which are 
not inactivated. infections such as HIV infection. Proteases are enzymes that 
cleave proteins or peptides and are classified into several 30 
groups. For example, cysteine proteases form a group of 
enzymes involved in numerous disease states, and inhibitors 
of these enzymes can be used therapeutically for the treat-





Enzymes Inactivated or Not Inactivated by E-64 
enzymes inactivated rate (M-1 s-1) enzymes not inactivated 
fie in 0.084 (ID50) trypsin 
fruit bromelain 0.110 (ID50) a-chymotrypsin 
stem bromelain 0.025 (ID50) kallikrein 
papain 0.104 (ID50) pepsin 
cathepsin B 89,400 plasmin 
cathepsin H 4,000 elastase 
cathepsin L 96,250 mold acid protease 
cathepsin K 1.8 nM (K;) LDH 
cathepsin S 99,000 thermolysin 
cathepsin X 775 collagenase 
cathepsin 0 >100 µM (IC50) clostripain 
cathepsin F caspase 1 (ICE) 
cathepsin V >0.1 µM (IC50) legwnain 
cathepsin J 
DPPI 100 
streptococcal proteinase 624 
papaya proteinase IV 58,000 
calpain II 7,500 
bleomycin hydrolase >160 µM (IC50) 
cruzain 70,600 
vignain 32,500 
To date, a structurally diverse variety of cysteine protease 
inhibitors have been identified. Palmer, (1995) J. Med. 
Chem., 38, 3193, discloses certain vinyl sulfones which act 
as cysteine protease inhibitors for cathepsins B, L, S, 02 and 
cruzain. Other classes of compounds, such as aldehydes, 
nitriles, a-ketocarbonyl compounds, halomethyl ketones, 
diazomethyl ketones, (acyloxy)methyl ketones, ketomethyl-
sulfonium salts and epoxy succinyl compounds have also 
been reported to inhibit cysteine proteases. See Palmer, id, 
and references cited therein. Many irreversible cysteine 
protease inhibitors have been described in the review by 
Powers, Asgian, Ekici, and James (2002) Chemical 
Reviews, 102, 4639. See Powers, id, and references cited 
therein. However, most of these known inhibitors are not 
considered suitable for use as therapeutic agents in animals, 
especially humans, because they suffer from various short-
comings. These shortcomings include lack of selectivity, 
cytotoxicity, poor solubility, and overly rapid plasma clear-
ance. 
Therefore, because of the aforementioned deficiencies in 
55 the art, there is a need for new compounds and methods for 
inhibiting proteases, in particular cysteine proteases. 
In addition, epoxides also have been shown to inhibit 
cysteine proteases. The first epoxysuccinyl peptide discov-
ered was E-64, a natural inhibitor, which was initially 
60 
isolated from Aspergillus japonicus by Hanada et al. in 
1978. The chemical structure was determined by optical 
rotation, NMR, IR, MS, elemental analysis, and amino acid 
analysis to be N-(N-(L-3-trans-carboxyoxiran-2-carbonyl)-
L-leucyl)agmatine. Hanada and his coworkers showed that 65 
E-64 would inactivate the plant cysteine proteases papain, 
ficin, and bromelain. 
SUMMARY OF THE INVENTION 
Aspects of the present invention provide compositions for 
inhibiting proteases, methods for synthesizing the compo-
sitions, and methods of using the disclosed protease inhibi-
tors. The compositions described herein can inhibit pro-
teases, for example cysteine proteases, either in vivo or in 
vitro, by contacting a cysteine protease with an aza-peptide 
epoxide. The disclosed compounds, pharmaceutically 
acceptable salts, pharmaceutically acceptable derivatives, 
prodrugs, or combinations thereof can be used to treat 
US 7,056,947 B2 
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aza-peptide epoxides inhibit proteases such as gingipain, 
separin, and clostripain. Aza-peptide epoxide inhibitors of 
gingipain can be used for treatment of periodontal diseases. 
Aza-peptide epoxide inhibitors of separin are useful for 
stopping, modulating, or interfering with cell division. 
Yet another aspect of the invention provides aza-peptide 
epoxide protease inhibitors with hydrophobic amino acid 
residues in the P2 site. These aza-peptide epoxide protease 
inhibitors inhibit proteases such as cathepsins, including 
cathepsin B, and papain. Aza-peptide epoxide inhibitors of 
cathepsin B are useful for treating hyperproliferative con-
ditions including cancer. 
Another aspect provides aza-peptide epoxides having 
small hydrophobic alkyl amino acid residues at P2 are good 
disease or pathological conditions related to the activity of 
proteases associated with a specific disease or condition. 
Such treatable conditions include viral infections, stroke, 
neurodegenerative disease, and inflammatory disease, 
among others. Methods disclosed herein for treating dis-
eases include administering an effective amount of an aza-
peptide epoxide to a host in need thereof to inhibit or reduce 
protease activity in the host, particularly cysteine protease 
activity, more particularly activity of caspases, calpains, 
cathepins, papain, gingipain, clostripain, separin, or legu- 10 
main. One or more aza-peptide epoxides of the present 
invention can also be used alone or in combination with each 
other, other protease inhibitors, or another therapeutic agent 
including anti-viral compounds such as anti-viral nucleo-
sides including nucleoside analogs. 15 inhibitors of calpain I and II. These inhibitors are useful as 
neuroprotectants and can be used as therapeutics for the 
treatment or prevention of neurodegeneration and stroke. 
Exemplary neuodegenerative disorders that can be treated 
with the disclosed aza-peptide epoxides include but are not 
One aspect of the invention provides aza-peptide epoxide 
compositions, for example a compound or pharmaceutically 
acceptable salt or pharmaceutically acceptable derivative 
thereof according to Formula I below. In some aspects of the 
present invention, aza-peptide epoxide inhibitors are specific 
for cysteine proteases and do not inhibit serine proteases or 
aspartyl proteases. In another aspect of the present inven-
tion, these aza-peptide epoxide compounds potently and 
specifically inhibit clan CD of cysteine proteases and are 
also inhibitors of clan CA. Exemplary differences between 
aza-peptide epoxides disclosed herein and other cysteine 
proteases inhibitors include different mechanisms of inhibi-
tion of the cysteine residue and the binding modes. 
20 limited to stroke, Alzheimer's disease, Parkinson's disease, 
multiple sclerosis, neuropathies, Huntington's disease, and 
myotrophic lateral sclerosis (ALS). 
In another aspect, this invention provides a method to 
identify proteolytic enzymes and a method to prevent pro-
25 teolysis. 
Some aza-peptide epoxides of the present invention can 
be constructed to selectively inhibit individual cysteine 30 
proteases or groups of cysteine proteases. These aza-peptide 
epoxides can, for example, contain acidic aza-amino acid 
residues in the Pl site. Such aza-peptide epoxides are potent 
inhibitors of caspases. Aza-peptide epoxide caspase inhibi-
tors are useful for the treatment of stroke and inflanmiatory 35 
diseases, and as inhibitors of apoptosis. Thus, another aspect 
provides a method of treating stroke, inflammatory disease, 
or inhibiting apoptosis including administering an effective 
amount of a aza-peptide epoxide to a patient in need thereof. 
Such patients can include any manmial, for example a 40 
mammal exhibiting symptoms characteristic protease 
related pathology or disease condition such as stroke, 
inflammatory disease, or pathology related to apoptosis. 
Another aspect of the present invention provides an 
aza-peptide epoxide composition containing an aza-aspar- 45 
agine residue at the Pl position. Aza-peptide epoxides 
having an aza-asparagine residue at the Pl position inhibit 
legumain and can, therefore, modulate the immune system 
through such inhibition. Cleavage of antigens by proteases 
such as legumain and related proteases is a step in antigen 50 
presentation including the display ofMHC class II peptides. 
Thus, another aspect of the invention provides a method of 
modulating the immune system of a patient by administering 
to a host an effective amount of an aza-peptide epoxide 
composition. The aza-peptide epoxide can modulate the 55 
immune system by inhibiting the cleavage of antigens in the 
patient and thereby reducing the display of antigen peptides 
on cell surfaces. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention may be understood more readily by 
reference to the following detailed description of the inven-
tion and the Examples included therein. 
Before the present compounds, compositions and meth-
ods are disclosed and described, it is to be understood that 
this invention is not limited to specific synthetic methods, 
specific pharmaceutical carriers, or to particular pharmaceu-
tical formulations or administration regimens, as such may, 
of course, vary. It is also to be understood that the termi-
nology used herein is for the purpose of describing particular 
embodiments only and is not intended to be limiting. 
Cysteine Proteases. The aza-peptide epoxide composi-
tions provided herein inhibit enzymatic cleavage of proteins 
or peptides, or a combination thereof. Exemplary enzymes 
inhibited by aza-peptide epoxides include cysteine pro-
teases, for example, calpain. Calpain uses a cysteine residue 
in the catalytic mechanism in contrast to serine proteases 
which utilize a serine residue. Exemplary cysteine proteases 
include papain, cathepsin B, calpains, caspases, gingipain, 
clostripain, legumain, and several viral enzymes. 
Caspases are a recently discovered family of cysteine 
endoproteases, which are highly selective for Asp at the Pl 
residue. As a result, this newly emerging family of proteases 
has been called caspases ( cysteinyl aspartate-specific pro-
tease). All caspases contain the conserved pentapeptide 
active site motif Gln-Ala-Cys-X-Gly (QACXG)(SEQ.ID 
NO.l), where X=Arg, Gin, Gly (R, Q, G), and are synthe-
sized as inactive proenzymes. The only other manmialian 
protease with specificity for Asp is the lymphocyte serine 
protease, granzyme B. Many of the proteolytic cleavages Yet another aspect of the invention provides a method of 
treating autoimmune disease by administering an effective 
amount of an aza-peptide epoxide to a host in need thereof. 
The host can be any mammal, including primates, which 
demonstrate symptoms associated with any number of 
autoimmune diseases including but not limited to lupus, for 
example lupus erythematosus, and cancers. 
60 that are observed during apoptosis and cytokine maturation 
are due to the action of various caspases. Indeed, many of 
the procaspases are activated by other caspases, which 
selectively cleave at Pl Asp residues in their recognition 
sites. 
Another aspect of the invention provides aza-peptide 
epoxides containing basic residues at the Pl position. Such 
65 At present, there are 14 homologous members of the 
caspase family in humans. Some caspases are important 
mediators of inflammation, where they are involved in the 
US 7,056,947 B2 
5 
production of inflannnatory cytokines, and others are 
involved in apoptosis, where they participate in signaling 
and effector pathways. Group I (1, 4, 5, 11, 12, 13, and 14) 
caspases are primarily mediators of inflarmnation and are 
involved in proteolytic activation of proinflarmnatory cytok-
ines. Caspase-1 is also involved in the Fas and TNFR 
apoptotic pathway. Group II (2, 3, and 7) caspases are late 
phase effectors of apoptosis and are involved in the cleavage 
of key structural and homeostatic proteins. Caspase-3, also 
known as CPP32 (cysteine protease protein 32-kDa), Yama 10 
or apopain, is believed to be one of the major effectors in 
apoptosis. This enzyme is a key executioner because it is 
responsible either partially or totally for proteolytic cleavage 
of key apoptotic proteins. It functions to decrease or destroy 
essential homeostatic pathways during the effector phase of 15 
apoptosis. Caspase-3 cleaves or activates nuclear enzymes, 
such as poly(ADP-ribose) polymerase (PARP), the 70 kDa 
subunit of the Ul small ribonucleoprotein, the catalytic 
subunit of DNA-dependent protein kinase, and protein 
kinase Co. Group III (6, 8, 9, 10) caspases are involved in 20 
the upstream early activation of effector caspases. Studies 
have shown that caspase-8 and 10 can cleave radiolabeled 
precursors for caspase-3. Caspase-6 is the only known 
caspase that cleaves the lamins, the major structural proteins 
in the nuclear envelope. Proteolysis oflamins is observed in 25 
cells undergoing apoptosis. Caspase-8 (MACH/FLICE), 
which can cleave all other known caspases, is suggested to 
6 
"calpain I" and "calpain II" are used herein to refer to the 
micromolar and millimolar activated calpains, respectively, 
as described above. While calpains degrade a wide variety of 
protein substrates, cytoskeletal proteins seem to be particu-
larly susceptible to attack. In some cases, the products of the 
proteolytic digestion of these proteins by calpain are dis-
tinctive and persistent over time. Since cytoskeletal proteins 
are major components of certain types of cells, this provides 
a simple method of detecting calpain activity in cells and 
tissues. Activation of calpains and/or accumulation of break-
down products of cytoskeletal elements have been observed 
in neural tissues of mammals exposed to a wide variety of 
neurodegenerative diseases and conditions. For example, 
these phenomena have been observed following ischemia in 
gerbils and rats, following stroke in humans, following 
administration of the toxins kainate, trimethyltin, or colchi-
cine in rats, and in human Alzheimer's disease. 
Cathepsin B is involved in muscular dystrophy, myocar-
dial tissue damage, tumor metastasis, and bone resorption. 
In addition, a number of viral processing enzymes, which 
are essential for viral infection, are cysteine proteases. 
Inhibitors of cysteine proteases would have multiple thera-
peutic uses. 
Other important cysteine proteases are the bacterial 
enzymes clostripain and gingipain. Gingipain causes tissue 
destruction during periodontal diseases. Legumain is a 
related cysteine proteases which is involved in inflannnatory 
diseases. Separin is involved in separation of sister chroma-
tids during cell division. 
The present invention includes all hydrates, solvates, 
complexes and prodrugs of the compounds of this invention. 
The term prodrug refers to a pharmacologically inactive 
compound that is converted to an active drug by a metabolic 
lie in the pinnacle of the apoptotic cascade, at least when 
apoptosis is initiated by some stimuli such as Fas-L and 
TNF. Accordingly, the present invention encompasses com- 30 
positions and methods of altering, inhibiting, or reducing the 
formation of enzymatic reaction products involving cysteine 
proteases. Inhibiting the formation of cysteine protease 
reaction products in vivo can provide therapeutic effects to 
patients suffering from unregulated or 35 biotransformation. Prodrugs include compounds wherein an 
amino acid residue, or a polypeptide chain of two or more 
(e.g., two, three or four) amino acid residues is covalently 
joined through an amide or ester bond to a free amino, 
Caspases have a specificity for at least the four amino 
acids to the left of the cleavage site (P side). The S4 subsite 
is the single most important determinant of specificity 
among caspases after the Pl Asp. The optimal sequences of 
the caspases were obtained using a positional-scanning 40 
combinatorial substrate library (PS-CSL). The optimal rec-
ognition sequences for these enzymes are closely related to 
the sequences found in known macromolecular substrates. 
Group I caspases' optimal sequence is Trp-Glu-His-Asp 
(WEHD) (SEQ.ID N0.2) with S4 favoring hydrophobic 45 
amino acids. Group II caspases' optimal sequence is Asp-
Glu-X-Asp (DEXD) (SEQ. ID N0.3) with a requirement for 
Asp in S4. Group III caspases' optimal sequence is N-Glu-
X-Asp where N=Val or Leu and X can be any amino acid 
((V,L)EXD) (SEQ. ID N0.4) with a preference for 50 
branched, aliphatic side chains in S4. The S3 subsite prefers 
glutamic acid (E) in most of the caspases which could be 
explained by the salt link between Arg-341 (involved in 
stabilization of the Pl aspartic acid) and the glutamic acid in 
P3. 
hydroxy or carboxylic acid group of compounds of Formula 
I. Additional types of prodrugs are also encompassed. For 
instance, free carboxyl groups can be derivatized as amides 
or alkyl esters. The amide and ester moieties may incorpo-
rate groups including but not limited to ether, amine and 
carboxylic acid functionalities. Free hydroxy groups may be 
derivatized using groups including but not limited to 
hemisuccinates, phosphate esters, dimethylaminoacetates, 
and phosphoryloxymethyloxycarbonyls, as outlined in D. 
Fleisher, R. Bong, B. H. Stewart, Advanced Drug Delivery 
Reviews (1996) 19, 115. Carbamate prodrugs of hydroxy 
and amino groups are also included, as are carbonate pro-
drugs and sulfate esters of hydroxy groups. Derivatization of 
hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl 
ethers wherein the acyl group may be an alkyl ester, option-
ally substituted with groups including but not limited to 
Neural tissues, including brain, are known to possess a 
large variety of proteases, including at least two calcium 
stimulated proteases termed calpains. Calpains are present in 
many tissues in addition to the brain. Calpain I is activated 
55 ether, amine and carboxylic acid functionalities, or where 
the acyl group is an amino acid ester as described above, are 
also encompassed. Prodrugs of this type are described in R. 
by micromolar concentrations of calcium while calpain II is 60 
activated by millimolar concentrations. In the brain, calpain 
II is the predominant form, but calpain I is found at synaptic 
endings and is thought to be the form involved in long term 
potentiation, synaptic plasticity, and cell death. Other Ca2+ 
activated cysteine proteases may exist, and the term 65 
"calpain" is used to refer to all Ca2 + activated cysteine 
proteases, including calpain I and calpain II. The terms 
P. Robinson et al., J. Medicinal Chemistry (1996) 39, 10. 
The subject invention also includes isotopically-labelled 
compounds, and the pharmaceutically acceptable salts 
thereof, which are identical to those recited in Formula I, but 
for the fact that one or more atoms are replaced by an atom 
having an atomic mass or mass number different from the 
atomic mass or mass number usually found in nature. 
Examples of isotopes that can be incorporated into com-
pounds of the invention include isotopes of hydrogen, car-
bon, nitrogen, oxygen, phosphorous, fluorine and chlorine. 
US 7,056,947 B2 
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Compounds of the present invention, prodrugs thereof, and 
pharmaceutically acceptable salts of said compounds or of 
said prodrugs which contain the aforementioned isotopes 
and/or other isotopes of other atoms are within the scope of 
this invention. Certain isotopically-labelled compounds of 
the present invention, for example those into which radio-
active isotopes such as 3 H and 14C are incorporated, are 
useful in drug and/or substrate tissue distribution assays. 
Tritiated, i.e., 3 H, and carbon-14, i.e., 14C, isotopes are 
particularly preferred for their ease of preparation and 10 
detectability. Further, substitution with heavier isotopes such 
as deuterium, i.e., 2H, can afford certain therapeutic advan-
tages resulting from greater metabolic stability, for example 
increased in vivo half-life or reduced dosage requirements 
and, hence, may be preferred in some circumstances. Iso- 15 
topically labelled compounds of Formula 1 of this invention 
and prodrugs thereof can generally be prepared by carrying 
out the procedures disclosed in the Schemes and/or in the 
Examples and Preparations below, by substituting a readily 
available isotopically labelled reagent for a non-isotopically 20 
labelled reagent. 
If a chiral center or another form of an isomeric center is 
present in a compound of the present invention, all forms of 
such isomer or isomers, including enantiomers and diaste-
reomers, are intended to be covered herein. Inventive com- 25 
pounds containing a chiral center may be used as a racemic 
mixture, an enantiomerically enriched mixture, or the race-
mic mixture may be separated using well-known techniques 
and an individual enantiomer may be used alone. An enan-
tiomerically enriched mixture means a mixture having 30 
greater than about 50% of a single enantiomer. In cases in 
which compounds have unsaturated carbon-carbon double 
bonds, both the cis (Z) and trans (E) isomers are within the 
scope of this invention. The compositions of the present 
invention can be substantially optically pure. Substantially 35 
optically pure means a composition having greater than 
90%, preferably greater than 95%, most preferably greater 
than 98% of a single optical isomer. 
8 
ally, have a non-peptide macromolecular carrier group 
covalently attached to their amino and/or carboxy termini. 
Such macromolecular carrier groups may include, for 
example, lipid-fatty acid conjugates, polyethylene glycol, or 
carbohydrates. 
The following figure shows the structure of an aza-peptide 
epoxide. An aza-amino acid residue is an alpha-amino acid 
residue where the alpha-carbon has been replaced by a 
nitrogen atom. It will be abbreviated as the three letter code 
for the amino acid preceded by an "A". Therefore, aza-
alanine will be abbreviated as AAla and aza-aspartic acid as 






The complete structures of several aza-peptide epoxides 




It must be noted that, as used in the specification and the 
appended claims, the singular forms "a," "an" and "the" 40 
include plural referents unless the context clearly dictates 
otherwise. Thus, for example, reference to "an aromatic 
compound" includes mixtures of aromatic compounds, ref-
erence to "a pharmaceutical carrier" includes mixtures of 
two or more stitch carriers, and the like. 
In discussing the interactions of peptides with cysteine 
proteases, we have utilized the nomenclature of Schechter 
and Berger [Biochem. Biophys. Res. Commun. 27, 157-162 
(1967); incorporated herein by reference]. The individual 
amino acid residues of a substrate or inhibitor are designated 50 
Pl, P2, etc. and the corresponding subsites of the enzyme are 
designated S 1, S2, etc. The scissile bond of the substrate is 
Ph..........,..oy~~o ~~~J/-:~/OO'< 
45 0 0 ~rrn 0 
OH 
S 1-1 '. The most important recognition subsites of cysteine 
proteases are Sl and S2. 
Amino acid residues and blocking groups are designated 55 
using standard abbreviations [see J. Biol. Chem. 260, 14-42 
(1985) for nomenclature rules; incorporated herein by ref-
erence]. An amino acid residue (AA) in a peptide or inhibitor 
structure refers to the part structure -NH-CHR1-CO-, 
where R1 is the side chain of the amino acid residue AA. It 60 
will be appreciated that at least one of the amino acid 
residues of the aza-peptide epoxides of the invention may be 
substituted by one of the well known non-naturally occur-
ring amino acid residues. Alterations such as these may 
serve to increase the stability, bioavailability and/or inhibi- 65 
tory action of the peptides of the invention. Moreover, any 
of the aza-peptide epoxides described herein may, addition-
Cbz-Leu-Glu-Thr-AAsp-EP-COOEt 
Cbz-Leu-Phe-AGln-EP-COOEt 
The R3 group would be abbreviated as C02H, C02Et, 
C02R, CONHR, CONRR', or CO-AA-T ifthe aza-peptide 
epoxide has an epoxysuccinate moiety in its structure. 
Otherwise, the structure of the R3 group would be drawn or 
abbreviated. 
There are four structural isomers at the epoxide moiety, 
two trans isomers (2S,3S and 2R,3R) and two cis isomers 
US 7,056,947 B2 
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(2R,3S and 2S,3R). The numbering of the carbons of the 
epoxide is shown above. The epoxide ring is also known as 
an oxirane ring. 
10 
sulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-meth-
ylene-bis-(2-hydroxy-3-naphthoate )] salts. Those com-
pounds of the Formula I that are acidic in nature, are capable 
of forming base salts with various pharmacologically 
acceptable cations. Examples of such salts include the alkali 
metal or alkaline earth metal salts and particularly, the 
sodium and potassium salts. 
The term "amino," as used herein, refers to -NH2 or 
derivatives thereof formed by independent replacement of 
one or both hydrogen atoms thereon with a substituent or 
substituents independently selected from alkyl, alkanoyl, 
aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, het-
eroarylalkyl, and an amino protecting group. 
The term "C1_10 acyl," as used herein, refers to a C1_10 
alkyl group, as defined herein, having an attached carbonyl 
group. 
The term "pharmaceutically acceptable derivative" refers 
to any homolog, analog, or fragment corresponding to the 
10 aza-peptide epoxides of the present invention provided 
herein which inhibits protease activity and is relatively 
non-toxic to the subject or host. 
The term "pharmaceutically acceptable" means a material 
that is not biologically or otherwise undesirable, i.e., the 
The term "C1_10 alkoxy," as used herein, refers to a C1_10 
alkyl group, as defined herein, attached to the parent 
molecular group through an oxygen atom. 
The term "C1_10 alkyl" as used herein refers to a branched 
or unbranched hydrocarbon group of carbon atoms, such as 
methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, I-butyl, 
and the like or branched or unbranched hydrocarbon groups 
15 material may be administered to an individual along with the 
selected bicyclic compound without causing any undesirable 
biological effects or interacting in a deleterious manner with 
any of the other components of the pharmaceutical compo-
sition in which it is contained. 
of carbon atoms that either contain double or triple carbon 20 
bonds. 
The term "C1_10 alkylamino," as used herein, refers to a 
C
110 
alkyl group, as defined herein, to which is attached at 
least one amino substituent. 
As used herein, and without limitation, the term "deriva-
tive" is used to refer to any compound which has a structure 
derived from the structure of the compounds of the present 
invention and whose structure is sufficiently similar to those 
disclosed herein and based upon that similarity, would be 
The term "C3 _15 cycloalkyl" as applied herein is meant to 
include cyclic hydrocarbon chains. Examples of these cyclic 
hydrocarbon chains include cyclopropane, cyclobutane, 
cyclopentane, cyclohexane, cycloheptane, cyclooctane, 
cyclononane, cyclodecane, cycloundecane, etc. 
25 expected, by one skilled in the art, to exhibit the same or 
similar activities and utilities as the claimed compounds. 
The term "C2_12 dialkylamino," as used herein, refers to 30 
two C1_10 alkyl groups, as defined herein, that are attached 
to an amino substituent. 
The following abbreviations have also been used: AFC, 
7-amino-4-trifluoromethylcoumarin; AAsp, aza-aspartic 
acid residue; AAsn , aza-asparagine; ALeu, aza-leucine; 
ALys, aza-lysine residue; AHph, aza-homophenylalanine 
residue; AOrn, aza-ornithine; AMC, 7-amino-4-methylcou-
marin; Cbz, Ph-CH20CO-; DCC, 1,3-dicyclohexylcarbo-
diimide; DMAP, 4-dimethylaminopyridine; DMF, N,N-dim-
The term "C1_10 fluoroalkyl," as used herein, refers to a 
C
110 
alkyl group, as defined herein, to which is attached at 
least one fluorine substituent. 
35 ethylformamide; EDC, 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride; EtOAc, ethyl acetate; 
HOBt, 1-hydroxybenzotriazole; HRMS, high resolution 
mass spectrometry; IBCF, isobutyl chloroformate; NMM, 4 
-methylmorpholine; Np2,2-naphthyl-alanyl; PhPr, Phenyl-
The term "C1_10 perfluoroalkyl," as used herein, refers to 
a C1_10 alkyl group in which all of the hydrogen atoms have 
been replaced with fluorine atoms. 
The term biotinyl, as use herein, refers to biotin without 
the biotin carboxyl hydroxyl group. 
By the term "effective amount" of a compound as pro-
vided herein is meant a nontoxic but sufficient amount of the 
compound to provide the desired utility. As will be pointed 
out below, the exact amount required will vary from subject 
40 propyl; TFA, trifluoroacetic acid; THF, tetrahydrofuran; 
TLC, thin layer chromatography. 
to subject, depending on the species, age, and general 45 
condition of the subject, the severity of the condition or 
disease that is being treated, the particular compound used, 
its mode of administration, and the like. Thus, it is not 
possible to specify an exact "effective amount." However, an 
appropriate effective amount may be determined by one of 50 
ordinary skill in the art using only routine experimentation. 
The term "pharmaceutically acceptable salt(s)", as used 
herein, unless otherwise indicated, includes salts of acidic or 
basic groups which may be present in the compounds of 
Formula I. The compounds of Formula I that are basic in 55 
nature are capable of forming a wide variety of salts with 
various inorganic and organic acids. The acids that may be 
used to prepare pharmaceutically acceptable acid addition 
salts of such basic compounds of Formula I are those that 
form non-toxic acid addition salts, i.e., salts containing 60 
pharmacologically acceptable anions, such as the hydrochlo-
ride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, 
phosphate, acid phosphate, isonicotinate, acetate, lactate, 
salicylate, citrate, acid citrate, tartrate, TFA, pantothenate, 
bitartrate, ascorbate, succinate, maleate, gentisinate, fuma- 65 
rate, gluconate, glucaronate, saccharate, formate, benzoate, 
glutamate, methanesulfonate, ethanesulfonate, benzene-
One embodiment of the present invention provides aza-
peptide epoxides having the following structural Formula I: 
wherein, 
R1 is selected from the group consisting of Mu M2-AA1, 
M2-AA2-AA1, and M2-AA3 -AA2-AA1; 
M1 is selected from the group consisting ofNH2--CO-, 
NH2--CS-, NH2-S02-, X-NH--CO-, X2N--CO-, 
X-NH-CS-, X2N--CS-, X-NH-S02-, X2N-
S02-, X--CO-, X-CS-, Y-S02-, Y-0---CO-, 
Y---0-CS-, phenyl substituted with K, phenyl disubsti-
tuted with K, and morpholine-CO-; 
M2 is selected from the group consisting of H, NH2-
CO-, NH2--CS-, NH2-S02-, X-NH--CO-, 
X2N--CO-, X-NH-CS-, X2N--CS-, X-NH-
S02-, X2N-S02-, X--CO-, X--CS-, Y-S02-, 
Y---0-CO-, Y---0-CS-, phenyl, phenyl substituted 
with K, phenyl disubstituted with K, and morpholine-CO-; 
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Xis selected from the group-consisting ofH, C1_10 alkyl, 
c3-1S cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substi-
tuted with J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, phenyl dis-
ubstituted with K, phenyl trisubstituted with K, naphthyl, 5 
naphthyl substituted with K, naphthyl disubstituted with K, 
naphthyl trisubstituted with K, C1_10 fluoroalkyl with an 
attached phenyl group, C1_10 alkyl with an attached phenyl 
group, cl-10 alkyl with two attached phenyl groups, cl-10 
alkyl with an attached phenyl group substituted with K, 10 
C110 alkyl with two attached phenyl groups substituted with 
K, C1_10 alkyl with an attached naphthyl group, C1_10 alkyl 
with an attached naphthyl group substituted with K, C1_10 
alkyl with an attached phenoxy group, biotinyl, and cl-10 
alkyl with an attached phenoxy group substituted with Kon 15 
the phenoxy group; 
Y is selected from the group consisting of C1_10 alkyl, 
c315 cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl substituted 
with J, cl-10 fluoroalkyl substituted with J, 1-admantyl, 
9-fluorenyl, phenyl, phenyl substituted with K, phenyl dis- 20 
ubstituted with K, phenyl trisubstituted with K, naphthyl, 
naphthyl substituted with K, naphthyl disubstituted with K, 
naphthyl trisubstituted with K, C1_10 fluoroalkyl with an 
attached phenyl group, C1_10 alkyl with an attached phenyl 
group, cl-10 alkyl with two attached phenyl groups, cl-10 25 
alkyl with an attached phenyl group substituted with K, 
C110 alkyl with two attached phenyl groups substituted with 
K, C1_10 alkyl with an attached naphthyl group, C1_10 alkyl 
with an attached naphthyl group substituted with K, C1_10 
alkyl with an attached phenoxy group, biotinyl, and cl-10 30 
alkyl with an attached phenoxy group substituted with Kon 
the phenoxy group; 
J is selected from the group consisting of halogen, C02H, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamino, C2_12 
dialkylamino, C1_10 alkyl-0-CO-, C1_10 alkyl-0-CO- 35 
NH-, and C1_10 alkyl-S-; 
K is selected from the group consisting of halogen, C1_10 
alkyl, C1_10 perfluoroalkyl, C1_10 alkoxy, phenoxy, N02, CN, 
OH, C02H, amino, C1_10 alkylamino, C2_12 dialkylamino, 
C1_10 acyl, and C1_10 alkoxy-CO-, and C1_10 alkyl-S-; 40 
AAu AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, or no 
chirality at the a-carbon selected from the group consisting 
of alanine, valine, leucine, isoleucine, praline, methionine, 
methionine sulfoxide, phenylalanine, tryptophan, glycine, 45 
serine, threonine, cysteine, tyrosine, asparagine, glutamine, 
aspartic acid, glutamic acid, lysine, arginine, histidine, phe-
nylglycine, beta-alanine, norleucine, norvaline, alpha-ami-
nobutanoic acid, epsilon-aminocaproic acid, citrulline, 
hydroxyproline, ornithine, homoarginine, sarcosine, indo- 50 
line 2-carboxylic acid, 2-azetidinecarboxylic acid, pipe-
colinic acid (2-piperidine carboxylic acid), 0-methylserine, 
0-ethylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2-CH(CH2CHEt2)---C02H, alpha-aminohep-
tanoic acid, NH2---CH(CH2-l-naphthyl)-C02H, NH2---CH 55 
(CH2-2-naphthyl)-C02H, NH2-CH(CH2-cyclohexyl)-
C02H, NH2-CH(CH2-cyclopentyl)-C02H, NH2---CH 
(CH2-cyclobutyl)-C02H, NH2---CH(CH2-cyclopropyl)-
C02H, trifluoroleucine, 4-fluorophenylalanine, lysine 
substituted on the epsilon nitrogen with a biotinyl group, and 60 
hexafluoroleucine; 
R2 is selected from the group consisting of C1_10 alkyl, 
cl 10 alkyl substituted with Q, cl-10 alkyl substituted with 
phenyl, C1_10 alkyl with an attached phenyl substituted with 
K, C1_10 alkyl substituted with naphthyl, C1_10 alkyl with an 65 
attached naphthyl substituted with K, phenyl, phenyl sub-
stituted with K, naphthyl, naphthyl substituted with K, C1_10 
12 
alkyl substituted with CONH2, C1_10 alkyl substituted with 
CONHR4 , C1_10 alkyl substituted with C02H, C1_10 alkyl 
substituted with C02R4 , CH2CH2SCH3, CH2-3-indolyl, 
CH2-2-thienyl, CH2-2-furyl, CH2-3-furyl, CH2-2-imidazyl, 
C110 alkyl substituted with G, C1_10 alkyl with an attached 
phenyl substituted with G, C1_10 alkyl with an attached 
naphthyl substituted with G, phenyl substituted with G, and 
naphthyl substituted with G; 
R4 is selected from the group consisting ofC1_10 alkyl and 
cl-10 alkyl substituted with phenyl; 
Q is selected independently from the group consisting of 
C1_10 alkoxy, C1_10 alkyl-S-, C1_10 alkoxy substituted with 
phenyl, and C1_10 alkyl-S- substituted with phenyl; 
G is selected independently from the group consisting of 
amidino (---C(=NH)NH2), guanidino (-NHC(=NH) 
NH2), isothiureido (-S---C(=NH)NH2), amino, C1_6 alky-
lamino, c2-12 dialkylamino, and imidazyl; 
R3 is selected independently from the group consisting of 






Rs is selected independently from the group consisting of 
cl-10 alkyl, c3-1S cyclized alkyl, cl-10 alkyl with a phenyl 
group attached to the cl-10 alkyl, c3-1S cyclized alkyl with 
an attached phenyl group, C1_10 alkyl with an attached 
phenyl group substituted with K, C1_10 alkyl with an 
attached phenyl group disubstituted with K, C1_10 alkyl with 
an attached phenyl group trisubstituted with K, C3_1s 
cyclized alkyl with an attached phenyl group substituted 
with K, C1_10 alkyl with a naphthyl group attached to the 
C110 alkyl, C3_1s cyclized alkyl with an attached naphthyl 
group, C1_10 alkyl with an attached naphthyl group substi-
tuted with K, C1_10 alkyl with an attached naphthyl group 
disubstituted with K, C1_10 alkyl with an attached naphthyl 
group trisubstituted with K, and C3_1s cyclized alkyl with an 
attached naphthyl group substituted with K; 
T is selected independently from the group consisting of 
OH, OR8 , NHR9 , and NR8R9 ; 
AA4 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at the 
a-carbon selected from the group consisting of alanine, 
valine, leucine, isoleucine, praline, methionine, methionine 
sulfoxide, phenylalanine, tryptophan, glycine, serine, threo-
nine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, 
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glutamic acid, lysine, arg1mne, histidine, phenylglycine, 
beta-alanine, norleucine, norvaline, alpha-aminobutanoic 
acid, epsilon-aminocaproic acid, citrulline, hydroxyproline, 
omithine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-piperi- 5 
dine carboxylic acid), 0-methylserine, 0-ethylserine, S-me-
thylcysteine, S-ethylcysteine, S-benzylcysteine, NH2---CH 
(CH2CHEt2)-C02H, alpha-aminoheptanoic acid, NH2-
CH(CH2-l-naphthyl) ---C02H, NH2-CH(CH2-2-

















clobutyl)-C02H, NH2-CH(CH2 -cyclopropyl)-C02H, trif-
luoroleucine, 4-fluorophenylalanine, lysine substituted on 
the epsilon nitrogen with a biotinyl group, and hexafluoro-




R6 and R7 are selected independently from the group 
consisting ofH, C1_10 alkyl, C3_20 cyclized alkyl, C1_10 alkyl 
with a phenyl group attached to the cl-10 alkyl, cl-10 alkyl 
with two phenyl groups attached to the cl-10 alkyl, c3-20 
cyclized alkyl with an attached phenyl group, phenyl, phenyl 20 
substituted with K, C1 _10 alkyl with an attached phenyl 
group substituted with K, C1 _10 alkyl with an attached 
phenyl group disubstituted with K, C1 _10 alkyl with an 
attached phenyl group trisubstituted with K, C1 _10 alkyl with 
two phenyl groups attached to the C1_10 alkyl and substituted 25 
with K on the phenyl group, C1 _10 alkyl with two phenyl 









on the phenyl groups, C3_20 cyclized alkyl with an attached 
phenyl group substituted with K, C1_10 alkyl with a mor-
pholine [-N(CH2CH2)0] ring attached through nitrogen to 30 
the alkyl, C1 _10 alkyl with a piperidine ring attached through 
nitrogen to the alkyl, cl-10 alkyl with a pyrrolidine ring 
attached through nitrogen to the alkyl, C1_20 alkyl with an 
OH group attached to the alkyl, -CH2CH2CH20CH3, C1_10 
alkyl with an attached 4-pyridyl group, C1_10 alkyl with an 35 
attached 3-pyridyl group, C1 _10 alkyl with an attached 2-py-
ridyl group, C1 _10 alkyl with an attached cyclohexyl group, 
-NH---CH2CH2-( 4-hydroxyphenyl), -NH---CH2CH2-(3-
indolyl), cl-10 alkyl with an attached 2-furyl group, cl-10 
alkyl with an attached 3-furyl group, and C1 _5 alkyl with an 40 
















R8 and R9 are selected independently from the group 
consisting of H, C1 _10 alkyl, phenyl, nitrophenyl, and C1_10 
alkyl substituted with phenyl; 
the stereochemistry at the epoxide carbons 2 and 3 is 45 
selected from the group consisting of cis, trans, R,R, S,S, 









The following compounds are representatives of the 
invention: 
APhe-(trans )-EP-COOEt, 






Boe-Nle-AHph-( trans )-EP-COO Et, 











Cbz-Ile-Glu-Thr-AAsp-(2S,3 S )-EP-CON ( CH2Ph )2, 
Cbz-Leu-Glu-Thr-AAsp-(2S,3S )-EP-CON ( CH3)CH2Ph, 
PhPr-Val-Ala-AAsp-(2S,3S)-EP-CON(CH3)CH2Ph, 








































Cbz-Asp-Glu-Val.........._N_...N..._ /1'.. .......l. N(X) 
H Ir 6/ - I , 
0 # 30 
H02CI 0 
Cbz-Asp-Glu-Val........_:ti,.N~~N~, 









Cbz-Ile-Glu-Thr-AAsp-(R,R )-EP-CONHCH2 Ph. 
EXEMPLARY METHODS OF PREPARATION 
A. Preparation of the Epoxide Portion 
A variety of epoxides can be synthesized by following the 
schemes shown below. Any aldehyde can be reacted with 
malonic acid to form the a,~-unsaturated acid, which can be 
60 further transformed into an ethyl ester. The double bond is 
epoxidized using t-butyl peroxide and t-butyl lithium, fol-
lowed by the deblocking of the ethyl ester to yield the 
substituted epoxide. This epoxide can then be coupled to the 
respective substituted hydrazide to yield an aza-peptide 
65 epoxide using peptide coupling procedures. 
The diethyl ester epoxysuccinate can also be deblocked to 
yield the diacid, which can be selectively coupled to differ-
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ent alcohols to yield a variety of epoxide monoesters. 
Hydrolysis of diethyl epoxysuccinate also yields the mono-
ethyl ester, which can be coupled with a variety of mono-
substituted and disubstituted amines to form amide deriva-
tives of ethyl epoxysuccinate. The ethyl ester can then be 
hydrolyzed to the acid. These epoxides can then be coupled 
to substituted hydrazides to yield aza-peptide epoxides. 
These processes are illustrated below. 
COOR r t-BuOOH/toluene t-BuLi/pentane 
ROOC THF 
0 COOR 0 COOR p KOH/EtOH p 
ROOC ROOC 
(trans) 
COO Et COO Et 
H+OH 33% H+OA< 33% HBr/AcOH HBr/AcOH 
HO H H Br EtOH 




COO Et COO Et 
H+OH NaOEt ":P EtOH H111... 0 H Br --
COO Et COO Et 
(R,R) 
COOR 






pyridine R~COOH ~ 
DMAP 
1) t-BuOOH, t-BuLi 


























B. Preparation of the Peptide Portion 
PCOOR 
HOOC 
The peptide portion of the aza-peptide epoxide inhibitor 
can be prepared using standard peptide chemistry which is 
well described in publications such as The Peptides, Analy-
sis, Synthesis, Biology, Vol. 1-9, published in 1979-1987 by 
Academic Press; Houben-Wey! Methoden der Organischen 
Chemie, Vol. 15, Parts 1 and 2, Synthese van Peptiden, 
published by Georg Thieme Verlag, Stuttgart in 1974; and 
Houben-Wey! Methods of Organic Chemistry, Vol. E22, 
Parts a, b, c, and d, Synthesis of Peptides and Peptidomi-
metics published by Georg Thieme Verlag, Stuttgart 
2000-2003 (references incorporated herein by reference). 
The M1 group can be introduced using a number of 
different reaction schemes. First, it could be introduced 
directly on an amino acid as shown in the following scheme 
(top), or the M 1 group could be introduced by reaction with 
an amino acid ester, followed by removal of the ester group 
to give the same product (bottom). 
H-AAOH~M1-AAOH 
H-AAOR'~M 1-AAOR'~M 1-AAOH 
The techniques for introduction of the M1 group are well 
documented in The Peptides, Houben-Weyel, and many 
other textbooks on organic synthesis. For example reaction 
with cyanate or p-nitrophenyl cyanate would introduce a 
carbamyl group (M1=NH2CO-). Reaction with 
Me2NCOCI would introduce the Me2NCO- group. Reac-
tion with p-nitrophenyl thiocarbamate would introduce a 
thio carbamyl group (M1=NH2CS-). Reaction with 
NH2 S02 Cl would introduce the NH2 S02- group. Reaction 
with Me2NS02 Cl would introduce the Me2NS02 - group. 
Reaction with a substituted alkyl or aryl isocyanate would 
introduce the X-NH-CO- group where Xis a substi-
tuted alkyl or aryl group. Reaction with a substituted alkyl 
50 or aryl isothiocyanate would introduce the X-NH--CS-
group where Xis a substituted alkyl or aryl group. Reaction 
with X-S02-Cl would introduce the X-S02 - group. 
Reaction with a substituted alkyl or aryl acid chloride would 
introduce an acyl group (M=X-CO-). For example, reac-
55 tion with Me0--CO-CH2CH2--CO-Cl would give the 
X--CO- group where Xis a C2 alkyl substituted with a C1 
alkyl-OCO- group. Reaction with a substituted alkyl or 
aryl thioacid chloride would introduce a thioacyl group 
60 
(M=X--CS-). Reaction with a substituted alkyl or aryl 
sulfonyl chloride would introduce the X-S02- group. For 
example, reaction with dansyl chloride would give the 
X-S02 - derivative where X was a naphthyl group mono 
substituted with a dimethylamino group. Reaction with a 
65 substituted alkyl or aryl chloroformate would introduce the 
X---0-CO- group. Reaction with a substituted alkyl or 
aryl chlorothioformate would introduce the X---0-CS-. 
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There are many alternate reaction schemes which could be 
used to introduce all of the above M1 groups to give either 
M1 -AA-OH or M1 -AA-OR'. 
The M1 -AA-OH derivatives could then be used directly in 
the preparation of peptide hydrazides or could be converted 
into the dipeptides, tripeptides, and tetrapeptides M1 -AA-
AA-OH, M1 -AA-AA-AA-OH, or M1 -AA-AA-AA-AA-OH 
which could then be converted to peptide hydrazides. The 10 
substituted peptides M1 -AA-AA-OH, M1 -AA-AA-AA-OH, 
or M1 -AA-AA-AA-AA-OH could also be prepared directly 
from H-AA-AA-OH, H-AA-AA-AA-OH, or H-AA-AA-
AA-AA-OH using the reactions described above for intro-
15 
duction of the M1 group. Alternatively, the M1 group could 
be introduced by reaction with carboxyl blocked peptides to 
give M1-AA-AA-OR', M1-AA-AA-AA-OR', or M1-AA-
AA-AA-AA-OR', followed by the removal of the blocking 
group R'. 
C. Peparation of Peptide Hydrazides 
Usually, peptide hydrazides are synthesized by reaction of 
20 
an amino acid or peptide ester with hydrazine or by direct 
coupling of an amino acid or peptide acid with hydrazine as 25 
shown in the following two figures. They can also be 
synthesized directly by reaction of an amino acid or peptide 














The side chain of the aza-amino acid residue can be 
introduced by reductive amination as shown specifically in 
the previous figure or by other methods known by those 
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The precursors for basic side chain aza-peptide epoxides 







R1 ~ ~ 
/~~ /NH~ /Boe 
R1 . N N 
~ H H 




H II H 
/N~/NH~N'-. 
R1 . N Boe 
~ H 
D. Preparation of the Aza-peptide Epoxide 1. EDC/HOBt 
Coupling Method 
The epoxide portion of the aza-peptide epoxide is coupled 
20 
to the substituted hydrazide by reacting the epoxide portion, 25 
the substituted hydrazide, EDC, and HOBt in DMF to form 
the aza-peptide epoxide (see the following figure). 
30 
EDC, HOBt, DMF 
Methods for the protection and deprotection and replace-
45 
ment of an amino protecting group with another moiety are 
well known. Deprotection of other side chain protecting 
groups were carried out by standard methods. 
2. The Mixed Anhydride Method 
Another coupling method is the mixed anhydride method. 
50 
In this method, the epoxide portion of the aza-peptide 
epoxide is coupled to the substituted hydrazide by reacting 
the epoxide portion (carboxylic acid) with NMM in DMF 
and IBCF followed by the substituted hydrazide to form the 55 
aza-peptide epoxide (see the following figure). Methods for 
the protection and deprotection of side chain protecting 




The following figure shows how these methods are used 
to build the AAsp and AAsn derivatives. 








aX~ OEt; b X~NH2; 







8 Y ~ CH2CH2Ph 
NMM, IBCF, DMF 
Reagents: (i) BrCH2COOEt, NMM, DMF; NH3/MeOH, 
0.1 eq NaCN, DMF. (ii) BrCH2COO-tBu, NMM DMF. (iii) 
65 3, EDC, HOBt, DMF or NMM, IBCF, DMF. (iv) TFA (can 
be used to deblock the t-Butyl Group in certain peptides 
where X=O-tBu). 
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Examples of the preceding methods are exhibited below 
and in the examples: 
E. Synthetic Procedures and Examples. 
24 
precipitated with 1:9 MeOH:CH
2
Cl2 and methanol to yield a 
white solid (68% yield). 1H NMR (DMSO-d6 ): 1.18 (d, 6H, 
CH3 ), 3.2 (d, 2H, NCH2CONH2), 4.0-4.12 (m, lH, a-H), 
4.2 (m, lH, a-H), S.03 (m, 2H, Cbz), S.22 (m, lH, NH), 7.18 
1. Material and Methods. Mono and dipeptidyl methyl 
esters were purchased from Bachem Bioscience Inc., King 
5 (d, lH, NH), 7.3-7.S (m, 6H, Ph and NH), 8.0 (m, lH, NH), 
9.38 (m, lH, NH). MS (FAB) m/z 366 [(M+ltJ. HRMS 
(FAB) Calcd. For C16H24N5 0 5 : 366.17774. Observed m/z 
366.1766S. 
of Prussia, Pa. Tripeptides were synthesized using standard 
coupling procedures such as the mixed anhydride method. 
The 1 H NMR spectra were obtained using a Varian Mercury 
300 MHz spectrometer. Electrospray ionization (ESI), fast-
10 
atom-bombardment (FAB) and high-resolution mass spec-
trometry were performed using Micromass Quattro LC and 
VG Analytical 70-SE instruments. Elemental analysis was 
performed by Atlantic Microlab Inc., Norcross, Ga. 
2. Preparation of Peptidyl Hydrazides (3). Anhydrous 
15 
hydrazine (10 eq) was added to a solution of the peptidyl 
methyl ester (1 eq) in MeOH at room temperature, and the 
resulting mixture was then stirred for 16 hours. As with most 
hydrazides, excess hydrazine and solvent were removed by 
evaporation. The resulting residue was washed with ethanol 
20 
and ether to give the desired peptidyl hydrazide (3) as a 
white solid. MS and 1H NMR (CDC13 or DMSO-d6 ) were 
consistent with the proposed structures. 
PhPr-Val-Ala-NH-NH2, white solid, yield 7S%. 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-NH-NH2 was puri- 25 
fied by chromatography on a silica gel colunm using 1:9 
MeOH:CH
2
Cl2 as the eluent; white solid, yield S6%. 
Cbz-Leu-Glu(O-tBu)-Thr-NH-NH2, white solid, yield 
97%. 
N-Benzyloxycarbonylalanylalanyl Hydrazide (Cbz-Ala- 30 
Ala-NH-NH2) was synthesized from Cbz-Ala-Ala-OMe 
by hydrazinolysis; white solid (S7% yield). 1H NMR 
(DMSO-d6): 1.1-1.3 (d, CH3 ), 4.0--4.1 (m, lH, a-H), 
4.1-4.3 (m, 2H, a-Hand NH), S.OS (s, 2H, Cbz), 7.3-7.4 (m, 
SH, Ph), 7.S (d, lH, NH), 7.9 (d, lH, NH), 9.0S (s, lH, NH). 35 
Cbz-Leu-Leu-NH-NH2, white solid, yield 98%. 
Cbz-Val-NH-NH2, white solid, yield 92%. 
Cbz-Glu(O-tBu)-Val-NH-NH2 was purified by chroma-
S. Preparation of Peptidyl-AA2-NH-NH--CH2COO-
tBu ( 4c ). Neat t-butyl bromoacetate (1 eq) was added to a 
stirred solution of the peptide hydrazide (3) and NMM (1 eq) 
in DMF pre-cooled at -10° C. The resulting solution was 
stirred for 30 min at -10° C., after which the mixture was 
allowed to react at room temperature for 20 hours. The DMF 
was removed by evaporation, and the resulting residue was 
washed with water, filtered, and dried in vacuo. Purification 
on a silica gel column using the appropriate solvent gave 4c 
(yields=48-6S%). MS and 1H NMR (DMSO-d6 or CDC13 ) 
were consistent with the proposed structure. 
PhPr-Val-Ala-NH-NH-CH2COO-tBu was purified by 
chromatography on silica gel colunm using 1:7 MeOH: 
CH
2
Cl2 as the eluent; white solid, yield S6%. 
Cbz-Val-NH-NH--CH2COO-tBu was purified by col-
unm chromatography on silica gel using 1 :20:4.2 MeOH: 
CH2Cl2:Et0Ac as the eluent; white solid, yield 64%. 
1H NMR (DMSO-d6): 0.90 (t, 6H, Val), 1.40 (s, 9H, tBu), 
1.86 (m, lH, Val), 3.37 (d, 2H, NHCH2COOH), 3.72 (t, lH, 
a-H), 4.99 (s, 2H, Cbz), S.13 (d, lH, NH), 7.30 (s, SH, Ph), 
9.38 (d, lH, NH). 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-NH-NH-CH2COO-
tBu was purified by colunm chromatography on silica gel 
using 2:18:S MeOH:CH2Cl2:EtOAc as the eluent; white 
solid, yield 6S%. MS (ESI) m/z 736.6 [(M+lt]. 1H NMR 
(DMSO-d6): 0.90 (d, 6H, Val), 1.49 (s, 27H, tBu), 1.8S-2.20 
(m, 3H, Val and Glu), 2.21 (m, 2H, Glu), 2.40-2.70 (m, 2H, 
Asp CH2), 3.30 and 3.38 (m, 3H, NHCH2 and NHCH2), 
4.0S-4.30 (m, 3H, a-H), S.OS (m, 2H, Cbz), 7.20--7.40 (m, 
SH, Ph), 7.60-7.9S (m, 3H, NH), 9.2 (m, lH, NH). 
Cbz-Glu(O-tBu)-Val-NH-NH--CH2COO-tBu was tography on a silica gel colunm using 1 :9 MeOH:CH2Cl2 as 
the eluent; white solid, yield 47-S3%. 
Cbz-Ile-Glu(O-tBu)-Thr-NH-NH2, white solid, yield 
91%. 
3. Preparation of Cbz-Ala-Ala-NH-NH-CH2C00Et 
40 purified by colunm chromatography on silica gel using 
2:18:S MeOH:CH2Cl2:EtOAc as the eluent; white solid, 
yield 78%. MS (ESI) m/z S6S.3 [(M+lt]. 1H NMR 
(CDC13 ): 0.9S (t, 6H, Val), 1.49 (s, 18H, tBu), 1.8S-2.20 (m, 
( 4a ). Ethyl bromoacetate (1.1 eq) was added dropwise to a 
stirred solution of Cbz-Ala-Ala-NH-NH2 (1 eq) and NMM 45 
(1.1 eq) in DMF that was cooled to -10° C. The resulting 
solution was stirred for 30 min at -10° C., after which the 
mixture was allowed to react at room temperature for 36 
hours. The DMF was evaporated, and the residue was 
purified on a silica gel colunm using 1 :9 MeOH:CH2Cl2 as 50 
the eluting solvent system to afford 4a as a white solid 
(yield=36%). 1H NMR (DMSO-d6 ): 1.18 (t, 9H, CH3 ), 3.S 
(d, 2H, NCH2C00Et), 4.0-4.lS (m, 3H, a-H and 
OCH2CH3 ), 4.2 (m, lH, a-H), S.03 (m, 2H, Cbz), S.18 (m, 
lH, NH), 7.22-7.40 (m, SH, Ph), 7.4-7.S (d, lH, NH), 7.9 55 
(m, lH, NH), 9.3S (m, lH, NH). MS (FAB) m/z 39S 
[(M+ltJ. 
4. Preparation of N1 -N-Benzyloxycarbonylalanylalanyl-
N2-carbamoylmethylhydrazine (Cbz-Ala-Ala-NH-NH-
CH2CO-NH2, 4b). The ethyl ester (4a) was converted to 60 
the amide ( 4b) by the method described by Hogberg et al. 
The ethyl ester Cbz-Ala-Ala-NH-NH--CH2C00Et ( 4a, 1 
eq) was dissolved in a 9 M solution ofNH3 in methanol and 
a small amount of DMF, and allowed to stir on an ice bath. 
To this solution was added NaCN (0.1 eq). The flask was 65 
closed with a rubber septum and allowed to stir at 0° C. for 
three days. The solvent was evaporated and the product was 
3H, Val and Glu), 2.21 (m, 2H, Glu), 3.4S-3.70 (m, 3H, 
NHCH
2 
and NHCH2), 4.2S-4.30 (m, 2H, a-H), S.OS (m, 2H, 
Cbz), S.8S (d, lH, NH), 7.0S (d, lH, NH), 7.20-7.40 (m, SH, 
Ph), 8.00 (m, lH, NH). 
Cbz-Leu-Glu(O-tBu )-Thr-NH-NH--CH2COO-tBu was 
purified by colunm chromatography on silica gel using 1:9 
MeOH:CH2Cl2 as the eluent; white solid, yield 34%. MS 
(ESI) m/z 680 [(M+ltJ. 1H NMR (DMSO-d6 ): 0.7-0.9 (t, 
6H, Leu CH3 ), 1.0 (d, 3H, Thr CH3 ), 1-1.3 (m, 2H, Leu 
CH2), 1.3-1.S (m, 18H, tBu), 1.S-1.8 (m, 2H, Leu CH and 
Glu CH2), 1.8-1.9S (m, lH, Glu CH2), 2.1-2.3 (m, 2H, Glu 
CH2), 3.4 (d, 2H, NCH2), 3.9 (m, lH, a-H), 4.1 (m, lH, a-H 
and Thr CH-OH), 4.3 (m, lH, a-H), 4.9 (d, lH, NH), S.03 
(m, 2H, Cbz), 7.3-7.4 (m, SH, phenyl), 7.S (d, lH, NH), 7.6 
(d, lH, NH), 8.0S (d, lH, NH), 9.2 (d, lH, NH). 
Cbz-Ile-Glu(O-tBu )-Thr-NH-NH-CH2COO-tBu was 
purified by colunm chromatography on silica gel using 1:9 
MeOH:CH2Cl2 as the eluent; white solid, yield 26%. MS 
(ESI) m/z 680 [(M+ltJ. 1H NMR (DMSO-d6 ): 0.7-0.9 (t, 
6H, Ile CH3 ), 0.9-1.0 (d, 3H, Thr CH3 ), 1-1.2 (m, 2H, Ile 
CH2), 1.3-1.S (s, 18H, tBu), 1.6-1.8 (m, 2H, Ile CH and Glu 
CH2), 1.8-1.9 (m, lH, Glu CH2), 2.1-2.3 (m, 2H, Glu CH2), 
3.4 (d, 2H, NCH2), 3.9 (m, 2H, a-H), 4.1 (m, lH, a-H), 4.3S 
(m, lH, Thr CH-OH), 4.8 (d, lH, NH), S.03 (s, 2H, Cbz), 
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S.OS (d, lH, NH), 7.3-7.4 (m, SH, phenyl), 7.7 (d, lH, NH), 
8.0S (d, lH, NH), 9.2 (s, lH, NH). 
6. Preparation of Cbz-Leu-Leu-NH-NH---CH2-CH-
(CH3)2- Reductive Amination Procedure. Isobutyralde-
hyde (1.1 eq) in THF was added dropwise to a solution of the 5 
peptidyl hydrazide Cbz-Leu-Leu-NHNH2 (1 eq) in THF. 
The reaction mixture was stirred at room temperature for 16 
hours, and monitored by TLC. The solvent was evaporated, 
and the resulting hydrazone was purified by colunm chro-
matography on silica gel using 1:9 MeOH:CH2Cl2 as the 10 
solvent system. The hydrazone (1 eq) in THF was reduced 
by the addition ofNaBH4 (Seq) in a small amount ofMeOH, 
and the mixture was monitored by TLC. The solvent was 
removed by evaporation and the residue was dissolved in 
CH2Cl2. Successive washings with saturated NH4 Cl 15 
removed the excess NaBH4 . The organic layer was washed 
with saturated NaCl and dried over MgS04 . The product 
Cbz-Leu-Leu-NH-NH---CH
2
-CH-(CH3)2 was purified 
by chromatography on a silica gel colunm using 1: 1 EtOAc: 
CH
2
Cl2 as the eluent, followed by recrystallization from 20 
MeOH/CH2Cl2/hexane to give a white solid (yield 78%). 
MS and 1H NMR (DMSO-d6 or CDC13) were consistent 
with the proposed structure. 
7. Preparation of (2S,3S) and (2R,3R)-Oxirane-2,3-dicar-
boxylic Acid Monoethyl Esters (or Monoethyl Epoxysucci- 25 
nates, S, Y=COOEt). Enantiomerically pure diethyl 
epoxysuccinate esters (2S,3S) and (2R,3R) were synthesized 
from diethyl D-(-) and L-( + )-tartrate, respectively, follow-
ing the general method developed by Mori and Iwasawa. 
This procedure involved three steps including bromination, 30 
elimination, and cyclizations. The selective hydrolysis of 
one ester to yield monoethyl epoxysuccinates was per-
formed by a method similar to that described previously by 
Rich and Schaschke. 
26 
(lSO mL), filtered and the solvent evaporated, to give 
trans-oxirane-2,3-dicarboxylic acid as a colorless semisolid 
(yield=97% ). 
10. Preparation of trans-Oxirane-2,3-dicarboxylic Acid 
Monobenzyl Ester (S, Y=COOBzl). The reagent EDC (2.32 
g, 11 mM) was added to a stirred solution of trans-oxirane-
2,3-dicarboxylic acid (1.32 g, 10 mM), benzyl alcohol (1.08 
g, 10 mM), and DMAP (122 mg, 1 mM) in DMF (100 mL), 
which has been cooled to 0° C. The resulting solution was 
stirred for lS hat room temperature. After removal ofDMF, 
the residue was purified by chromatography on two succes-
sive colunms using 1:9 MeOH:CH2Cl2 as the eluent, fol-
lowed by colunm chromatography using 1 :4 MeOH:CH2Cl2 
as the eluent to give S (Y=COOBzl), as a dark yellow oil 
(yield=66%). 1H NMR: 3.60 (d, lH, epoxy), 3.7S (d, lH, 
epoxy), S.18 (s, 2H, PhCH20), 7.38 (d, SH, Ph). 
11. Preparation of trans-3-Phenethy loxirane-2-carboxy lie 
Acid (S, Y=CH2CH2Ph). A stirred solution of 3-phenylpro-
pionaldehyde (6.7 g, SO mM) and malonic acid (S.2 g, SO 
mM) in pyridine (4 mL) was heated at 100-10S° C. for 6 
hours. The reaction mixture was poured onto ice/HCI. The 
solid precipitate was washed with water sufficiently to give 
S-phenylpent-2-enoic acid (6.2 g, 3S mM, yield=70%). 
The reagents DCC (33 mM) and DMAP (30 mM) were 
added to a solution of S-phenylpent-2-enoic acid (S.3 g, 30 
mM) in EtOH (SO mL) and THF (20 mL), which was cooled 
to 0° C. The resulting mixture was stirred for 30 min at 0° 
C., then allowed to react for lS hat room temperature. The 
suspension was filtered, and the filtrate was concentrated. 
The residue was dissolved in EtOAc and washed with 1 M 
HCl (3x30 mL), H20 (10 mL), saturated NaHC03 (3x30 
mL), H20 (10 mL), saturated NaCl (20 mL), dried over 
MgS04 , and concentrated. Chromatography on a silica gel 
colurmi using 1 :2 EtOAc:hexane as the eluent afforded 
35 S-phenyl-pent-2-enoic acid ethyl ester (3.7S g, yield=61 %). 8. Preparation of trans-Oxirane-2,3-dicarboxylic Acid 
Diethyl Ester (or Diethyl Epoxysuccinate). The trans-ox-
irane-2,3-dicarboxylic acid diethyl ester was synthesized 
using a general procedure for the stereocontrolled epoxida-
tion of a,~-unsaturated carbonyl compounds, which was 
similar to the method previously described by Meth-Cohn. 40 
An anhydrous solution oft-butyl hydroperoxide in toluene 
(3.3 M solution, 46 mL, l.S eq), was added to freshly 
distilled THF (240 mL) at - 78° C. under argon. This was 
followed by the addition of a solution of butyl lithium in 
pentane (1.7 M solution, 6S mL, 1.1 eq). The mixture was 45 
stirred at - 78° C. for S min, then a solution of diethyl 
fumarate (17.2 g, 0.1 M, 1 eq) in THF (SO mL) was added. 
The reaction mixture was stirred at room temperature for 2 
hours (monitored by TLC). Sodium sulfite (10 g) was added 
and the mixture was stirred for 20 min. The mixture was 50 
concentrated to ca. 100 mL, diluted with ether (100 mL), 
filtered through yiatomaceous earth ( celite ), and evaporated. 
This compound was epoxidized using the procedure 
described above in the synthesis of trans-oxirane-2,3-dicar-
boxylic acid diethyl ester and purified on a silica gel colurmi 
with 1: 1 EtOAc:hexanes as the eluent to afford trans-3-
phenethyloxirane-2-carboxylic acid ethyl ester as a light 
yellow oil (yield=46%). 1H NMR: l.2S (t, 3H, Oet); 1.90 (t, 
2H, PhCH2CH2), 2.80 (t, 2H, PhCH2), 3.2 (s, 2H, epoxy), 
4.2 (q, 2H, Oet), 7.3 (m, SHb, Ph). 
A solution of 1 M NaOH (1.1 eq, S.S mL) was added to 
a stirred solution of trans-3-phenethyloxirane-2-carboxylic 
acid ethyl ester (1.1 g, S mM) in MeOH (10 mL) at room 
temperature. After stirring for 1 h at room temperature, the 
solution was acidified to pH 3, and extracted with EtOAc 
(2x30 mL). The organic layer was washed with water (2x30 
mL), saturated NaCl (20 mL), dried over MgS04 , and 
concentrated to give trans-3-phenylethyloxirane-2-carboxy-
lic acid (S, Y=CH2CH2Ph) as a light yellow oil (yield=72%). 
1H NMR: 1.90 (t, 2H, PhCH2CH2), 2.80 (t, 2H, PhCH2), 
3.30 (s, 2H, epoxy), 7.30 (m, SH, Ph). HRMS (FAB) Calcd. 
For C12H120 5 : 237. Observed m/z 236.9. 
12. General Procedure for Coupling Oxirane Dicarboxylic 
Acid Monoethyl Esters to Amines. The procedure used to 
synthesize amide derivatives of epoxysuccinate monoethyl 
esters was similar to that of Therrien et al (Biochemistry 
To the residue was added 1 M HCl (100 mL). The product 
trans-oxirane-2,3-dicarboxylic acid diethyl ester was 
extracted with EtOAc (3x100 mL), and the organic layer 55 
was washed with saturated NaCl (3xSO mL), dried over 
MgS04 , and the solvent evaporated. Chromatography on a 
silica gel colunm with 2:3 EtOAc:hexane afforded the 
product trans-oxirane-2,3-dicarboxylic acid diethyl ester 
(yield=S2%). 
9. Preparation of trans-Oxirane-2,3-dicarboxylic Acid. A 
solution of 1 M NaOH (98 mL, 1.9 eq) was added to 
trans-oxirane-2,3-dicarboxylic acid diethyl ester (9.8 g, S2 
mM) in MeOH (30 mL) at 0° C. The resulting solution was 
stirred for 1 hat 0° C., then for 30 min at room temperature, 65 
after which the solution was acidified to pH 3. Water and 
MeOH were evaporated. The residue was treated with EtOH 
60 2001 40 p 2702). To a solution of epoxysuccinate monoethyl 
ester (1 g, 6.2S mM), amine/amino acid (1.2 eq) and HOBt 
(1 eq) in CHC13 (30 mL) at 0° C. was added EDC (1.1 eq) 
slowly in S portions. The reaction was stirred for one hour 
at 0° C. and then subsequently at room temperature for 16 
hours. The solvent was evaporated and the residue was 
partitioned between EtOAc (SO mL) and dH20 (S mL). The 
organic layer was washed with O.S M HCl (2x10 mL), sat 
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NaHC03 (2xSO mL), dried over MgS04 and concentrated. 
In general, the oxirane-2,3-dicarboxylic acid monoamides 
were obtained in 43-74% yield. The crude product was 
purified by chromatography on a silica gel colunm using 1: 1 
EtOAc:hexanes as the eluent to yield a white solid. Hydroly- 5 
sis of the ester by KOH (1.2 eq) gave the desired amides 
(yields=6S-9S% ). 
13. (2S,3S)-3-(Dibutylcarbamoyl)oxirane-2-carboxylic 
Acid (HOOC-EP-CON(CH2CH2CH2CH3)2). This com-
pound was synthesized using the above procedure with 10 
dibutylamine as the starting material. 1H NMR (CDC13): 
0.93 (t, 6H, CH3), 1.32 (m, 4H, CH2), l .S4 (m, 4H, CH2), 
3.3S (m, 4H, CH2), 3.67 and 3.88 (d, 2H, epoxy). 
14. (2S,3S)-3-(N-Methyl-N-benzylcarbamoyl)oxirane-2-
carboxylic Acid (HOOC-EP-CON(CH3)CH2Ph). This com- 15 
pound was synthesized using the above procedure with 
NH(CH3)CH2Ph as the starting material. 
1 H NMR (CDC13): 
2.94 and 3.02 (d, 3H, CH3N), 3.72 and 3.96 (d, 2H, epoxy), 
4.78 (d, 2H, CH2Ph), 7.18-7.32 (m, SH, Ph). 
IS. (2S,3S)-3-(Dibenzylcarbamoyl)oxirane-2-carboxylic 20 
Acid (HOOC-EP-CON(CH2Ph)2). This compound was syn-
thesized using the above procedure with dibenzylamine as 
the starting material. 1H NMR (CDC13): 3.77 and 3.93 (d, 
2H, epoxy), 4.S8 (m, 4H, CH2Ph), 7.14-7.36 (m, !OH, Ph). 
16. Preparation of trans-3-(4-Chlorophenyl)oxirane-2- 25 
carboxylic Acid (HOOC-EP-Ph-4-Cl). The starting material, 
4-chloro-trans-cinnamic acid (1 eq), was cooled to -20° C. 
in dry methanol. Thionyl chloride (3 eq) was added drop-
wise to the cooled solution over one hour. The mixture was 
stirred at -lS° C. for an additional 30 minutes and subse- 30 
28 
1ri. 1H NMR (CDCl3): 1.2-1.4 (m, 3H, OCH2CH3), 
2.4-2.6 (m, 6H, NCH2 morph), 3.2-3.4 (m, 2H, CON-
HCH2), 3.4S and 3.6S (m, epoxy), 3.6-3.8 (m, 4H, OCH2 
morph), 4.2S (m, 2H, OCH2CH3), 7.8S (m, lH, NH). 
19. (2S,3S)-Oxirane-2,3-dicarboxylic Acid Monobenzyl 
Ester (HOOC-EP-COOCH2Ph). 
1H NMR (CDC13): 3.70 (d, 
2H, epoxy), S.22 (d, 2H, CH2Ph), 7.3S (m, SH, Ph). 
20. (2R,3R)-Oxirane-2,3-dicarboxylic Acid Monobenzyl 
Ester (HOOC-EP-COOCH2Ph). 
1H NMR (CDC13): 3.6S (d, 
2H, epoxy), S.17 (d, 2H, CH2Ph), 7.32 (m, SH, Ph). 
21. (2S,3S)-Oxirane-2,3-dicarboxylic Acid Monophen-
ethyl Ester (HOOC-EP-COOCH2CH2Ph). This epoxide was 
synthesized using the above procedure for trans-oxirane-2, 
3-dicarboxylic acid monobenzyl ester by using (2S,3S)-
oxirane-2,3-dicarboxylic acid and phenethyl alcohol as the 
starting materials. 1 H NMR (CDC13): 2.98 (t, 2H, CH2), 3.6S 
(d, 2H, epoxy), 4.41 (m, 2H, OCH2), 7.2S (m, SH, Ph). 
22. (2R,3R)-3-(2-Phenethylcarbamoyl)oxirane-2-car-
boxylic Acid (HOOC-(2R,3R)-EP-CONHCH2CH2Ph). 
1H 
NMR (CDC13): 2.82 (t, 2H, CH2Ph), 3.3S and 3.69 (d, 2H, 
epoxy), 3.S4 (m, 2H, NCH2), 6.20 (b, lH, NH), 7.lS-7.33 
(m, SH, Ph). 
23. (2S,3S)-3-(3-Benzylcarbamoyl)oxirane-2-carboxylic 
Acid (HOOC-(2S,3S)-EP-CONHCH2Ph). This compound 
was synthesized using PhCH2NH2 as the starting material. 
1H NMR (CDC13): 3.S3 and 3.78 (d, 2H, epoxy), 4.4S (d, 
2H, CH2Ph), 6.40 (b, lH, NH), 7.2S-7.33 (m, SH, Ph). 
24. (2R,3R)-3-(3-Benzylcarbamoyl)oxirane-2-carboxylic 
Acid (HOOC-(2R,3R)-EP-CONHCH2Ph). This compound 
was synthesized using PhCH2NH2 as the starting material. 
1H NMR (DMSO-d6): 3.SO and 3.60 (d, 2H, epoxy), 4.29 (d, quently stirred at room temperature for 24 hours. Evapora-
tion of the volatiles yielded the methyl ester MeOOC-
CH=CH-Ph-4-Cl as a white solid (yield=89%). Without 
further purification the methyl ester was epoxidized. An 
anhydrous solution oft-butyl hydroperoxide in toluene (3.3 
M, l .S eq) was added to freshly distilled THF at - 78° C. 
under argon. A solution of butyllithium in pentane (1.7 M, 
1.1 eq) was added dropwise. The mixture was stirred at - 78° 
C. for S minutes and then a solution ofMeOOC--CH=CH-
2H, CH2Ph), 7.23-7.33 (m, SH, Ph), 8.89 (b, lH, NH). 
2S. (2S,3S)-3-(3-Ethylcarbamoyl)oxirane-2-carboxylic 
Acid (HOOC-(2S,3S)-EP-CONHCH2CH3). This compound 
35 was synthesized using CH3CH2NH2 as the starting material. 
1H NMR (CDC13): 1.16 (t, 3H, CH3), 3.29 (q, 2H, CH2), 
3.46 and 3.6S (d, 2H, epoxy), 6.10 (b, lH, NH). 
Ph-Cl (1 eq) in toluene was added dropwise. The reaction 40 
was stirred at - 78° C. for 30 minutes then at room tempera-
ture for 16 hours. Solid sodium sulfite was added and the 
mixture was allowed to stir for 20 minutes, then diluted with 
ether and filtered over celite. The solvent was evaporated, 
and the crude product was purified by colunm chromatog- 45 
raphy on silica gel using 3: 1 hexane/EtOAc as the eluent. 1 H 
NMR (CDC13): 3.47 (d, lH, epoxy), 3.83 (s, 3H, CH3), 4.08 
26. (2S,3S)-3-(2-Hydroxy-2-phenylethylcarbamoyl)ox-
irane-2-carboxylic Acid (PhCH(OH)CH2NHC0-(2S,3S)-
EP-COOH). This compound was synthesized using PhCH 
(OH)CH
2
NH2 as the starting material. 
1H NMR (CDC13): 
3.3S (m, lH, NCH2), 3.S4 (m, 2H, epoxy and NCH2), 3.63 
(s, lH, epoxy), 4.80 (m, lH, OCH2), 7.20 (t, lH, NH), 
7.33-7.41 (m, SH, Ph and NH). 
27. (2R,3R)-3-(2-Hydroxy-2-phenylethylcarbamoyl)ox-
irane-2-carboxylic Acid (PhCH(OH)CH2NHC0-(2R,3R)-
EP-COOH). This compound was synthesized using PhCH 
(OH)CH
2
NH2 as the starting material. 
1H NMR (CDC13): 
3.37 (m, lH, NCH2), 3.S4 (m, 2H, epoxy and NCH2), 3.63 
(d, lH, epoxy), 7.21 (d, 2H, Ph), 7.33 (d, 2H, Ph). Standard 
deblocking of the methyl ester with sodium hydroxide (1 N) 
followed by acidic workup (1 N HCl) produced the 3-(4-
chlorophenyl) glycidic acid. 1H NMR (DMSO-d6): 3.6S (s, 
lH, epoxy), 4.14 (s, lH, epoxy), 7.37 (d, 2H, Ph), 7.43 (d, 
2H, Ph). 
17. (2S,3S)-3-(3-Methoxypropylcarbamoyl)oxirane-2-
carboxylic Acid Ethyl Ester (EtOOC-EP-
CONHCH2CH2CH20CH3) was synthesized using the 
epoxide and amine coupling method with methoxypropy-
lamine as the starting material. The crude product was 
purified by colunm chromatography with 1 :S MeOH:CH
2
Cl2 
as the eluent. MS (ESI) m/z 232 [(M+ltJ. 
18. (2S,3S)-3-(3-( 4-Morpholinyl)propylcarbamoyl)ox-
irane-2-carboxylic Acid Ethyl Ester (EtOOC-EP-
CONHCH2CH2CH2morpholinyl) was synthesized using the 
epoxide and amine coupling method with 4-(3-aminopropyl) 
morpholine as the starting material. The crude product was 
purified by column chromatography using 1 :S MeOH: 
CH
2
Cl2 as the eluent (7% yield). MS (ESI) m/z 287 [(M+ 
50 (s, lH, epoxy), 4.80 (m, lH, NCH2), 7.20 (t, lH, NH), 
7.33-7.41 (m, SH, Ph and NH). 
28. (2S,3S)-3-(1-Benzylcarbamoylethylcarbamoyl)ox-
irane-2-carboxylic Acid (HOOC-(2S,3S)-EP-CO-Ala-NH-
Bzl). This compound was synthesized using NH2CH(CH3) 
55 CONHBzl as the starting material. 1H NMR (DMSO-d6): 
1.26 (d, 3H,Ala), 3.4S and3.6S (d, 2H, epoxy), 4.26 (d, 2H, 
CH2Ph), 4.33 (m, lH, a-H), 7.19 and 7.29 (m, SH, Ph), 8.Sl 
(t, lH, NH), 8.67 (d, lH, NH). 
29. (2R,3R)-3-(1-Benzylcarbamoylethylcarbamoyl)ox-
60 irane-2-carboxylic Acid (HOOC-(2R,3R)-EP-CO-Ala-NH-
Bzl). This compound was synthesized using NH2CH(CH3) 
CONHBzl as the starting material. 1H NMR (DMSO-d6): 
l.2S (d, 3H, Ala), 3.49 and 3.6S (d, 2H, epoxy), 4.26 (d, 2H, 
CH2Ph), 4.33 (m, lH, a-H), 7.19 and 7.29 (m, SH, Ph), 8.Sl 
65 (t, lH, NH), 8.67 (d, lH, NH). 
30. (2S,3S)-3-(1-Carbamoyl-3-methylbutylcarbamoyl) 
oxirane-2-carboxylic Acid (HOOC-(2S,3S)-EP-CO-Leu-
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NH2). This compound was synthesized using NH2CH 
(CH2CH(CH3 ) 2)CONH2 as the starting material. 
1 H NMR 
(DMSO-d6): 0.84 (d, 6H, CH3 ), 1.46 (m, 2H, CH2), 1.55 (m, 
lH, CH), 3.48 and 3.64 (d, 2H, epoxy), 4.20 (m, lH, a-H), 
7.00 (s, lH, NH), 7.45 (s, lH, NH), 8.50 (d, lH, NH). 
31. (2R,3R)-3-(1-Carbamoyl-3-methylbutylcarbamoyl) 
oxirane-2-carboxylic Acid (HOOC-(2R,3R)-EP-CO-Leu-
NH2). This compound was synthesized using NH
2
CH 
(CH2CH(CH3 ) 2)CONH2 as the starting material. 
1 H NMR 
(DMSO-d6): 0.85 (d, 6H, CH3 ), 1.46 (m, 2H, CH2), 1.56 (m, 
lH, CH), 3.48 and 3.64 (d, 2H, epoxy), 4.20 (m, lH, a-H), 
7.00 (s, lH, NH), 7.45 (s, lH, NH), 8.50 (d, lH, NH). 
32. (2S,3S)-3-(1-Carbamoyl-2-phenylethylcarbamoyl) 
oxirane-2-carboxylic Acid (HOOC-(2S,3S)-EP-CO-Phe-
NH2). This compound was synthesized using NH CH 
(CH2Ph)CONH2 as the starting material. 
1H NMR (DMSO-
d6): 2.78 (m, lH, CH2Ph), 3.02 (m, lH, CH2Ph), 3.25 and 
3.56 (d, 2H, epoxy), 4.45 (m, lH, a-H), 7.13-7.25 (m, 6H, 
Ph and NH), 7.57 (s, lH, NH), 8.52 (d, lH, NH). 
33. (2R,3R)-3-(1-Carbamoyl-2-phenylethylcarbamoyl) 
oxirane-2-carboxylic Acid (HOOC-(2R,3R)-EP-CO-Phe-
NH2). This compound was synthesized using NH CH 
(CH2Ph)CONH2 as the starting material. 
1H NMR (DMSO-
d6): 2.78 (m, lH, CH2Ph), 3.02 (m, lH, CH2Ph), 3.32 and 
3'.59 (d, 2H, epoxy), 4.42 (m, lH, a-H), 7.13- 7.25 (m, 6H, 
Ph and NH), 7.57 (s, lH, NH), 8.60 (d, lH, NH). 
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which renders it resistant to autolytic inactivation, but has no 
detectable affect on enzyme activity as compared to the 
naturally occurring enzyme. The enzyme variant was 
expressed in E. coli, purified first by immobilized metal 
5 chromatography via the N-terminal N-His tag, treated with 
excess oxidized glutathione to stabilize the reactive thiolate, 
and then re-purified by size-exclusion chromatography. 
Inhibition data was measured using the progress curve 
assay method. Serial dilutions of each compound were 
10 prepared using an initial 8-fold dilution of a DMSO stock 
into HGE (100 mM HEPES,20% glycerol v/v, 0.5 mM 
EDTA), followed by seven serial two-fold dilutions into 
HGE and 12.5% DMSO, thus maintaining constant DMSO 
through the dilution series. Ten µL of diluted stocks or of 
15 vehicle (HGE and 12.5% DMSO) were placed in triplicate 
onto a 96-well microtiter plate, allowing several compounds 
to be tested on each plate. The plate was covered to 
minimize evaporation, and the plate was pre-warmed to 30° 
C. for 20 minutes. Enzyme was diluted into 10.0 mL of assay 
20 buffer (HGE, 5 mM DTT, plus 15 µM Ac-YVAD-AMC, 2 
nM approximate final enzyme concentration), and this acti-
vated reaction mixture was added to the plate at 90 µL/well. 
Progress of substrate hydrolysis was monitored for 900 s in 
a LabSystems (Needham, Mass.) Fluoroskan Ascent fluo-
25 rescent plate-reader using 385 and 460 nm excitation and 
emission filters, respectively, and a photomultiplier gain 
setting of 10. Triplicate curves were averaged and fit by 
nonlinear regression to the equation for irreversible inacti-
vation shown below. 
33. (2S,3S)-3-(1-Carbamoyl-2( 4-hydroxyphenyl)ethyl-
carbamoyl)oxirane-2-carboxylic Acid (HOOC-(2S,3S)-EP-
CO-Tyr-NH2). This compound was synthesized using 
NH
2
CH(CH2Ph-4-0H)CONH2 as the starting material. 
1H 30 
NMR (CD3 COCD3 ): 2.85 (m, lH, CH2Ph), 3.10 (m, lH, 
CH2Ph), 3.40 and 3.59 (d, 2H, epoxy), 4.60 (m, lH, a-H), 
6.50 (b, lH, OH), 6.74 and 7.07(d of d, 4H, Ph), 7.15 (s, lH, 
NH), 7.35 (d, lH, NH). 
V;(l - e-kofa1) 




UTILITY OF THE PRESENT INVENTION where F 0 was routinely fixed to zero, since fluorescence 
values were always adjusted to an origin of 0. The second 
order rate constant k
0
n (M- 1s- 1 ) was obtained from the 
slopes by linear regression, and errors represent the standard 
Peptide aza-peptide epoxides are irreversible inhibitors 
for cysteine proteases. Peptide aza-peptide epoxides con-
taining hydrophobic aza-amino acid residues in the Pl 
and/or P2 site have been found to be excellent inhibitors of 
cysteine proteases including cathepsin B and papain. We 
show that peptide aza-peptide epoxides containing aza-
amino acid residues with anionic side chains in the Pl site 
are excellent inhibitors of caspases. Legumain is inhibited 
40 deviation of the regression slope. 
Caspase-3, -6, and -8. Caspase-3, -6 and -8 were 
expressed in E. coli and purified according to methods 
previously described by Stennicke and Salvesen. Assays 
using the fluorogenic substrate Z-DEVD-AFC O'-ex =400 nm, 
45 "-em =505 nm) were carried out on a Molecular Devices fMax 
fluorescence microplate reader. Inhibition rates and equilib-
ria were determined by the progress curve method. The 
standard 100 µL reaction was started by adding enzyme to 
a mixture of substrate (final concentration of Z-DEVD-AFC 
by aza-peptide expoxides with a Pl aza-asparagine residue. 
Clostripain and gingipain are inhibited by aza-peptide 
epoxides with Pl basic side chains. Peptide aza-peptide 
epoxides containing aza-amino acid residues with hydro-
phobic side chains at the P2 site have also been found to be 
excellent inhibitors of several cysteine proteases including 
papain, cathepsin B, calpain I, and calpain II. These struc-
tures may be used in vivo to treat diseases such as cancer and 
neurodegenerative diseases which result from the uncon-
trolled proteolysis by cathepsin B, calpain, caspases, and 55 
related cysteine proteases. These inhibitors may be used in 
vitro to prevent proteolysis which occurs in the process of 
production, isolation, purification, storage, or transport of 
peptides and proteins. These inhibitors may be useful as 
therapeutic agents for treatment of neurodegeneration, viral 60 
infections, muscular dystrophy, myocardial tissue damage, 
tumor metastasis, and bone resorption. 
1. Enzyme Assays 
Caspase-1. The preparation of the autolytically stable 
caspase-1 variant used in these studies has been described 
previously. Briefly, the variant contains a mutation (D381E) 
50 100 µM) and various amounts of inhibitor in buffer ( 50 mM 
Hepes, 100 mM NaCl, 0.1% (w/v) CHAPS, sucrose 10% 
(w/v), and 10 mM DTT, at pH 7.4). The caspases were 
pre-activated for 10 min at 37° C. in the presence of 10 mM 
DTT. 
Legumain Assays with legumain were performed as fol-
lows. A fluorometric assay for legumain has been described 
previously. Legumain, purified from pig kidney tissue, was 
assayed at 30° C. in buffer (39.5 mM citric acid, 121 mM 
Na
2
HP04 at pH 5.8 containing 1 mM EDTA, 1 mM TCEP, 
and 0.01 % CHAPS) with Cbz-Ala-Ala-Asn-AMC as the 
substrate (10 µM final concentration). The assays were 
carried out in a Perkin Elmer LS 3B fluorescence spectrom-
eter C"-ex =360 nm, kem =460 nm) under the control of an 
IBM-compatible computer running the FLUSYS software. 
65 The rate of substrate hydrolysis in the absence of inhibitor 
was recorded, after which the inhibitor was added in a 
negligible volume and the new rate was monitored. Rate 
US 7,056,947 B2 
31 
constants for irreversible inactivation were found by non-
linear regression analysis of the pseudo first-order curves 
using the FLUSYS software, giving k065. The second-order 
rate constant k2 was calculated as k06)[I], at [S]<KM" The 
test substrates were used at [S]<KM, so no corrections for 
competition with the inhibitors were required. A minimum 
of three different concentrations of inhibitor were used to 
determine second-order rate constants with legumain (range 
used 100 µM-100 nM). 
Studies with the aza-peptide epoxides using the schisto- 10 
some legumain SmAE (Schistosoma mansoni asparaginyl 
endopeptidase) were also performed. The enzymatically 
pure enzyme (zymogen form) was expressed in Pichia 
without interference from other proteases (ref FEBS lett 
2000 466 244-248 Caffrey). The actual active site enzyme 15 
concentration is unknown. The lyophilized enzyme (50--100 
mg) was reconstituted in 1.5 mL 0.5 M sodium acetate, pH 
4.5 containing 4 mM DTT, and left to stand at 37° C. for 3-4 
hours to allow for auto-activation of the zymogen. In a black 
96-well microtiter plate, 50 uL of activated enzyme was 20 
added to an equal volume of0.1 M citrate-phosphate buffer 
pH 6.8 containing 4 mM DTT. Inhibitor stock solutions (20 
mM) were prepared in DMSO. Serial dilutions (using water) 
of inhibitor were added (as 1 uL aliquots) to yield concen-
trations of between 2 and 0.00002 uM inhibitor. The inhibi- 25 
32 
and added to 200 µL of a 0.1 M potassium phosphate buffer 
containing 1.25 mM EDTA, 0.01 % Brij 35 at pH 6.0, and the 
substrate Z-Arg-Arg-AMC ( 499 µM). The release of 
7-amino-4-methylcoumarin was monitored O'-ex =360 nm, 
"-em =465 nm) using a Tecan Spectra Fluor microplate reader. 
Pseudo first-order inactivation rate constants were obtained 
from plots of In v /v 
0 
versus time. 
The incubation method was also used for papain. The 
inhibition incubation buffer for papain was 50 mM Hepes 
buffer at pH 7.5, containing 2.5 mM DTT and 2.5 mM 
EDTA. The assay used the substrate Z-Phe-Arg-pNA (53.7 
µM) in the same buffer. The approximate concentration of 
papain added to the incubation buffer was 0.29 mg/mL. The 
release of p-nitroanilide was monitored at 405 nm with a 
Molecular Devices Thermomax microplate reader. 
Aspartyl Proteases. Assays with the following aspartyl 
proteases were performed: porcine pepsin, human cathepsin 
D, plasmepsin 2 (from P. falciparum), and the secreted 
aspartic proteinase 2 (SAP-2) from Candida albicans. The 
inhibitors were also assayed with HIV-1 protease. The 
inhibitors were preincubated for 30 minutes with HIV-1 
protease and 20 minutes with the other enzymes. Substrate 
was then added and the substrate hydrolysis was monitored. 
The following buffers were used: 0.05 M sodium acetate, 
0.15 M NaCl, and 1 mM DTT for HIV-1 protease; 0.1 M 
sodium formate at pH 4.5 for plasmepsin-2 and SAP-2; and 
0.1 M sodium formate at pH 3.5 for pepsin and cathepsin D. 
The inhibitor Cbz-Ala-Ala-AAsn-(2S,3S)-EP-COOEt 
tors were preincubated with the protease at room tempera-
ture for 20 minutes before the assay (IC50s were the same 
when incubated for only 5 minutes). After incubating vari-
ous inhibitor concentrations with enzyme, 100 uL of the 
same buffer containing 20 uM substrate (Cbz-Ala-Ala-Asn-
AMC) was added to the wells and the reaction monitored at 
room temperature with linear kinetics up to 20 minutes. 
Inhibitors are tested in duplicate. A plot of the RFU/min 
versus the inhibitor concentration [µM] permitted calcula-
tion of an IC50 value and estimation of the k06/[I]. 
30 showed almost no inhibition (less than 20% inhibition) of 
any of the enzymes. 
Granzyme B. Assays with granzyme B were also per-
formed. In the preliminary assays, the inhibitor (10 µL, 5 
mM stock solution in DMSO) was incubated with granzyme 
Papain and Cathepsin B. The incubation method was used 
35 B (90 µL) for 1 hour. After the incubation period, to these 
wells was added IETD-pNA (100 µL) and the rate was 
monitored at 405 nm. The inhibitor Cbz-Ala-Ala-AAsn-(2S, 
3S)-EP-COOEt showed no inhibition. 
to measure the irreversible inhibition of papain and cathe-
psin B. With cathepsin B, 30 µL of a stock inhibitor solution 
was added to 300 µL of 0.1 M potassium phosphate buffer 
containing 1.25 mM EDTA, 0.01 % Brij 35 at pH 6.0, 40 
followed by the addition of 30 µL of a freshly prepared 
cathepsin B solution (approximate concentration 6.98x10-3 
µg/µL) in the same potassium phosphate buffer containing 1 
mM DTT (freshly prepared). Aliquots (50 µL) from the 
inhibition mixture were withdrawn at various time intervals 
2. Structure-Activity Relationships 
Table I shows the inhibition rate constants (k06/[I]) for 
the inhibition of papain, cathepsin B, and calpain by aza-
peptide epoxides. The inhibition constants are second-order 
rate constants and the inhibitors with the higher numbers are 
more potent. 
TABLE I 
Inhibition of Papain. Catbepsin B. and Calpain by Aza-peptide Epoxides. 
Inhibitor papain catbepsin B 
Boc-Nva-AHph-trans-EP-COOEt 1.4 2.7 
Boc-Nle-AHph-trans-EP-COOEt 1.6 1.3 
Boc-Abu-AHph-trans-EP-CH2CH2 Ph 0.2 NI 
Boc-Nle-AHph-trans-EP-CH2 CH2 Ph 0.5 NI 
Cbz-APhe-trans-EP-COOEt 8.5 1.8 
Cbz-APhe-trans-EP-CH2 CH2 Ph 0.92 
Cbz-ALeu-trans-EP-COOEt 16.1 4.43 
Cbz-AHph-trans-EP-COOEt 18.8 8.91 
Ac-AHph-trans-EP-COOEt 26.88 40.62 
Cbz-Leu-ALeu-(2S, 3S)-EP-COOEt 10.53 1.8 
Cbz-Leu-ALeu-(2R, 3R)-EP-COOEt 6.70 NI 
Cbz-Leu-ALeu-trans-EP-COOEt 6.37 23.32 
Cbz-Leu-ALeu-cis-EP-COOEt 0.38 6.27 
Cbz-Phe-ALeu-trans-EP-COOEt 0.91 3.61 
Cbz-Phe-ALeu-trans-EP-CH2 CH2Ph 0.7 NI 
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TABLE I-continued 
Inhibition of Papain, Cathepsin B, and Calpain by Aza-peptide Epoxides. 
Inhibitor papain cathepsin B cal pain 
Cbz-Leu-AAbu-trans-EP-COOEt 4.94 1.98 
Cbz-Leu-AAbu-trans-EP-COOH 1.47 NI 0.57 
Cbz-Leu-AHph-cis-EP-COOEt 1.03 NI 1.09 
Cbz-Leu-AHph-(2S, 3S)-EP-COOEt 5.68 0.67 2.28 
Cbz-Leu-AHph-(2R, 3R)-EP-COOEt 2.16 NI 2.12 
Cbz-Leu-AHph-(2S, 3S)-EP-COOH 2.12 
Boc-Np2-ALeu-trans-EP-COOEt 3.9 0.39 
Suc-Np2-ALeu-trans-EP-COOEt 1.39 0.8 
Ac-Leu-AHph-trans-EP-COOEt 1.9 0.59 0.84 
Ac-Leu-ALeu-trans-EP-COOEt 2.09 8.0 1.48 
Cbz-Leu-Leu-ALeu-trans-EP-COOEt 34.77 NI 2.65 
Cbz-Leu-Leu-ALeu-(2S, 3S)-EP-COOEt 10.53 0.98 2.48 
Cbz-Leu-Leu-ALeu-(2R, 3R)-EP-COOEt 20.58 NI NI 
Cbz-Leu-Leu-ALeu-(2S, 3S)-EP-COOH 6.93 7.02 0.82 
Cbz-Leu-Phe-AGln-trans-EP-COOEt 0.9 1.3 
Cbz-Leu-Phe-AGln-(2S, 3S)-EP-COOEt 4.73 
Cbz-Leu-Phe-AGln-(2R, 3R)-EP-COOEt NI 
Cbz-Ala-Ala-AAsn-trans-EP-COOEt 0.9 1.27 
Cbz-Ala-Ala-AAsn-(2R, 3R)-EP-COOEt NI 
Cbz-Ala-Ala-AAsn-(2S, 3S)-EP-COOEt 4 
Cbz-Ala-Ala-AAsn-cis-EP-COOEt NI NI 
Cbz-Ala-Ala-AAsn-trans-EP-COOCH2 Ph 1.09 
Cbz-Ala-Ala-NHN(CH2 COOEt)-trans-EP-COOEt 8.17 2.53 
PhPr-Val-Ala-AAsp-trans-EP-COOCH2 Ph <10 <10 
PhPr-Val-Ala-AAsp-trans-EP-CH2CH2Ph NI NI 
PhPr-Val-Ala-AAsp-(2S, 3S)-EP-COOCH2Ph 0.81 
PhPr-Val-Ala-AAsp-(2R, 3R)-EP-COOCH2 Ph NI 
Cbz-Asp-Glu-Val-AAsp-(2S, 3S)-EP-COOEt NI NI 
Cbz-Asp-Glu-Val-AAsp-(2R, 3R)-EP-COOEt NI NI 
Cbz-Leu-Glu-Thr-AAsp-(2S, 3S)-EP-COOEt 0.47 NI 
Cbz-Leu-Glu-Thr-AAsp-(2R, 3R)-EP-COOEt 0.24 NI 
Cbz-Ile-Glu-Thr-AAsp-(2S, 3S)-EP-COOEt NI 
NI = no inhibition, 
EP ~ epoxide, 
PhPr ~ PhCH2 CH2CO-. 
The aza-peptide epoxide inhibitors are quite specific and 
do not react with serine proteases. Table II shows tests of a 
number of aza-peptide epoxide inhibitors with chymot-
rypsin. None of the aza-peptide epoxide derivatives inhib-
ited this serine protease. 
Table III shows the rate of inhibition of dipeptidyl pep-
40 tidase I (DPPI, cathepsin C) by aza-peptide epoxides. 
TABLE II 












NI = no inhibition, 
EP ~ epoxide. 
k
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Nva-AHph-trans-EP-CH2 CH2 Ph.TFA 
Nle-AHph-trans-EP-COOEt.TFA 
EP ~ epoxide. 
k
0







Table IV and V show the rates of inhibition of caspases 
aza-peptide epoxides. Several of the inhibitors are highly 
effective with inhibition rate constants in the range of 
300,000 to over 1 million M- 1s-1 . They also exhibit a high 
degree of selectivity for the target enzyme. They don't 
65 inhibit aspartyl protease, serine proteases such as granzyme 
B, which is also specific for a Pl Asp. 
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TABLE IV 
Inhibition of Caspases by Aza-peptide Epoxides. 
k M-1s-1 
inhibitor EP caspase-1 caspase-3 (1) 
22c Cbz-Val-AAsp-EP-COOEt s,s NA 3650 ± 570 (1) 
22n Cbz-Val-AAsp-EP-COOH s,s NA 1110 ± 340 
22a Cbz-Val-AAsp-EP-CH2 CH2Ph trans NA 310 ± 5 
22b Cbz-Val-AAsp-EP-Ph-4-Cl trans NA 145 ± 18 
23a PhPr-Val-Ala-AAsp-EP-CH2CH2Ph trans 300 ± 144 NA (1) 
23c PhPr-Val-Ala-AAsp-EP-COOEt s,s 32200 ± 14560 1040 ± 80 
R,R 6290 ± 1524 NI 
23d PhPr-Val-Ala-AAsp-EP-COOCH2 Ph trans 18070 ± 2625 680 ± 140 (1) 
s,s 52140 ± 5295 1470 ± 40 (1) 
R,R 1860 ± 302 NI 
23e PhPr-Val-Ala-AAsp-EP-COOCH2 CH2 Ph s,s 56640 ± 9322 2110 ± 50 (1) 
23f PhPr-Val-Ala-AAsp-EP-CONHCH2 CH 3 s,s 1910 ± 370 (1) 
23g PhPr-Val-Ala-AAsp-EP-CONHCH2 Ph s,s 65900 ± 9153 1610 ± 5 (1) 
R,R 1630 ± 522 NI 
23h PhPr-Val-Ala-AAsp-EP-CONHCH2 CH2 Ph s,s 17150 ± 2254 1110 ± 100 (1) 
R,R 950 ± 51 NI 
23i PhPr-Val-Ala-AAsp-EP-CONHCH2 CH(OH)Ph s,s 12260 ± 19 510 ± 100 
R,R 400 ± 19 NI 
23j PhPr-Val-Ala-AAsp-EP-CO-Ala-NHCH2Ph s,s 13400 260 ± 25 
R,R 268± 75 NI 
23k PhPr-Val-Ala-AAsp-EP-CO-Leu-NH2 s,s 26090±2562 420 ± 6 
231 PhPr-Val-Ala-AAsp-EP-CO-Phe-NH2 s,s 32740±9937 625 ± 160 
R,R 330 NI 
23m PhPr-Val-Ala-AAsp-EP-CO-Tyr-NH2 s,s 3245 ± 2330 87 ± 4 
24c Cbz-Glu-Val-AAsp-EP-COOEt s,s 58500 50500 ± 2075 41 
241 Cbz-Glu-Val-AAsp-EP-CO-Phe-NH2 R,R 1040 ± 455 470 ± 77 
24h Cbz-Glu-Val-AAsp-EP-CONHCH2CH2Ph s,s 41070 ± 440 27330 ± 5430 31 
25c Cbz-Asp-Glu-Val-AAsp-EP-COOEt s,s 11840 ± 1214 1074440 ± 154710 54 
R,R 4320 ± 830 464420 ± 186300 4 
251 Cbz-Asp-Glu-Val-AAsp-EP-CO-Phe-NH2 s,s 9250 ± 2835 722180 ± 340860 61 
25g Cbz-Asp-Glu-Val-AAsp-EP-CONHCH2 Ph s,s 25420 ± 4013 1097820 ± 94860 60 
25d Cbz-Asp-Glu-Val-AAsp-EP-COOCH2 Ph s,s 54690 ± 15913 1915200 ± 209200 127 
26c Cbz-Leu-Glu-Thr-AAsp-EP-COOEt s,s 25730 3210 ± 315 86 
R,R 19570 3250 ± 160 43 
26d Cbz-Leu-Glu-Thr-AAsp-EP-COOCH2Ph s,s 43500 ± 2150 3520 ± 600 102 
26h Cbz-Leu-Glu-Thr-AAsp-EP-CONHCH2CH2 Ph s,s NA 2550 ± 25 100 
26j Cbz-Leu-Glu-Thr-AAsp-EP-CO-Ala-NHCH2Ph s,s NA 1280 ± 77 66 
27c Cbz-Ile-Glu-Thr-AAsp-EP-COOEt s,s 12372 4080 ± 360 4577 
R,R 13260±3684 2630 ± 365 340 
27d Cbz-Ile-Glu-Thr-AAsp-EP-COOCH2Ph s, s 45788 9545 ± 960 862 
R,R 13000±980 3115 ± 125 454 
27g Cbz-Ile-Glu-Thr-AAsp-EP-CONHCH2Ph R,R 18140±4085 6475 ± 240 601 
27j Cbz-Ile-Glu-Thr-AAsp-EP-CO-Ala-NHCH2 Ph s,s NA 3050 382 
PhPr ~ Ph-CHr-'=Hr-'=0-, 
NI = no inhibition, 
EP ~ epoxide, 
AAsp = aza-Asp, 
Cbz ~ Ph-CH2---{:0-. 
TABLE V 
Inhibition of Caspases by Aza-peptide Epoxides with Disubstituted Amides. 
inhibitor EP caspase-1 caspase-3 caspase-6 
10-129 PhPr-Val-Ala-AAsp-EP-CON(CH2 CH2 CH2CH3h s, s 26150 ± 5460 520 ± 10 53 ± 9 
10-127 PhPr-Val-Ala-AAsp-EP-CON(CH2 Phh s, s 101140 ± 9547 830 ± 40 145 ± 1 
11-4 Cbz-Leu-Glu-Thr-AAsp-EP-CON(CH2 Phh s, s NA 2750 ± 205 13840 ± 270 
11-11 Cbz-Ile-Glu-Thr-AAsp-EP-CON(CH2Phh s, s NA 3550 32000 ± 1680 
11-16 Cbz-Leu-Glu-Thr-AAsp-EP-CON(CH3)CH2Ph s, s NA 2640 ± 100 9680 ± 875 
11-17 PhPr-Val-Ala-AAsp-EP-CON(CH3)CH2Ph s, s NA 1950 ± 150 136 
11-18 Cbz-Ile-Glu-Thr-AAsp-EP-CON(CH 3)CH2 Ph s, s NA 4780 47730 ± 420 
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TABLE VI 
Inhibition of Legumain by Aza-peptide Epoxides. 
inhibitor R3 




12b COOCH2 Ph 
COOCH2 Ph 
12c COOCH2 CH2 Ph 
12d CONHCH2 Ph 


























53 ± 25 
788 ± 88 





68 ± 4 
63 ± 11 
70 ± 14 
90 ± 0 
Legumain is inhibited by a variety of AAsn derivatives 
which are either not inhibitors for-caspases or very poor. 
Both Schistosome and pig kidney legumain are inhibited. 
Overall, the aza-peptide epoxide inhibitors have worked 
with every cysteine protease we have tested. The rates are 
higher with cysteine proteases that belong to clan CD 
compared to clan CA. 
3. Inhibition Mechanism 
The active site of cysteine proteases contains a cysteine 
and a histidine residue. The proposed mechanism involves 
the attack of the active site cysteine residue on the epoxide 
functional group to form a covalent adduct. An example of 
a caspase inhibitor is shown in the following figure. The 
enzyme recognizes the Pl AAsp residue and inhibition 
occurs. Additional interactions would occur between the 
extended substrate binding site of the cysteine protease and 
the inhibitor which would increase the binding affinity and 
specificity of the inhibitors. 
The peptide and amino acid aza-peptide epoxide deriva-
tives, as shown above, bind to the enzymes using many of 
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the interactions that are found in complexes of a particular 
enzyme with its substrates and/or inhibitors. Additional 
interactions with the enzyme can be obtained by tailoring the 
R3 group of the inhibitor to imitate the amino acid residues 
which are preferred by an individual protease at the Sl' and 
S2 subsites. For example, aza-peptide epoxides with R3 
phenylalkyl groups would interact effectively with caspase-
1, which is shown to prefer such structures in alpha-
ketoamide peptide inhibitors. Likewise, the M1 group can 
10 interact with the S subsites of the target cysteine protease. 
Once a good inhibitor structure for a particular enzyme is 
found, it is then possible to change other characteristics such 
as solubility or hydrophobicity by adding substituents to the 
M1 or R1 and R2 groups. 
15 The following structures are inhibitors for the listed 
enzymes. The inhibitor sequences were obtained from pep-










3o Cbz-Phe-Leu-Leu-AMet(02 )-EP-COOH 
Ph-CH2-SOrAAsp-EP-COOCH2Ph 
Ph-CH2CHFCO-Val-Ala-AAsp-EP-COOCH2 Ph 
4-Cl-PhCH2CH2 CO-Val-Ala-AAsp-EP-COOCH2 Ph 
4-NOr PhCH2 CH2 CO-Val-Ala-AAsp-EP-COOCH2 Ph 
35 4-CH30-PhCH2CH2CO-Val-Ala-AAsp-EP-COOCH2Ph 
3-F-PhCH2 CH2 CO-Val-Ala-AAsp-EP-COOCH2Ph 
3,4-dichloro-PhCH2CH2CO-Val-Ala-AAsp-EP-COOCH2Ph 



















PhCH2 CH2CO-Val-Ala-AAsp-EP-COO(CH2 )o-2-naphthyl 
Cbz-Leu-Glu-Thr-AAsp-EP-COO(CH2)oC6H4 -p-N02 
Cbz-Ala-Ala-AAsn-EP-COO(CH2)oC6H4 -p-CN 

























































To use the above inhibitors in vitro, they are dissolved in 
65 an organic solvent such as dimethylsulfoxide or ethanol, and 
are added to an aqueous solution containing serine and/or 
cysteine proteases. The final concentration of the organic 
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solvent should be less than 25%. The inhibitors may also be 
added as solids or in suspension. The cysteine protease 
inhibitors of this invention would be useful in a variety of 
experimental procedures where proteolysis is a significant 
problem. Inclusion of these inhibitors in radioimmunoassay 
experiments would result in higher sensitivity. The use of 
these inhibitors in plasma fractionation procedures would 
result in higher yields of valuable plasma proteins and would 
make purification of the proteins easier. The inhibitors 
disclosed here could be used in cloning experiments utiliz- 10 
ing bacterial cultures, yeast, and human cells to produce a 
purified cloned product in higher yield. 
The novel compounds ofthis invention are effective in the 
prevention of unnecessary proteolysis caused by cysteine 
proteases in the process of purification, transport and storage 15 
of peptides and proteins as shown in Table I-VI by effective 
inhibition of many cysteine proteases. 
Diagnostic Reagents 
40 
diseases such as dentatorubropallidoluysian atrophy 
(DRPLA), spinocerebellar atrophy type 3 (SCA-3), and 
spinal bulbar muscular atrophy (SBMA). 
Effector caspases cleave Alzheimer's gene products, pre-
senilins 1 and 2 proteins. Recently, it has been shown that 
caspase-6 is involved in human neuronal cell apoptosis, 
amyloidogenesis, and Alzheimer's disease. Amyloid ~pep­
tide (A~), which builds up in the brains of people with 
Alzheimer's disease, causes cultured neurons to die by 
apoptosis. Thus effective caspase-6 aza-peptide epoxide 
inhibitors (Table IV and V) can be used for the treatment of 
Alzheimer's disease. 
In models related to Parkinson disease, peptide caspase 
inhibitors protect against l-methyl-4-phenylpyridinium 
(MPP+)-induced apoptosis of cultured cerebellar granular 
neurons and increase the rate of survival. Also, in mice 
overexpressing Bcl-2, dopaminergic l-methyl-4-phenyl-1,2, 
3,6-tetrahydropyridine (MPTP) caspase activity is blocked, 
20 toxicity is decreased, and substantial nigra neurons survive. 
Aza-peptide epoxides of the present invention can be used 
for the identification of proteases, for example novel cys-
teine proteases. One embodiment provides a method for 
screening a sample for the presence of a protease, particu-
larly a cysteine protease, by contacting the sample with an 
aza-peptide epoxide, for example an aza-peptide epoxide of 
25 
Formula I, and detecting the presence of the the aza-peptide 
epoxide-protease conjugate. Detection of the conjugate may 
be accomplished using known techniques. For example, 
aza-peptide epoxides of the present invention can be modi-
fied with a detectable label including but not limited to a 
30 
radioisotope, fluorescent marker, biotin, antibody, enzyme 
conjugate such as horseradish peroxidase, or the like. The 
aza-peptide conjugates can be fixed to a support, for 
example using known chemical fixatives, and a sample can 
then by added to the aza-peptide epoxide. Such support can 
35 
be microarrays or the like. The fixed aza-peptide epodixe 
can then irreverisible or reverisibly bind a protease, for 
example a cysteine protease, in the sample. The support can 
be washed to remove excess sample. The aza-peptide 
epoxide-protease conjugate can then be eluted from the 
40 
support and the protease can be detected or identified using 
conventional techniques. The support can be any durable 
substance including but not limited to metal, plastic, glass, 
quartz or the like. The aza-peptide epoxides can be linked to 
the support with a linker, for example a cleavable linker to 
45 
facilliate the removal of aza-peptide epoxide-protease con-
jugates. 
5. In Vivo Uses 
Thus, effective caspase aza-peptide epoxide inhibitors 
(Table IV) can be used for the treatment of Parkinson's 
disease. 
Neuronal apoptosis is also seen after acute injuries such as 
stroke, trauma, and ischemia. Apoptosis has been observed 
in striatal and cortical neurons in animal models of stroke. 
Transgenic mice, expressing a caspase-1 inhibitor, are pro-
tected from ischemic damage after middle cerebral artery 
occlusion. During ischemia, activated caspases dismantle 
the cell by cleaving multiple substrates such as the enzymes 
essential for cell repair and cytoskeletal proteins. Therefore, 
caspase activation develops in models of global ischemia 
and may accompany the ischemic component of head injury. 
The effect of irreversible inhibitors (Z-VAD-FMK, 
Z-DEVD-FMK, and YVAD-CMK) on ischemia-induced 
tissue shows that caspase-1 and caspase-3 are involved in 
the mechanism of cell death in ischemic and excitotoxic 
brain injury. Caspases are recognized as novel therapeutic 
targets for central nervous diseases in which cell death 
occurs mainly by the mechanism of apoptosis. Thus effec-
tive caspase aza-peptide epoxide inhibitors (Table IV and V) 
can be used for the treatment of many diseases involving 
apoptosis. 
Legumain is involved in Schistosomiasis (blood flukes) 
and in immune disorders. Thus, legumain inhibitors can be 
used to treat Schistosomiasis and many immunological 
problems. Gingipain is involved in periodontal disease and 
thus gingipain inhibitors can be use to treat periodontal 
50 disease. Clostripain inhibitors should be useful as antibac-
terial agents. Separin inhibitors can be use to treat disease 
which involve cell mitosis. 
Effective inhibitors of the proteolytic function of caspases 
(Table IV and V) can be used to treat a variety of diseases. 
Excessive cell death can result from acquired or genetic 
conditions which increase the accumulation of signals that 
induce apoptosis or that diminish the threshold at which 
such events induce apoptosis. Excessive apoptosis has been 
associated with a variety of disease states including neuro- 55 
degenerative disorders, ischemic injuries, acquired immu-
nodeficiency syndrome (AIDS), and osteoporosis. Apoptosis 
is involved in amyotrophic lateral sclerosis (ALS), Hunting-
ton's disease, Alzheimer's disease, Parkinson's disease, and 
spinal muscular atrophy. In multiple sclerosis (MS), the 60 
death of the oligodendrocytes is an important example of the 
glial degeneration through apoptosis. 
Huntingtin, the first protein identified as a caspase sub-
strate that is specifically involved in a neurodegenerative 
disease, is a substrate for proteolytic cleavage by caspase-3. 65 
Thus, aza-peptide epoxides would be useful for the treat-
ment of Huntington's disease and other neurodegenerative 
Aza-peptide epoxides can be used to control protein 
turnover, muscular dystrophy, myocardial tissue damage, 
tumor metastasis, and bone resorption as shown in Table I by 
effective inhibition of lysosomal cathepsin B in buffer. 
Peptide aza-peptide epoxides can also be used as neuropro-
tectants or for the treatment of ischemia, stroke, or Alzhe-
imer's disease as shown in Table I by effective inhibition of 
calpain I and calpain II. 
6. Drug Delivery 
This invention also provides a pharmaceutical composi-
tion which comprises a compound according to Formula I 
and a pharmaceutically accepted carrier, dilutent or excipi-
ent. Accordingly, the compounds of Formula I may be used 
in the manufacture of a medicament. For therapeutic use, the 
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peptide aza-peptide epoxides may be administered orally, 
topically, or parenterally. The term parenteral, as used, 
includes subcutaneous injection, intravenous, intramuscular, 
intrastemal injection, or infusion techniques. The dosage 
depends primarily on the specific formulation and on the 5 
object of the therapy or prophylaxis. The amount of the 
individual doses as well as the administration is best deter-
mined by individually assessing each case. 
42 
Example 2 
Pentafluorophenol Coupling Method. (2R,3R)-3-(N2-(N-
Benzy loxycarbony lleucy 1-t-butoxyglutamylthreony 1)-N 1 -t-
butoxycarbonylmethylhydrazinocarbony l)oxirane-2-car-
boxylic Acid Ethyl Ester (Cbz-Leu-Glu(O-tBu)-Thr-AAsp 
(O-tBu)-(2R,3R)-EP-COOEt). Coupling of Cbz-Leu-Glu 
(O-tBu)-Thr-NH-NH-CH2COO-tBu with 5 (Y=COOEt) 
The pharmaceutical compositions containing the active 
ingredient may be in a form suitable for oral use, for 
example, as tablets, troches, lozenges, aqueous or oily 
suspensions, dispersible powders or granules, emulsions, 
hard or soft capsules, syrups, or elixirs. Dosage levels of the 
order of 0.2 mg to 140 mg per kilogram of body weight per 
day are useful in the treatment of the above-indicated 
conditions ( 10 mg to 7 gms per patient per day). The amount 
10 
was accomplished using the pentafluorophenol method. The 
epoxide 5 (1 eq, Y=COOEt) in DMF was reacted with 
pentafluorophenol (1 eq) and DCC (1 eq) in DMF at 0° C. 
The reaction was allowed to reach room temperature and 
then was stirred for 24 hours. Dicyclohexylurea was 
15 removed by filtration and the filtrate was evaporated to 
dryness under reduced pressure. The peptide Cbz-Leu-Glu 
(O-tBu)-Thr-NH-NH-CH2COO-tBu (1 eq) in DMF was 
added to the residue and the reaction was allowed to stir at of active ingredient that may be combined with carrier 
materials to produce a single dosage form will vary depend-
ing upon the host treated and the particular mode of admin- 20 
istration. 
For injection, the therapeutic amount of the peptide aza-
peptide epoxides or their pharmaceutically acceptable salts 
will normally be in the dosage range from 0.2 to 140 mg/kg 
of body weight. Administration is made by intravenous, 25 
intramuscular, or subcutaneous injection. Accordingly, phar-
maceutical compositions for parenteral administration will 
contain from about 10 mg to 7 gms of the compounds per 
dose. In addition to the active ingredient, these pharmaceu-
tical compositions will usually contain a buffer, e.g. a 30 
phosphate buffer which keeps the pH in the range from 3.5 
to 7 and sodium chloride, mannitol, or sorbitol for adjusting 
the isotonic pressure. 
A composition for topical application can be formulated 
as an aqueous solution, lotion, jelly or an oily solution or 35 
suspension. A composition in the form of an aqueous solu-
tion is obtained by dissolving the compounds of this inven-
tion in aqueous buffer solution of pH 4 to 6.5 and, if desired, 
adding a polymeric binder. An oily formulation for topical 
application is obtained by suspending the compounds ofthis 40 
invention in an oil, optionally with the addition of a swelling 
agent such as aluminium stearate and/or a surfactant. 
EXAMPLES 
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room temperature for 24 hours. The solvent was evaporated 
and the product was purified by chromatography using two 
silica gels colunms, the first colunm with 1 :9 MeOH:CH2Cl2 
as the eluent, followed by another column with 2:1 EtOAc: 
hexane as the eluent; white solid, yield 16%. MS and 1H 
NMR (CDC13 ) were consistent with the proposed structure. 
Example 3 
Mixed Anhydride Coupling Method. Coupling of bulky 
peptides, such as Z-Asp(O-tBu)-Glu(O-tBu)-Val-NH-
NH2--COO-tBu and Cbz-Leu-Glu(O-tBu)-Thr-NH-
NH--CH2COO-tBu, with 5 (Y=COOEt), was accomplished 
using the mixed anhydride method. To a solution of 5 (5 eq) 
in DMF at 0° C. was added N-methylmorpholine (NMM, 5 
eq) followed isobutyl chloroformate (IBCF, 5 eq). After the 
reaction mixture was allowed to stir for 30 min, the substi-
tuted hydrazide (1 eq) dissolved in DMF was added to the 
mixture. After 10 min the ice bath was removed and the 
reaction was stirred for 16 hr at room temperature. The D MF 
was evaporated and the residue was washed and purified 
using the same procedure as described above for the EDC/ 
HOBT coupling. MS and 1H NMR (DMSO-d6 or CDC13 ) 
were consistent with the proposed structures. Examples 
3A-3C were prepared using this mixed anhydride method. 
Example 3A 
The following detailed examples are given to illustrate the 
invention and are not intended to limit it in any manner. 
Example 1 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-AAsp(O-tBu)-(2S,3S)-
EP-COOEt was purified using column chromatography on 
50 silica gel using 2:18:5 MeOH:CH2Cl2:EtOAc as the eluent; 
white solid, yield 58%. 
EDC/HOBt Coupling Method. trans-3-(N2-(N-3-Phenyl-
propanoylvalylalany 1)-N 1 -t-butoxycarbonylmethylhydrazi-
nocarbony l)oxirane-2-carboxylic Acid Benzyl Ester (PhPr-
Val-Ala-AAsp(O-tBu)-trans-EP-COOCH2Ph). To a stirred 55 
solution of monobenzyl epoxysuccinate 5 (Y=COOBzl), 
HOBt, and PhPr-Val-Ala-NH-NH--CH2COO-tBu in 
DMF, was added EDC. The mixture was allowed to react for 
16 hat room temperature. The DMF was evaporated, and the 
residue was treated with EtOAc (20 mL). The organic layer 60 
was washed with 2% citric acid (2x20 mL), saturated 
NaHC0
3 
(2x20mL), H20 (10 mL), saturated NaCl (10 mL), 
dried over MgS04 , and concentrated. Chromatography on 
silica gel colunm using 1:19 MeOH:CH2Cl2 as eluent 
afforded PhPr-Val-Ala-AAsp(O-tBu)-trans-EP-COOCH2Ph 65 
as white solid, yield=36%. MS and 1 H NMR (CDC13 ) was 
consistent with the proposed structures. 
Example 3B 
Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-AAsp(O-tBu)-(2R, 
3R)-EP-COOEt was purified using column chromatography 
on silica gel using 2:18:5 MeOH:CH2Cl2:EtOAc as the 
eluent; white solid, yield 57%. 
Example 3C 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-(2S,3S)-EP-
COOEt was purified by chromatography on two successive 
columns, using 1:13 MeOH:CH2Cl2 as the eluent, followed 
by colunm chromatography using 2:1 EtOAc:hexane as the 
eluent; white solid, yield 44%. 




obtained using the EDC/HOBt coupling method, purified by 
colunm chromatography on silica gel with 19:1 CH2 Cl2 : 
44 
eluent; white solid, yield 41%. 1H NMR (Acetone-d6 ): 0.91 
(t, 6H, Leu CH3), 1.16 (m, 3H, Thr CH3), 1.30 (m, 2H, Leu 
CH2), l.4S (s, 18H, tBu), l.6S (m, lH, Leu CH), l.9S and 
2.lS (d ofm, 2H, Glu CH2 ), 2.40 (m, 2H, Glu CH2), 2.87 (d, 
5 2H,AAsp CH2 ), 3.80 (d, 2H, epoxy), 4.2S-4.4S (m, 4H, a-H 
and Thr CH), 4.66 (m, 4H, CH2Ph), S.10 (q, 2H, Z), 6.80 (d, 
lH, NH), 7.20--7.40 (m, !SH, Ph), 7.4S (d, lH, NH), 7.78 (d, 
lH, NH), 9.70 (s, lH, NH). 
MeOH as the eluent, and then rechromatographed using 
S0:4S:S CH2 Cl2 :EtOAc:MeOH as the eluent; white solid, 
yield 38%. 1H NMR (CDC13): 0.8S and 0.9S (m, 12H, Val 
and n-butyl CH3), l .3S (m, 7H, Ala CH3 and CH2 ), l .4S (s, 
9H, tBu), 1.60 (m, 4H, CH2), 2.00 (m, lH, Val CH), 2.SS (m, 10 
2H, PhCH2), 2.9S (m, 2H, PhCH2CH2 ), 3.20 (s, 2H, AAsp 
CH2 COOH), 3.3S (m, 4H, CH2N), 3.80 (d, 2H, epoxy), 4.20 
(m, 2H, a-H), 6.20 (s, lH, NH), 7.10-7.2S (m, SH, Ph), 7.60 
Example 31 
Cbz-Ile-Glu(O-tBu )-Thr-AAsp(O-tBu )-(2S,3S)-EP-
CO-N(CH3)Bzl was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica (b, lH, NH), 9.2S (b, lH, NH). 
Example 3E 
PhPr-Val-Ala-AAsp(O-tBu)-(2S,3S)-EP-CON(CH3)Bzl 
15 gel with 19: 1 CH2Cl2 :MeOH as the eluent, and then rechro-
matographed using S0:3S:10:S CH2 Cl2 :EtOAc:THF:MeOH 
as the eluent; white solid, yield 42%. 1H NMR (CDC13): 
0.92 (t, 6H, Ile CH3), 1.16 (m, SH, Thr CH3 and Ile CH2), 
l.4S (m, 19H, tBu and Ile CH), 1.90 and 2.10 (d ofm, 2H, was obtained using the EDC/HOBt coupling method, puri-
fied by colunm chromatography on silica gel with 19: 1 
CH2 Cl2 :MeOH as the eluent, and then rechromatographed 
using S0:4S:S CH2 Cl2 :EtOAc:MeOH as the eluent; white 
solid, yield 39%. 1 H NMR (CDC13): 0.86 (m, 6H, Val CH3), 
1.30 (m, 3H, Ala CH3), l .4S (s, 9H, tBu), 2.00 (m, lH, Val 
CH), 2.SS (m, 2H, PhCH2 ), 2.94 (m, 3.SH, PhCH2 CH2CO 25 
and CH3N), 3.10 (s, 1.5H, CH3N), 3.20 (s, 2H, AAsp 
CH2 COOH), 3.70 (d, 2H, epoxy), 4.18 (m, 2H, a-H), 4.62 
(m, 2H, PhCH2N), 6.20 (b, lH, NH), 7.10--7.3S (m, !OH, 
Ph), 7.60 (b, lH, NH), 9.40 (b, lH, NH). 
20 Glu CH2), 2.4S (m, 2H, Glu CH2), 3.00 (m, 3H, NCH3), 3.22 
(s, 2H, AAsp CH2), 3.76 (s, 2H, epoxy), 4.20 (m, 3H, a-H), 
4.40 (d, lH, Thr CH), 4.SO (m, 2H, CH2 Ph), S.11 (q, 2H, Z), 




CO-N(Bzl)2 was obtained using the EDC/HOBt coupling 
Example 3F 
PhPr-Val-Ala-AAsp(O-tBu)-(2S,3S)-EP-CON(Bzl)2 was 
obtained using the EDC/HOBt coupling method, purified by 
colunm chromatography on silica gel with 19:1 CH2 Cl2 : 
MeOH as the eluent, and then rechromatographed using 
S0:3S:10:S CH2Cl2 :EtOAc:THF:MeOH as the eluent; white 
solid, yield 40%. 1H NMR (CDC13): 0.84 (m, 6H, Val CH3), 
1.33 (m, 3H, Ala CH3), 1.46 (s, 9H, tBu), 2.00 (m, lH, Val 
CH), 2.SS (m, 2H, PhCH2 ), 2.93 (m, 2H, PhCH2 CH2CO), 
3.20 (m, 2H, AAsp CH2 COOH), 3.80 (s, 2H, epoxy), 4.20 
(m, 2H, a-H), 4.62 (m, 4H, PhCH2N), 6.20 (b, lH, NH), 
7.10-7.40 (m, !SH, Ph), 7.4S (b, lH, NH), 9.20 (s, lH, NH). 
Example 3G 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-(2S,3S)-EP-
CON(CH3)Bzl was obtained using the EDC/HOBt coupling 
method, purified by colunm chromatography on silica gel 
with 19:1 CH2Cl2 :MeOH as the eluent, and then rechro-
matographed using S0:3S:10:S CH2 Cl2 :EtOAc:THF:MeOH 
as the eluent; white solid, yield S3%. 1H NMR (CDC13): 
0.93 (t, 6H, Leu CH3), 1.18 (m, 3H, Thr CH3), 1.27 (m, 2H, 
Leu CH2 ), 1.46 (s, 18H, tBu), 1.8S (m, lH, Leu CH), 2.lS 
(m, 2H, Glu CH2), 2.4S (m, 2H, Glu CH2), 3.10 (m, 3H, 
NCH3), 3.20 (s, 2H, AAsp CH2), 3.76 (d, 2H, epoxy), 4.2S 
(m, 3H, a-H), 4.4S (m, lH, Thr CH), 4.70 (s, 2H, CH2 Ph), 
S.12 (q, 2H, Z), 7.10-7.40 (m, 12H, Ph and NH), 7.9S (b, 
lH, NH), 9.4S (b, lH, NH). 
Example 3H 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-(2S,3S)-EP-
CON(Bzl)2 was obtained using the EDC/HOBt coupling 
method, purified by colunm chromatography on silica gel 
with 19:1 CH2Cl2 :MeOH as the eluent, and then rechro-
matographed using S0:4S:S CH2 Cl2 :EtOAc:MeOH as the 
30 method, purified by colunm chromatography on silica gel 
with 19:1 CH2Cl2 :MeOH as the eluent, and then rechro-
matographed using S0:3S:10:S CH2 Cl2 :EtOAc:THF:MeOH 
as the eluent; white solid, yield 37%. 1H NMR (CDC13): 
0.90 and 1.00 (m, 6H,Ile CH3), 1.14 (d, 3H, Thr CH3), 1.19 
35 (m, 2H, Ile CH2), l .4S (m, 19H, tBu and Ile CH), 1.90 and 
2.10 (d ofm, 2H, Glu CH2 ), 2.4S (m, 2H, Glu CH2 ), 3.21 (s, 
2H,AAsp CH2 ), 3.80 (s, 2H, epoxy), 4.lS (b, lH, a-H), 4.30 
(m, 2H, a-H), 4.4S-4.60 (m, SH, Thr CH and CH2Ph), S.10 
(s, 2H, Z), 7.10--7.40 (m, 17H, Ph and NH), 7.8S (d, lH, 




obtained using the EDC/HOBt coupling method and purified 
by colunm chromatography on silica gel with 19:1 CH2 Cl2 : 
MeOH as the eluent, and then rechromatographed using 
S0:3S:10:S CH2Cl2 :EtOAc:THF:MeOH as the eluent; white 
50 solid, yield 31 %. 
1 H NMR (CDC13): 0.84 (m, 6H, Val CH3), 
1.34 (m, 6H, Ala CH3 and OEt), 1.44 (s, 9H, tBu), 2.00 (m, 
lH, Val CH), 2.S8 (m, 2H, PhCH2), 2.97 (t, 2H, 
PhCH2 CH2 CO), 3.6S (s, 2H, AAsp CH2), 3.62 and 3.91 (d, 
2H, epoxy), 4.23 (m, 4H, a-Hand OEt), 6.00 (d, lH, NH), 
55 6.60 (d, lH, NH), 7.16-7.30 (m, SH, Ph), 9.0S (s, lH, NH). 
Example 3L 
PhPr-Val-Ala-AAsp(O-tBu)-(2R,3R)-EP-COOEt was 
60 obtained using the EDC/HOBt coupling method and purified 
by colunm chromatography on silica gel with 19:1 CH2 Cl2 : 
MeOH as the eluent, and then rechromatographed using 
S0:3S:10:S CH2Cl2 :EtOAc:THF:MeOH as the eluent; white 
solid, yield 69%. 1H NMR (CDC13): 0.82 (m, 6H, Val CH3), 
65 1.30 (t, 3H, OEt), 1.37 (d, 2H, Ala CH3), 1.46 (s, 9H, tBu), 
2.00 (m, lH, Val CH), 2.S8 (m, 2H, PhCH2), 2.97 (t, 2H, 
PhCH2 CH2 CO), 3.22 (s, 2H, AAsp CH2), 3.62 and 3.9S (d, 
US 7,056,947 B2 
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2H, epoxy), 4.23 (m, 4H, a-Hand OEt), 6.20 (d, lH, NH), 
6.70 (d, lH, NH), 7.16-7.27 (m, SH, Ph), 9.10 (s, lH, NH). 
Example 3M 
46 
fied by colunm chromatography on silica gel with 19:1 
CH2Cl2:MeOH as the eluent, and then rechromatographed 
using 50:35:10:5 CH2Cl2:EtOAc:THF:MeOH as the eluent; 
white solid, yield 49%. 1H NMR (CDC13 ): 0.82 (m, 6H, Val 
PhPr-Val-Ala-AAsp(O-tBu)-(2S,3S)-EP-COOCH2Ph 
5 CH3 ), 1.32 (m, 3H, Ala CH3 ), 1.45 (s, 9H, tBu), 2.00 (m, lH, 
Val CH), 2.53 (m, 2H, PhCH2), 2.93 (m, 2H, 
PhCH2CH2CO), 3.65 (d, 2H, AAsp CH2), 3.62 and 3.79 (d, 
2H, epoxy), 4.15 (m, 2H, a-H), 4.43 (m, 2H, PhCH2N), 6.35 
(b, lH, NH), 6.90 (b, lH, NH), 7.00 (b, lH, NH), 7.13-7.31 
was obtained using the EDC/HOBt coupling method, puri-
fied by colunm chromatography on silica gel with 19: 1 
CH2Cl2:MeOH as the eluent, and then rechromatographed 
using 50:35:10:5 CH2Cl2:EtOAc:THF:MeOH as the eluent; 
white solid, yield 56%. 1H NMR (CDC13 ): 0.82 (m, 6H, Val 
CH3 ), 1.26 (m, 3H, Ala CH3 ), 1.42 (s, 9H, tBu), 2.00 (m, lH, 
Val CH), 2.56 (m, 2H, PhCH2), 2.93 (m, 2H, 
PhCH2CH2CO), 3.67 (s, 2H, AAsp CH2), 3.75 and 3.94 (d, 
2H, epoxy), 4.20 and 4.35 (m, 2H, a-H), 5.19 (m, 2H, 15 
Benzyl), 6.20 (d, lH, NH), 6.75 (d, lH, NH), 7.15-7.37 (m, 
lOH, Ph), 9.25 (s, lH, NH). 
Example 3N 
PhPr-Val-Ala-AAsp(O-tBu)-(2R,3R)-EP-COOCH2Ph 
10 (m, lOH, Ph), 9.40 (s, lH, NH). 
Example 3R 
PhPr-Val-Ala-AAsp(O-tBu)-(2R,3R)-EP-CONHCH2Ph 
was obtained using the EDC/HOBt coupling method, puri-
fied by colunm chromatography on silica gel with 19:1 
CH2Cl2:MeOH as the eluent, and then rechromatographed 
using 50:35:10:5 CH2Cl2:EtOAc:THF:MeOH as the eluent; 
white solid, yield 48%. 1 H NMR (CDC13 ): 0.82 (m, 6H, Val 
20 CH3 ), 1.32 (m, 3H, Ala CH3 ), 1.46 (s, 9H, tBu), 2.00 (m, lH, 
Val CH), 2.57 (m, 2H, PhCH2), 2.95 (m, 2H, 
PhCH2CH2CO), 3.68 (d, 2H, AAsp CH2), 3.62 and 3.80 (d, 
2H, epoxy), 4.20 (m, 2H, a-H), 4.40 (m, 2H, PhCH2N), 6.20 
(b, lH, NH), 6.70 (b, lH, NH), 7.00 (b, lH, NH), 7.13-7.31 
was obtained using the EDC/HOBt coupling method, puri-
fied by colunm chromatography on silica gel with 19: 1 
CH2Cl2:MeOH as the eluent, and then rechromatographed 
using 50:35:10:5 CH2Cl2:EtOAc:THF:MeOH as the eluent; 
white solid, yield 48%. 1 H NMR (CDC13 ): 0.82 (m, 6H, Val 
CH3 ), 1.26 (m, 3H, Ala CH3 ), 1.42 (s, 9H, tBu), 2.00 (m, lH, 
Val CH), 2.56 (m, 2H, PhCH2), 2.95 (m, 2H, 
PhCH2CH2CO), 3.62 (s, 2H, AAsp CH2), 3.70 and 3.94 (d, 
2H, epoxy), 4.20 and 4.35 (m, 2H, a-H), 5.20 (m, 2H, 30 
Benzyl), 6.25 (d, lH, NH), 6.75 (d, lH, NH), 7.15-7.37 (m, 
lOH, Ph), 9.30 (s, lH, NH). 
25 (m, lOH, Ph), 9.20 (s, lH, NH). 
Example 3S 
PhPr-Val-Ala-AAsp(O-tBu )-(2S,3S)-EP-
CONHCH2CH2Ph was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel with 19: 1 CH2Cl2:MeOH as the eluent, and then rechro-
matographed using 50:35:10:5 CH2Cl2:EtOAc:THF:MeOH 
as the eluent; white solid, yield 47%. 1H NMR (CDC13 ): Example 30 
PhPr-Val-Ala-AAsp(O-tBu)-(2S,3S)-EP-
COOCH2CH2Ph was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel with 19: 1 CH2Cl2:MeOH as the eluent, and then rechro-
matographed using 50:35:10:5 CH2Cl2:EtOAc:THF:MeOH 
35 0.83 (m, 6H, Val CH3 ), 1.35 (m, 3H, Ala CH3 ), 1.43 (s, 9H, 
tBu), 2.05 (m, lH, Val CH), 2.56 (t, 2H, PhCH2), 2.78 (t, 2H, 
PhCH2CH2N), 2.95 (t, 2H, PhCH2CH2CO), 3.40 and 3.53 (d 
ofm, 2H,AAsp CH2), 3.53 and3.69 (d, 2H, epoxy), 4.20 (m, 
2H, a-H), 4.45 (m, 2H, NCH2CH2Ph), 6.30 (d, lH, NH), 
40 6.40 (t, lH, NH), 7.00(d, lH, NH), 7.13-7.31 (m, lOH, Ph), 
9.30 (s, lH, NH). as the eluent; white solid, yield 61 %. 1 H NMR (CDC13 ): 
0.83 (m, 6H, Val CH3 ), 1.34 (d, 3H, Ala CH3 ), 1.45 (s, 9H, 
tBu), 2.00 (m, lH, Val CH), 2.58 (m, 2H, PhCH2), 2.96 (m, 
4H, PhCH2CH2CO and PhCH2), 3.63 (s, 2H, AAsp CH2), 
3.75 and 3.90 (d, 2H, epoxy), 4.35 (m, 4H, a-Hand OCH2), 45 
6.20 (m, lH, NH), 7.85 (d, lH, NH), 7.12-7.30 (m, lOH, 
Ph), 9.20 (s, lH, NH). 
Example 3T 
PhPr-Val-Ala-AAsp(O-tBu)-(2R,3R)-EP-
CONHCH2CH2Ph was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel with 19: 1 CH2Cl2:MeOH as the eluent, and then rechro-
matographed using 50:35:10:5 CH2Cl2:EtOAc:THF:MeOH Example 3P 
PhPr-Val-Aia-AAsp(O-tBu)-(2S,3S)-EP-CONHCH2CH3 
was obtained using the EDC/HOBt coupling method, puri-
fied by colunm chromatography on silica gel with 19: 1 
CH2Cl2:MeOH as the eluent, and then rechromatographed 
using 50:35:10:5 CH2Cl2:EtOAc:THF:MeOH as the eluent; 
white solid, yield 62%. 1 H NMR (Acetone-d6 ): 0.88 (m, 6H, 
Val CH3 ), 1.10 (t, 3H, CH3 ), 1.35 (d, 3H, Ala CH3 ), 1.46 (s, 
9H, tBu), 2.00 (m, lH, Val CH), 2.61 (m, 2H, PhCH2), 2.82 
50 as the eluent; white solid, yield 41%. 1H NMR (CDC13 ): 
0.83 (m, 6H, Val CH3 ), 1.35 (m, 3H, Ala CH3 ), 1.43 (s, 9H, 
tBu), 2.05 (m, lH, Val CH), 2.56 (t, 2H, PhCH2), 2.78 (t, 2H, 
PhCH2CH2N), 2.95 (t, 2H, PhCH2CH2CO), 3.48 and 3.70 (d 
ofm, 2H,AAsp CH2), 3.53 and3.65 (d, 2H, epoxy), 4.17 (m, 
55 2H, a-H), 4.43 (m, 2H, NCH2CH2Ph), 6.30 (d, lH, NH), 
6.40 (t, lH, NH), 6.80 (d, lH, NH), 7.15-7.35 (m, lOH, Ph), 
9.20 (s, lH, NH). 
(s, 2H, AAsp CH2), 2.95 (t, 2H, PhCH2CH2CO), 3.25 (m, 
2H, CH2N), 3.41 (s, 2H, epoxy), 4.20 and 4.40 (m, 2H, 60 
a-H), 7.15 (b, lH, NH), 7.25 (m, 6H, Ph and NH), 7.40 (b, 
lH, NH), 7.60 (d, lH, NH). 
Example 3U 
PhPr-Val-Ala-AAsp(O-tBu)-(2S,3S)-EP-CONHCH2CH 
(OH)Ph was obtained using the EDC/HOBt coupling 
method, purified by colunm chromatography on silica gel 
with 19:1 CH2Cl2:MeOH as the eluent, and then rechro-Example 3Q 
PhPr-Val-Ala-AAsp(O-tBu)-(2S,3S)-EP-CONHCH2Ph 
was obtained using the EDC/HOBt coupling method, puri-
65 matographed using 50:35:10:5 CH2Cl2:EtOAc:THF:MeOH 
as the eluent; white solid, yield 33%. 1 H NMR (Acetone-d6): 
0.86 (m, 6H, Val CH3 ), 1.38 (m, 3H, Ala CH3 ), 1.46 (s, 9H, 
US 7,056,947 B2 
47 
tBu), 2.0S (m, lH, Val CH), 2.49 (m, 2H, PhCH2), 2.90,(m, 
4H, PhCH2 CH2 andAAsp CH2), 3.SS (d, 2H, epoxy), 3.4S 
and 3.60 (d of m, 2H, NCH2 ), 4.20 and 4.37 (m, 2H, a-H), 
4.8S (t lH, CH), 7.lS-7.40 (m, 12H, Ph and NH), 7.80 (b, 
lH, NH), 7 .90 (m, lH, NH). 
Example 3V 
PhPr-Val-Ala-AAsp(O-tBu)-(2R,3R)-EP-CONHCH2 CH 
(OH)Ph was obtained using the EDC/HOBt coupling 
method, purified by colunm chromatography on silica gel 
with 19:1 CH2Cl2 :MeOH as the eluent, and then rechro-
matographed using S0:3S:10:S CH2 Cl2 :EtOAc:THF:MeOH 
as the eluent; white solid, yield37%. 1H NMR (Acetone-d6): 
0.86 (m, 6H, Val CH3 ), 1.40 (m, 3H, Ala CH3 ), 1.46 (s, 9H, 
tBu), 2.0S (m, lH, Val CH), 2.4S (m, 2H, PhCH2 ), 2.90 (m, 
4H, PhCH2CH2 andAAsp CH2 ), 3.40 and 3.60 (d ofm, 2H, 
NCH2 ), 3.60 and 3.76 (d, 2H, epoxy), 4.20 and 4.3S (m, 2H, 
a-H), 4.80 (b, lH, CH), 7.00-7.40 (m, 12H, Ph and NH), 





was obtained using the EDC/HOBt coupling method, puri-
fied by colunm chromatography on silica gel with 19:1 
CH2Cl2 :MeOH as the eluent, and then rechromatographed 
using S0:3S:10:S CH2 Cl2 :EtOAc:THF:MeOH as the eluent; 
white solid, yield 64%. 1 H NMR (DMSO-d6 ): 0.86-0.96 (m, 
10 
12H, Val and Leu CH3 ), 1.37 (d, 3H, Ala CH3 ), l.4S (t, 9H, 
tBu), l.6S (m, 2H, Leu CH2), l.7S (m, lH, Leu CH), 2.0S 
(m, lH, Val CH), 2.60 (m, 2H, PhCH2 ), 2.88 (s, 2H, AAsp 
CH2), 2.90 (t, 2H, PhCH2CH2 CO), 3.SO (d, 2H, epoxy), 
4.20, 4.40 and 4.4S (m, 3H, a-H), 7.lS (d, lH, NH), 7.2S (s, 





was obtained using the EDC/HOBt coupling method, puri-
fied by colunm chromatography on silica gel with 19:1 
CH2Cl2 :MeOH as the eluent, and then rechromatographed 
25 
using S0:3S:10:S CH2 Cl2 :EtOAc:THF:MeOH as the eluent; 
white solid, yield 39%. 1 H NMR (Acetone-d6): 0.88 (m, 6H, 
Val CH3 ), 1.39 (d, 3H, Ala CH3 ), 1.46 (s, 9H, tBu), 2.0S (m, 
lH, Val CH), 2.60 (m, 2H, PhCH2 ), 2.83 (s, 2H,AAsp CH2), 
2.9S (m, 3H, Phe PhCH2 and PhCH2CH2 CO), 3.20 (m, lH, 
30 Phe PhCH2 ), 3.SO (d, 2H, epoxy), 4.20 and 4.3S (m, 2H, 
a-H), 4.6S (m, lH, Phe a-H), 7.lS-7.3S (m, llH, Ph and 
NH), 7.SO (s, lH, NH), 7.80 (d, lH, NH), 7.9S (d, lH, NH), 
8.lS (b, lH, NH), 9.80 (s, lH, NH). 
PhPr-Val-Ala-AAsp(O-tBu)-(2S,3S)-EP-CO-Ala-NHBzl 
was obtained using the EDC/HOBt coupling method, puri-
fied by colunm chromatography on silica gel with 19: 1 
CH2 Cl2 :MeOH as the eluent, and then rechromatographed 
using S0:3S:10:S CH2 Cl2 :EtOAc:THF:MeOH as the eluent; 
white solid, yield 41%. 1H NMR (Acetone-d6 ): 0.87 (m, 6H, 
Val CH3 ), 1.37 (m, 6H, Ala CH3 ), 1.46 (s, 9H, tBu), 2.0S (m, 
lH, Val CH), 2.63 (m, 2H, PhCH2 ), 2.87 (s, 2H, AAsp CH2), 
2.93 (t, 2H, PhCH2CH2 CO), 3.SS (s, 2H, epoxy), 4.lS and 
4.4S (m, 3H, a-H), 4.43 (d, 2H, PhCH2N), 7.lS (d, lH, NH), 
7.20-7.30 (m, !OH, Ph), 7.40 (d, lH, NH), 7.7S (s, lH, NH), 
8.00 (b, 2H, NH). 35 Example 3BB 
Example 3X 
PhPr-Val-Ala-AAsp(O-tBu)-(2R,3R)-EP-CO-Ala-NHBzl 
was obtained using the EDC/HOBt coupling method, puri-
fied by colunm chromatography on silica gel with 19: 1 
CH2 Cl2 :MeOH as the eluent, and then rechromatographed 
using S0:3S:10:S CH2 Cl2 :EtOAc:THF:MeOH as the eluent; 
white solid, yield SO%. 1 H NMR (Acetone-d6 ): 0.87 (m, 6H, 
Val CH3 ), 1.37 (m, 6H, Ala CH3 ), 1.46 (s, 9H, tBu), 2.0S (m, 
lH, Val CH), 2.60 (m, 2H, PhCH2 ), 2.87 (s, 2H, AAsp CH2), 
2.90 (t, 2H, PhCH2CH2 CO), 3.6S (s, 2H, epoxy), 4.2S (m, 
3H, a-H), 4.40 (d, 2H, PhCH2N), 7.lS (d, lH, NH), 




was obtained using the EDC/HOBt coupling method, puri-
fied by colunm chromatography on silica gel with 19: 1 
CH2 Cl2 :MeOH as the eluent, and then rechromatographed 
using S0:3S:10:S CH2 Cl2 :EtOAc:THF:MeOH as the eluent; 
white solid, yield 23%. 1 H NMR (DMSO-d6 ): 0.86-0.96 (m, 
12H, Val and Leu CH3 ), 1.37 (d, 3H, Ala CH3 ), 1.46 (t, 9H, 
tBu), l.6S (m, 2H, Leu CH2 ), l.7S (m, lH, Leu CH), 2.0S 
(m, lH, Val CH), 2.63 (m, 2H, PhCH2 ), 2.86 (s, 2H, AAsp 
CH2 ), 2.94 (t, 2H, PhCH2CH2 CO), 3.S7 (s, 2H, epoxy), 
4.19, 4.3S and 4.SO (m, 3H, a-H), 7.lS (d, lH, NH), 7.2S (s, 
SH, Ph), 7.3S (s, lH, NH), 7.4S (d, lH, NH), 7.80 (d, lH, 
NH), 8.lS (d, lH, NH), 9.7S (s, lH, NH). 
PhPr-Val-Ala-AAsp(O-tBu)-(2R,3R)-EP-CO-Phe-NH2 
was obtained using the EDC/HOBt coupling method, puri-
40 fied by colunm chromatography on silica gel with 19:1 
CH2Cl2 :MeOH as the eluent, and then rechromatographed 
using S0:3S:10:S CH2 Cl2 :EtOAc:THF:MeOH as the eluent; 
white solid, yield S6%. 1H NMR (Acetone-d6): 0.88 (m, 6H, 
Val CH3 ), 1.37 (d, 3H, Ala CH3 ), 1.46 (s, 9H, tBu), 2.0S (m, 
45 lH, Val CH), 2.S8 (m, 2H, PhCH2 ), 2.83 (s, 2H,AAsp CH2), 
2.93 (m, 2H, PhCH2CH2 CO), 3.00 and 3.40 (d ofm, 2H, Phe 
PhCH2 ), 3.4S (d, 2H, epoxy), 4.2S and 4.3S (m, 2H, a-H), 
4.6S (m, lH, Phe a-H), 7.lS-7.3S (m, llH, Ph and NH), 
7.40 (d, lH, NH), 7.SO (b, lH, NH), 8.00 (b, lH, NH), 8.60 




was obtained using the EDC/HOBt coupling method, puri-
fied by colunm chromatography on silica gel with 19:1 
CH2Cl2 :MeOH as the eluent, and then rechromatographed 
using S0:3S:10:S CH2 Cl2 :EtOAc:THF:MeOH as the eluent; 
60 white solid, yield SO%. 
1H NMR (Acetone-d6): 0.87 (m, 6H, 
Val CH3 ), l.3S (d, 3H, Ala CH3 ), l.4S (s, 9H, tBu), 2.0S (m, 
lH, Val CH), 2.60 (m, 2H, PhCH2 ), 2.88 (s, 2H,AAsp CH2), 
2.94 (m, 3H, Tyr PhCH2 and PhCH2 CH2CO), 3.10 (m, lH, 
Tyr PhCH2 ), 3.72 (d, 2H, epoxy), 4.30 and 4.SS (m, 3H, 
65 a-H), 6.SO (s, lH, NH), 6.7S (d, 2H, Ph), 7.lS (m, SH, Ph), 
7.20 (d, 2H, Ph), 7.30 (d, lH, NH), 7.SO (d, lH, NH), 7.80 
(d, lH, NH), 8.20 (d, 2H, NH). 






EP-CONHCH2Ph was obtained using the mixed anhydride 
Cbz-Val-AAsp(O-tBu)-(2S,3S)-EP-COOEt was obtained 
using the EDC/HOBt coupling method, and purified by 
colunm chromatography on silica gel with 1:20:4.2 MeOH: 
CH2Cl2:Et0Ac as the eluent; white solid, yield Sl %. MS 
(ESI) m/z S22.2 [(M+lt]. 1H NMR (CDC13): 0.9S-l.02 (m, 
6H, Val), 1.28 (t, 3H, OCH2CH3), 1.63 (s, 9H, tBu), 2.0S (m, 
lH, Val), 3.62 (s, lH, epoxy), 3.97 (d, 2H, NHCH2COOH), 
4.lS (t, lH, a-H), 4.2S (q, 2H, OCH2CH3), S.12 (m, 2H, 
Cbz), 7.3S (s, SH, Ph), 8.61 (s, lH, NH). 
5 coupling method and was purified using colunm chroma-
tography on silica gel using 1 :2 EtOAc:hexane as the eluent; 
white solid, yield 31%. MS (ESI) m/z 939.6 [(M+lt]. 1H 
NMR (CDC13): 0.97 (m, 6H, Val), 1.40 (m, 27H, tBu), 
1.9-2.3 (m, 3H, Val and Glu), 2.41 (m, 2H, Glu), 2.80-2.9S 
Example 3EE 
10 (m, 2H, Asp), 3.63 and 3.97 (d, 2H, epoxy), 4.0S-4.22 (m, 
4H, NCH2), 4.20-4.SS (m, 3H, a-H), 4.4S (m, 2H, 
NHCH2Ph), S.OS (m, 2H, Cbz), 7.20-7.40 (m, !OH, Ph), 
6.lS (m, lH, NH), 6.60 (lH, NH), 7.8S (m, 2H, NH). 
Cbz-Val-AAsp(O-tBu)-trans-EP-CH2CH2Ph was 
15 
obtained using the EDC/HOBt coupling method, and puri-
fied by colunm chromatography on silica gel with l:SO:Sl 
MeOH:CH2Cl2:EtOAc as the eluent; white solid, yield 48%. 
HRMS (FAB) Calcd. for C30H39N30 7 : SS3.27878. 
Observed m/z SS3.28663. 1 H NMR (CDC13): 0.90-1.04 ( d, 
20 
6H, Val), 1.46 (s, 9H, tBu), 1.78-1.96 ( d, 2H, CH2CH2Ph), 
2.00-2.14 (m, lH, Val), 2.66-2.87 (m, 2H, CH2CH2Ph), 
3.16 (t, lH, epoxy), 3.S3 (s, lH, NHCH2COOH), 3.8S (t, 
lH, a-H), 4.81 (d, lH, NH), 4.99-S.20 (m, 2H, Cbz), 
7.13-7.37 (m, !OH, Ph), 8.2S (s, lH, NH). 25 
Example 3FF 
Cbz-Val-AAsp(O-tBu)-trans-EP-Ph-4-Cl was obtained 
30 
using the EDC/HOBt coupling method, and purified by 
colunm chromatography on silica gel with 1:100:100 
MeOH:CH2Cl2:EtOAc as the eluent; white solid, yield Sl %. 
MS (ESI) m/z S60.4 [(M+ 1ri. 1H NMR (DMSO-d6): 
0.64--0.92 (d, 6H, Val), 1.20 (s, 9H, tBu), 1.84 (m, lH, Val), 
35 
3.68 (m, lH, NHCH2COOH), 3.7S (s, lH, epoxy), 4.0S (d, 
lH, a-H), 4.80-S.09 (s, 2H, Cbz), 7.18-7.46 (m, 9H, Ph), 
11.02 (m, lH, NH). 
Example 3JJ 
Cbz-Glu(O-tBu)-Val-AAsp(O-tBu)-(2S,3S)-EP-COOEt 
was obtained using the mixed anhydride coupling method 
and was purified using colunm chromatography on silica gel 
with 1 :2 EtOAc:hexane as the eluent, and recrystallized 
from EtOAc/hexane; white solid, yield 44%. MS (ESI) m/z 
706.1 [(M+ltJ. 1H NMR (DMSO-d6): 0.90 (m, 6H, Val), 
1.20 (t, 3H, OCH2CH3), 1.40 (m, 18H, tBu), 1.60-2.00 (m, 
3H, Val and Glu), 2.21 (m, 2H, Glu), 3.SO and 3.98 (d, 2H, 
epoxy), 4.00-4.20 (m, 4H, NCH2 and OCH2CH3), 
4.20--4.40 (m, 2H, a-H), S.OS (m, 2H, Cbz), 7.20--7.40 (m, 
SH, Ph), 8.00 (m, 2H, NH). 
Example 3KK 
Cbz-Glu(O-tBu)-Val-AAsp(O-tBu)-(2R,3R)-EP-COOEt 
was obtained using the mixed anhydride coupling method 
and was purified using colunm chromatography on silica gel 
with 7:13:1:19 hexane:EtOAc:MeOH:CH2Cl2 as the eluent, 
and thenrechromatographed using 3:1 EtOAc:hexane as the 
eluent; white solid, yield 3S%. MS (ESI) m/z 706.1 [(M+ 
1ri. 1H NMR (CDCl3): 0.94 (m, 6H, Val), 1.21 (t, 3H, 
OCH2CH3), 1.43 (m, 18H, tBu), 1.60-2.00 (m, 3H, Val and 
Glu), 2.21 (m, 2H, Glu), 3.60 and 3.98 (d, 2H, epoxy), 
Example 3GG 
40 4.00--4.20 (m, 4H, NCH2 and OCH2CH3), 4.20-4.40 (m, 
2H, a-H), S.10 (m, 2H, Cbz), 7.20-7.40 (m, SH, Ph), 8.00 
(m, 2H, NH). Cbz-Glu(O-tBu)-Val-AAsp(O-tBu)-(2S,3S)-EP-
CONHCH2CH2Ph was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel with 7:13:1:1 hexane:EtOAc:MeOH:CH2Cl2 as the elu- 45 
ent, and then rechromatographed using 3: 1 EtOAc:hexane as 
the eluent; white solid, yield 3S%. MS (ESI) m/z 782.4 
[(M+lt]. 1H NMR (CDC13): 0.9S (d, 6H, Val), 1.4S (s, 18H, 
tBu), 1.90-2.30 (m, 3H, Val and Glu), 2.4S (m, 2H, Glu), 
2.72 (t, 2H, NHCH2CH2Ph), 3.40 and 3.60 (m, 2H, 50 
NHCH2CH2Ph), 3.SO and 3.8 (d, 2H, epoxy), 4.10-4.30 (m, 
4H, NCH2 anda-H), S.10 (m, 2H, Cbz), 6.10 and 6.2S (m, 
2H, NH), 7.20--7.40 (m, SH, Ph), 9.00 (m, lH, NH). 
Example 3LL 
Cbz-Glu(O-tBu)-Val-AAsp(O-tBu)-(2R,3R)-EP-CO-
Phe-NH2 was obtained using the mixed anhydride coupling 
method and was purified by colunm chromatography on 
silica gel using 10:1:9 EtOAc:MeOH:CH2Cl2 as the eluent, 
and thenrechromatographed using 10:7:3:1 CH2Cl2:Et0Ac: 
THF:MeOH as the eluent; white solid, yield 32%. MS (ESI) 
m/z 82S.4 [(M+lt]. 1H NMR (CDC13): 0.94 (m, 6H, Val), 
1.43 (m, 18H, tBu), 1.60--2.00 (m, 3H, Val and Glu), 2.21 
(m, 2H, Glu), 2.80 and 2.9S (m, 2H, Phe), 3.SO and 3.98 (d, 
Example 3HH 55 2H, epoxy), 3.90-4.20 (m, 2H, NCH2), 4.00-4.40 (m, 3H, 
a-H), S.10 (m, 2H, Cbz), 7.0 (s, 2H, NH2), 7.20-7.40 (m, 
!OH, Ph), 8.00 (m, 2H, NH). Cbz-Asp(O-tBu)-Glu(O-tBu)-Val-AAsp(O-tBu)-(2S,3S)-
EP-COOCH2Ph was obtained using the mixed anhydride 
coupling method, and purified using colunm chromatogra-
phy on silica gel using S:1:19 EtOAc:MeOH:CH2Cl2 as the 60 
eluent; white solid, yield 23%. MS (ESI) m/z 940.S [(M+ 
1ri. 1H NMR (CDCl3): 0.8S (m, 6H, Val), l.3S (m, 27H, 
tBu), 1.80-2.24 (m, 3H, Val and Glu), 2.41 (m, 2H, Glu), 
2.6S-2.90 (m, 2H, Asp), 3.60 and 4.00 (d, 2H, epoxy), 
4.0S-4.12 (m, 2H, NCH2), 4.10-4.40 (m, 3H, a-H), S.OS (m, 65 
4H, Cbz), 6.0S (m, lH, NH), 7.20--7.40 (m, !OH, Ph), 7.8S 
(m, 2H, NH), 9.0S (m, lH, NH). 
Example 3MM 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-(2S,3S)-EP-
COOCH2Ph was synthesized using the mixed anhydride 
coupling method, purified by column chromatography using 
4:1 (10% MeOH:CH2Cl2):EtOAc as an eluent, and then 
rechromatographed using 4:1 (S% MeOH:CH2Cl2):EtOAc 
as the eluent; white solid, yield 44%. MS (ESI) m/z 884.4 
[(M+ltJ. 




CONHCH2CH2Ph was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 5 
gel with 19: 1 CH2Cl2:MeOH as the eluent, and then rechro-
matographed using S0:3S:10:S CH2Cl2:EtOAc:THF:MeOH 
52 
then rechromatographed using 4:1 (S% MeOH:CH2Cl2): 




CONHCH2Ph was synthesized using the mixed anhydride 
coupling method, purified by colunm chromatography using 
4:1 (10% MeOH:CH2Cl2):EtOAc as the eluent, and then 
rechromatographed using 4:1 (S% MeOH:CH2Cl2):EtOAc 
as the eluent; white solid, yield 47%. MS (ESI) m/z SS3.6 
[(M+ltJ. 1H NMR (DMSO-d6 ): 0.7--0.9 (m, 6H, Ile CH3 ), 
0.9-1.2 (m, 4H, Thr CH3 and Ile CH2), 1.2-1.S (m, 19H, tBu 
as the eluent; white solid, yield S2%. 1H NMR (CDC13 ): 
0.90 (t, 6H, Leu CH3 ), 1.14 (m, 3H, Thr CH3 ), 1.26 (m, 2H, 
Leu CH2), l.4S (s, !SH, tBu), l.6S (m, lH, Leu CH), 2.02 10 
(m, 2H, Glu CH2), 2.40 (m, 2H, Glu CH2), 2.77 (t, 2H, 
CH2Ph), 3.40--3.70 (m, 6H, epoxy, AAsp CH2 and NCH2), 
4.20 (m, 3H, a-H), 4.40 (m, lH, Thr CH), S.07 (s, 2H, Z), 
6.40 (b, lH, NH), 7.lS-7.3S (m, 12H, Ph and NH), S.00 (s, 
lH, NH), 9.4S (s, lH, NH). 15 and Ile CH2), 1.6-1.S (m, 2H, CH Ile and Glu CH2), 1.S-1.9 
(m, lH, Glu CH2), 2.1-2.3 (m, 2H, Glu CH2), 3.S (d, lH, 
epoxy), 3.S-4.0 (m, 3H, NCH2COOH and CH-OH), 4.03 
(d, lH, epoxy), 4.1- 4.2 (m, lH, a-H), 4.2-4.S (m, 4H, 
NHCH2Ph and a-H), 4.9-S.l (m, 2H, Cbz), 7.lS-7.40 (m, 
Example 300 
Cbz-Leu-Glu(O-tBu )-Thr-AAsp(O-tBu )-(2S,3 S )-EP-CO-
Ala-NHBzl was obtained using the EDC/HOBt coupling 
method, purified by colunm chromatography on silica gel 
with 19:1 CH2Cl2:MeOH as the eluent, and then rechro-
matographed using S0:3S:10:S CH2Cl2:EtOAc:THF:MeOH 
20 !OH, Ph), 7.SS (m, lH, NH), S.OS (m, lH, NH). 
as the eluent; white solid, yield 42%. 1 H NMR (Acetone-d6): 
0.90 (t, 6H, Leu CH3 ), l.lS (d, 3H, Thr CH3 ), l.2S (m, 2H, 25 
Leu CH2), 1.30 ( d, 3H, Ala CH3 ), l .4S (t, 1 SH, tBu), 1.60 
(m, lH, Leu CH), l.9S and 2.10 (d ofm, 2H, Glu CH2), 2.40 
(m, 2H, Glu CH2), 2.90 (s, 2H, AAsp CH2), 3.S6 and 3.64 
(d, 2H, epoxy), 4.2S (m, 3H, a-H), 4.3S (m, lH, a-H), 
4.40-4.SO(m, 3H, Thr CH and CH2Ph), S.OS (q, 2H, Z), 6.SO 30 
(d, lH, NH), 7.10-7.3S (m, !OH, Ph), 7.40 (d, lH, NH), 7.7S 




COOEt was synthesized using the mixed anhydride cou-
pling method, purified by colunm chromatography using 
1:13 MeOH:CH2Cl2 as an eluent, and then rechromato-
graphed using 2:1 EtOAc:hexane as an eluent; white solid, 
yield 43%. HRMS (FAB) Calcd. for C39H60N5 0 14: 
S22.4136S. Observed m/z S22.412S7. 1H NMR (CDC13 ): 
O.S-1.0 (m, 6H, Ile CH3 ), 1.1-1.3S (m, SH, Thr CH3 , Ile 
CH2, and OCH2CH3 ), 1.4-1.S (d, !SH, tBu), 1.9-2.lS (m, 
3H, CH Ile and Glu CH2), 2.3-2.4S and 2.S-2.6 (m, 2H, Glu 
CH2), 3.0--3.2 (m, 2H, NCH2COOH), 3.6 (d, lH, epoxy), 
Cbz-Ile-Glu( 0-tBu )-Thr-AAsp( 0-tBu )-(2S,3S )-EP-
35 4.0-4.S (m, 7H, epoxy, OCH2CH3 , CH-OH, and a-H), S.l 
(m, 2H, Cbz), S.4 (m, lH, NH), 7.20-7.40 (m, SH, Ph), S.2S 
(m, lH, NH), 9.4 (m, lH, NH). COO Et was synthesized using the mixed anhydride cou-
pling method, purified by colunm chromatography using 
1:13 MeOH:CH2Cl2 as an eluent, and then rechromato-
graphed using 2:1 EtOAc:hexane as the eluent. The crude 40 
product was then rechromatographed using 1:13 MeOH: 
CH
2
Cl2 as an eluent and placed on a preparatory TLC plate 
using 1:13 MeOH:CH2Cl2 as the eluent; white solid, yield 
37%. HRMS (FAB) Calcd. for C39H60N5 0 14: S22.4136S. 
Observed m/z S22.41366. 1H NMR (CDC13 ): O.S-1.0 (m, 45 
6H, Ile CH3 ), 1.1-1.4 (m, SH, Thr CH3 , Ile CH2, and 
OCH2CH3 ), 1.4-1.S (s, !SH, tBu), 1.9-2.2 (m, 3H, CH Ile 
and Glu CH2), 2.3-2.4S and 2.S-2.6 (m, 2H, Glu CH2), 
3.0-3.2 (m, 2H, NCH2COOH), 3.6 (d, lH, epoxy), 4.0-4.3 
(m, SH, epoxy, a-H, OCH2CH3 , and CH-OH), 4.3-4.S (m, 50 
2H, a-H), S.l (m, 2H, Cbz), S.3S (m, lH, NH), 7.20-7.40 





Ala-NHBzl was obtained using the EDC/HOBt coupling 
method, purified by colunm chromatography on silica gel 
with 19:1 CH2Cl2:MeOH as the eluent, and then rechro-
matographed using S0:3S:10:S CH2Cl2:EtOAc:THF:MeOH 
as the eluent; white solid, yield 36%. 1 H NMR (Acetone-d6): 
0.90 (t, 3H, Ile CH3 ), 0.9S (d, 3H, Ile CH3 ), 1.14 (d, 3H, Thr 
CH3 ), 1.22 (m, 2H, Ile CH2), 1.37 (d, 3H,Ala CH3 ), 1.42 (m, 
19H, Ile CH and tBu), 1.90 and 2.10 (d ofm, 2H, Glu CH2), 
2.40 (m, 2H, Glu CH2), 2.93 (s, 2H,AAsp CH2), 3.72 (d, 2H, 
epoxy), 4.20 (m, 3H, a-H), 4.30 (m, lH, a-H), 4.40-4.SO 
(m, 3H, Thr CH and CH2Ph), S.07 (q, 2H, Z), 6.70 (d, lH, 
NH), 7.10--7.3S (m, !OH, Ph), 7.SO (d, lH, NH), 7.SO (b, lH, 
NH), 7.90 (b, 2H, NH), 9.SO (s, lH, NH). 
Example 4 
trans-3-(N2 -(N-3-Phenylpropanoylvalylalanyl)-N1-t-bu-
toxycarbony lmethy lhydrazinocarbonyl )-2-(2-pheny lethy 1) 
Cbz-Ile-Glu( 0-tBu )-Thr-AAsp( 0-tBu )-(2S,3S )-EP-
COOCH2Ph was synthesized using the mixed anhydride 
coupling method and purified by colunm chromatography 
using 4: 1 (S% MeOH:CH2Cl2):EtOAc as the eluent; white 
solid, yield 3S%. MS (FAB) m/z SS4 [(M+ltJ. 60 oxirane (PhPr-Val-Ala-AAsp(O-tBu)-trans-EP-
Example 3RR 
Cbz-Ile-Glu( 0-tBu )-Thr-AAsp( 0-tBu )-(2R,3R )-EP-
COOCH2Ph was synthesized using the mixed anhydride 
coupling method and purified by colunm chromatography 
using 4:1 (10% MeOH:CH2Cl2):EtOAc as the eluent, and 
CH2CH2Ph). This compound was obtained using EDC/ 
HOBt coupling of PhPr-Val-Ala-NH-NH--CH2COO-tBu 
with trans-3-phenethyloxirane-2-carboxylic acid (S, 
Y=CH2CH2Ph), followed by purification by chromatogra-
65 phy on a silica gel colunm with 1:19 MeOH:CH2Cl2; white 
solid, yield=3S%. MS and 1H NMR (CDC13 ) were consis-
tent with the proposed structure. 




carbamoy lmethy lhydrazinocarbony 1 )oxirane-2-carboxylic 
Acid Ethyl Ester (Cbz-Ala-Ala-AAsn-(2S,3S)-EP-COOEt). 5 
This compound was obtained using the EDC/HOBt coupling 
method, purified by chromatography on silica gel column 
using 1:7 MeOH:CH2Cl2 as the eluting solvent system and 
recrystallized from EtOAc/hexane; white solid, yield 17%. 
1H NMR (DMSO-d6 ): 1.2 (m, 9H, CH3 ), 3.2 (m, 2H, 10 
NCH2CO), 3.S (s, lH, epoxy), 4-4.0S (m, 2H, a-H and 
epoxy), 4.0S-4.2S (m, 3H, OCH2CH3 and a-H), S.20 (m, 
2H, Cbz), 7.2 (s, lH, NH), 7.22-7.4 (m, SH, Ph), 7.S (s, lH, 
NH), 8.17 (d, lH, NH). HRMS (FAB) Calcd. for 
C22H30N5 0 9:S08.2043S. Observed m/z S08.20S40. Anal. 15 
Calcd. for C22H29N5 0 9.0.SH20: C, Sl.16; H, S.81; N, 
l3.S6. Found: C, Sl.31; H, S.82;N, 13.24. 
Example 6 
54 
8.18 (m, lH, NH). HRMS (FAB) Calcd. for C22H30N50 9: 
S08.2043S. Observed m/z S08.20490. Anal. Calcd. for 
C22H29N5 0 9.0.6H20: C, S0.98; H, S.83; N, 13.Sl. Found: 
C, S0.74; H, S.80; N, 13.20. 
Example 9 
(2S,3S)-3-(N2 -(N-Benzyloxycarbonylleucylleucyl)-N1-
iso buty lhydrazinocarbony l)oxirane-2-carboxy lie Acid Ethy 1 
Ester (Cbz-Leu-Leu-ALeu-(2S,3S)-EP-COOEt). This com-
pound was obtained using the EDC/HOBt coupling method, 
purified by chromatography on silica gel colunm using 
S:78: 17 MeOH:CH2Cl2:EtOAc as the eluting solvent system 
and recrystallized from EtOAc/hexane; white solid, yield 
49%. 1H NMR (CDC13 ): 0.90 (m, 18H, Leu), 1.21 (t, 3H, 
OCH2CH3 ), 1.40-1.90 (m, 7H, Leu), 3.20-3.4S (m, 2H, 
ALeu), 3.60 and 3.82 (d, 2H, epoxy), 4.lS (m, lH, a-H), 
4.20 (q, 2H, OCH2CH3 ), 4.4S (m, lH, a-H) S.20 (m, 2H, 
Cbz), S.30 (m, lH, NH), 6.41 (m, lH, NH), 7.16-7.37 (m, 
20 SH, Ph), 9.00 (m, lH, NH). HRMS (FAB) Calcd. for 
C30H47N4 0 8 : S91.3394. Observed m/z S9l.342S. Anal. 
Calcd. for C30H46N4 0 8 .0.6H20: C, S9.90; H, 7.90; N, 9.31. 
Found: C, S9.90; H, 7.77; N, 9.32. 
(2R,3R)-3-(N2-(N-Benzyloxycarbonylalanylalanyl)-N1-
carbamoy lmethy lhydrazinocarbony 1 )oxirane-2-carboxylic 
Acid Ethyl Ester (Cbz-Ala-Ala-AAsn-(2R,3R)-EP-COOEt). 
This compound was obtained using the EDC/HOBt coupling 
method, purified by chromatography on silica gel column 25 
using 1:7 MeOH:CH2Cl2 as the eluting solvent system and 
recrystallized from EtOAc/hexane; white solid, yield 19%. 
Example 10 
(2R,3 R )-3-(N2 -(N-Benzy loxycarbony lleucy lleucy 1)-N1 -
iso buty lhydrazinocarbony l)oxirane-2-carboxy lie Acid Ethy 1 
Ester (Cbz-Leu-Leu-ALeu-(2R,3R)-EP-COOEt). This com-
pound was obtained using the EDC/HOBt coupling method, 
purified by chromatography on silica gel column using 1 :9 
MeOH:CH2Cl2 as the eluting solvent system and recrystal-
lized from ether/hexane; white solid, yield 39%. 1 H NMR 
(CDC13 ): 0.90 (m, 18H, Leu), 1.21 (t, 3H, OCH2CH3 ), 
1 H NMR (DMSO-d6 ): 1.2 (m, 9H, CH3 ), 3.2 (m, 2H, 
NCH2CO), 3.S (s, lH, epoxy), 3.9 (s, lH, epoxy), 4-4.3 (m, 
4H, a-Hs and OCH2CH3 ), S.20 (m, 2H, Cbz), 7.2 (s, lH, 30 
NH), 7.2S-7.4 (m, SH, Ph), 7.S (s, lH, NH), 8.18 (d, lH, 
NH). ORMS (FAB) Calcd. for C22H30N50 9: S08.2043S. 
Observed m/z S08.2084S. Anal. Calcd. for 
C22H29N5 0 9.0.S7H20: C, Sl.038; H, S.827; N, l3.S3. 
Found: C, Sl.28; H, 6.00; N, 13.0S. 35 1.40--1.90 (m, 7H, Leu), 3.20-3.4S (m, 2H, ALeu), 3.60 and 
3.82 (d, 2H, epoxy), 4.lS (m, lH, a-H), 4.20 (q, 2H, 
OCH2CH3 ), 4.4S (m, lH, a-H) S.20 (m, 2H, Cbz), S.30 (m, 
lH, NH), 6.41 (m, lH, NH), 7.16-7.37 (m, SH, Ph), 9.00 (m, 
lH, NH). HRMS (FAB) Calcd. for C30H47N4 0 8 : S91.3394. 
Example 7 
trans-3-(N2 -(N-Benzy loxycarbony lalanylalany 1)-N 1 -car-
bamoy lmethy lhydrazinocarbonyl )oxirane-2-carboxy lie 40 Observed m/z S9l .343S. Anal. Calcd. for 
Acid Ethyl Ester (Cbz-Ala-Ala-AAsn-trans-EP-COOEt). 
This compound was obtained using the EDC/HOBt coupling 
method, purified by chromatography on silica gel column 
using 1:9 MeOH:CH2Cl2 as the eluting solvent system and 
recrystallized from EtOAc/hexane; white solid, yield 8%. 1 H 45 
NMR (CDC13 ): 1.2 (m, 9H, CH3 ), 3.4 (m, 2H, NCH2CO), 
3.6 (s, lH, epoxy), 3.9 (s, lH, epoxy), 4.1-4.3 (m, 3H, a-H 
and OCH2CH3 ), 4.4 (m, lH, a-H), S.lS (m, 2H, Cbz), S.S 
(m, lH, NH), 6.6 (m, lH, NH), 7.2 (s, lH, NH), 7.3 (m, SH, 
Ph). HRMS (FAB) Calcd. for C22H30N50 9: S08.2043S. 50 
Observed m/z S08.20362. Anal. Calcd. for 
C22H29N5 0 9.0.7H20: C, S0.81; H, S.8S; N, 13.47. Found: 
C, SI.OS; H, S.89; N, 13.19. 
C30H46N4 0 8 .0.SSH20: C, S9.99; H, 7.90; N, 9.33. Found: 
C, 60.02; H, 7.78; N, 9.33. 
Example 11 
trans-3-(N2 -(N-Benzyloxycarbonylleucylleucyl)-N1 -
iso buty lhydrazinocarbony l)oxirane-2-carboxy lie Acid Ethy 1 
Ester (Cbz-Leu-Leu-ALeu-trans-EP-COOEt). This com-
pound was obtained using the EDC/HOBt coupling method, 
purified by chromatography on silica gel column using 1 :9 
MeOH:CH2Cl2 as the eluting solvent system and recrystal-
lized from ether/hexane; white solid, yield 42%. 1 H NMR 
(CDC13 ): 0.90 (m, 18H, Leu), 1.21 (t, 3H, OCH2CH3 ), 
1.40--1.90 (m, 7H, Leu), 3.20-3.4S (m, 2H, ALeu), 3.60 and 
Example 8 
cis-3-(N2 -(N-Benzyloxycarbonylalanylalanyl)-N1 -car-
bamoy lmethy lhydrazinocarbonyl )oxirane-2-carboxy lie 
55 3.82 (d, 2H, epoxy), 4.lS (m, lH, a-H), 4.20 (q, 2H, 
OCH2CH3 ), 4.4S (m, lH, a-H) S.20 (m, 2H, Cbz), S.30 (m, 
lH, NH), 6.41 (m, lH, NH), 7.16-7.37 (m, SH, Ph), 9.00 (m, 
lH, NH). HRMS (FAB) Calcd. for: C30H47N4 0 8 S91.3394. 
Observed m/z S91.3419. Anal. Calcd. for Acid Ethyl Ester (Cbz-Ala-Ala-AAsn-cis-EP-COOEt). This 
compound was obtained using the EDC/HOBt coupling 
method, purified by chromatography on silica gel column 
using 1:7 MeOH:CH2Cl2 as the eluting solvent system and 
recrystallized from EtOAc/hexane; white solid, yield 4%. 1 H 
NMR (DMSO-d6 ): 1.1-1.3 (m, 9H, CH3 ), 3.4 (s, 2H, 
NCH2CO), 3.7-3.8 and 3.8S (m, 2H, epoxy), 4.0-4.18 (m, 65 
3H, a-Hand OCH2CH3 ), 4.19-4.3 (m, lH, a-H), S.03 (m, 
2H, Cbz), 7.2 (m, lH, NH), 7.3-7.S (m, 6H, Ph and NH), 
60 C30H46N4 0 8 .0.SH20: C, 60.08; H, 7.90; N, 9.34. Found: C, 
60.09; H, 7.86; N, 9.28. 
Example 12 
Deblocking of the t-Butyl Group in Aza-Asp Peptides. 
Epoxysuccinyl peptides (PhPr-Val-Ala-AAsp(O-tBu)-trans-
EP-COOCH2Ph), (PhPr-Val-Ala-AAsp(O-tBu)-trans-EP-






11.00 (m, COOH). HRMS (FAB) Calcd. for C30H39N50 15 : 
710.2S209. Observed m/z 7l0.2Sl9S. Anal. Calcd. for 
C30H39N50 15 .0.9H20: C, 49.64; H, S.66; N, 9.6S. Found: C, 
49.S9; H, S.S6; N, 9.66. 
Example 12E 
(2R,3 R )-3-(N2 -(N-Benzy loxycarbony lleucy 1-
glutamy lthreonyl )-N1 -carboxymethy lhydrazinocarbonyl) 
COOEt), and peptidyl-AAsp(O-tBu)-EP-R3 derivatives all 
were separately reacted with TFA at 0° C. for 1 h-i.s hr. The 5 
excess TF A was removed under vacuum, and the final 
products were recrystallized from methanol/ether and ether/ 
hexane to give the final epoxysuccinyl peptides as white 
solids (yields S9-8S% ). The products of these reactions are 
listed in Examples 12A-12F. 10 oxirane-2-carboxylic Acid Ethyl Ester (Cbz-Leu-Glu-Thr-
AAsp-(2R,3R)-EP-COOEt). 1H NMR (DMSO-d6): 0.82 (t, 
6H, Leu CH3), 1.0 ( d, 3H, Thr CH3), 1.2 (t, 3H, OCH2 CH3), 
1.4 (m, 2H, Leu CH2 ), 1.6 (m, lH, CH Leu), 1.78 (m, lH, 
Glu CH2 ), 1.9 (m, lH, Glu CH2 ), 2.2S (m, 2H, Glu), 3.S (s, 
Example 12A 
trans-3-(N2 -(N-3-Phenylpropanoylvalylalanyl)-N1-car-
boxy lmethy lhydrazinocarbonyl )oxirane-2-carboxy lie Acid 
Benzyl Ester (PhPr-Val-Ala-AAsp-trans-EP-COOCH2Ph). 
15 lH, epoxy), 3.9-4.0 (m, lH, a-H), 4.0--4.1 (m, 3H, 
NCH2COOH, epoxy), 4.1-4.2 (m, 3H, OCH2 CH3 and 
CH-OH), 4.32-4.41 (m, 2H, a-H), S.OS (m, 2H, Cbz), 
7.30--7.40 (m, SH, Ph), 7.4S (d, lH, NH), 7.80 (m, lH, NH), 
1H NMR (CDCl3): 0.80 (m, 6H, Val), 1.21 (m, 3H, Ala), 
1.90 (m, lH, Val), 2.S4 (m, 3H, PhCH2 and Asp), 2.90 (m, 
3H, PhCH2CH2 CO and Asp), 3.64 and 3.71 (d, 2H, epoxy), 
4.lS (m, 2H, NCH2COOH), 4.SO (m, 2H, a-H), S.20 (m, 2H, 20 
Benzyl), 6.Sl (m, lH, NH), 6.9S (M, lH, NH), 7.16-7.37 
(m, !OH, Ph), 9.60 (M, lH, NH). HRMS (FAB) Calcd. for 
C30H36N40 9: S97.2S6l. Observed m/z S97.2647. Anal. 
Calcd. for C30H36N40 9.0.SH20: C, S9.48; H, 6.33; N, 9.2S. 
Found: C, S9.47; H, 6.13; N, 9.31. 25 
Example 12B 
8.0S (m, lH, NH), 11.00 (m, COOH). 
HRMS (FAB) Calcd. for C31 H44N50 14: 710.28848. 
Observed m/z 710.29480. Anal. Calcd. for 
C31 H43N50wH20: C, Sl.17; H, 6.19; N, 9.63. Found: C, 
Sl.33; H, 6.02; N, 9.66. 
Example 12F 
(2S,3S)-3-(N2 -(N-Benzyloxycarbonylleucyl-
glutamy lthreonyl )-N1 -carboxymethy lhydrazinocarbonyl) 
oxirane-2-carboxylic Acid Ethyl Ester (Cbz-Leu-Glu-Thr-trans-3-(N2 -(N-3-Phenylpropanoylvalylalanyl)-N1 -car-
boxy lmethy lhydrazinocarbonyl )-2-(2-pheny lethy l)oxirane 
(PhPr-Val-Ala-AAsp-trans-EP-CH2CH2 Ph). 
1H NMR 
(CDCl3): 0.78 (m, 6H, Val), 1.20 (t, 3H, Ala), 1.90 (m, 2H, 
PhCH2), 2.S2 (m, 2H, PhCH2 CH2CO), 2.67 (m, 2H, 
PhCH2CH2 -EP), 2.88 (m, 2H, PhCH2CH2 CO), 4.18 (M, 2H, 
NCH2 COOH), 4.S2 (M, 2H, a-H), 6.SS (m, lH, NH), 6.9S 
(m, lH, NH), 7.16-7, 26 (M, !OH, Ph), 9.60 (m, lH, NH). 
HRMS (FAB) Calcd. for C30H38N40 7: S97.2819. Observed 
mlz S67.2868. Anal. Calcd. for C30H36N40 9H20: C, 61.62; 
H, 6.88; N, 9.S8. Found: C, 6l.S2; H, 6.S8; N, 9.S6. 
30 AAsp-(2S,3S)-EP-COOEt). 1H NMR (DMSO-d6): 0.8S (t, 
6H, Leu CH3), I.OS (d, 3H, Thr CH3), 1.2 (t, 3H, 
OCH2CH3), 1.4 (m, 2H, Leu CH2), 1.6 (m, lH, CH Leu), 
1.77 (m, lH, Glu CH2), 1.9 (m, lH, Glu CH2), 2.3 (m, 2H, 
Glu CH2 ), 3.S (s, lH, epoxy), 3.9-4.1(m,4H, NCH2 COOH, 
35 epoxy, a-H), 4.1-4.3 (m, 3H, OCH2 CH3 and CH-OH), 
4.3-4.4 (m, 2H, a-H), 4.9S (m, lH, NH), S.02 (m, 2H, Cbz), 
7.30--7.40 (m, SH, Ph), 7.SO (d, lH, NH), 7.78 (m, lH, NH), 
8.0S (m, lH, NH), 11.00 (m, COOH). HRMS (FAB) Calcd. 
for C31 H44N50 14: 710.28848. Observed m/z 710.284SO. 
Example 12C 
40 Anal. Calcd. for C31 H43N50wl.2SH20: C, S0.8S; H, 6.22; 
N, 9.S7. Found: C, S0.74; H, 6.27; N, 9.67. 
(2S,3S)-3-(N2 -(N-Benzyloxycarbonylaspartyl-
glutamy lvaly 1)-N 1 -carboxymethy lhydrazinocarbony l)ox-
irane-2-carboxy lic Acid Ethyl Ester (Cbz-Asp-Glu-Val- 45 
AAsp-(2S,3S)-EP-COOEt). 1H NMR (DMSO-d6): 0.84 (m, 
6H, Val), 1.20, 1.21 (t, 3H, OCH2 CH3), 1.7-2.1 (m, 3H, Val, 
Glu), 2.21 (m, 2H, Glu), 2.40--2.6S (m, 2H Asp), 3.S8 and 
4.10 (d, 2H, epoxy), 4.0S-4.22 (m, 4H, NCH2 COOH and 
OCH2 CH3), 4.S0-4.60 (m, 3H, a-H), S.OS (m, 2H, Cbz), 50 
7.20-7.40 (m, SH, Ph), 7.60 (lH, NH), 7.8S (m, 2H, NH), 
11.00 (m, COOH). HRMS (FAB) Calcd. for C30H39N50 15 : 
710.2S209. Observed m/z 7l0.2SSO. Anal. Calcd. for 




oxirane (PhPr-Val-Ala-AAsp-(2S,3S)-EP-CON(nBu)2 ). 
1H 
NMR (DMSO-d6): 0.74 and 0.79 (m, 12H, Val and n-butyl 
CH3), 1.20 (m, 7H, Ala CH3 and CH2 ), l .4S (m, 4H, CH2), 
1.88 (m, lH, Val CH), 2.44 (m, 2H, PhCH2 ), 2.79 (m, 2H, 
PhCH2 CH2 ), 3.20 (m, 4H, CH2N), 3.32 (s, 2H, AAsp 
CH2COOH), 3.7S (d, 2H, epoxy), 4.17 (m, 2H, a-H), 
7.13-7.24 (m, 6H, Ph and NH), 7.82 (d, lH, NH), 8.20 (b, 
lH, NH), 10.90 (b, lH, COOH). HRMS (FAB) Calcd. for 
C, 48.73; H, S.63; N, 9.4S. 55 C31 H48N50 8: 618.3S03. Observed m/z 618.3S34. Anal. 
Example 12D 
(2R,3 R )-3-(N2 -(N-Benzy loxycarbony laspartyl-
glutamy lvaly 1)-N 1 -carboxymethy lhydrazinocarbony !)ox- 60 
irane-2-carboxylic Acid Ethyl Ester (Cbz-Asp-Glu-Val-
AAsp-(2R,3R)-EP-COOEt). 1H NMR (DMSO-d6): 0.84 (m, 
6H, Val), 1.20, 1.21 (t, 3H, OCH2 CH3), 1.7-2.1 (m, 3H, Val, 
Glu), 2.21 (m, 2H, Glu), 2.40--2.6S (m, 2H Asp), 3.S8 and 
4.10 (d, 2H, epoxy), 4.0S-4.22 (m, 4H, NCH2 COOH and 65 
OCH2 CH3), 4.S0-4.60 (m, 3H, a-H), S.OS (m, 2H, Cbz), 
7.20-7.40 (m, SH, Ph), 7.60 (lH, NH), 7.8S (m, 2H, NH), 
Calcd. for C31 H47N50 8.H20: C, S8.S7; H, 7.77; N, 11.02. 
Found: C, S8.62; H, 7.S9; N, 11.26. 
Example 12H 
(2S,3S)-2-(N-Methyl-N-benzylcarbamoyl)-3-(N2 -(3-phe-
nylpropanoy lvaly lalanyl )-N 1 -carboxymethy lhydrazinocar-
bony l)oxirane (PhPr-Val-Ala-AAsp-(2S,3S)-EP-CON(CH3) 
Bzl). 1H NMR (DMSO-d6): 0.76 (m, 6H, Val CH3), 1.16 (m, 
3H, Ala CH3), 1.89 (m, lH, Val CH), 2.42 (m, 2H, PhCH2), 
2.77 (m, 3.SH, PhCH2 CH2CO and CH3N), 3.00 (m, 1.5H, 
CH3N), 3.40 (d, 2H,AAsp CH2COOH), 3.96 (s, 2H, epoxy), 
US 7,056,947 B2 
57 58 
4.lS (m, 2H, a-H), 4.4S (m, 2H, PhCH2N), 7.12-7.37 (m, 
llH, Ph and NH), 7.83 (m, lH, NH), 8.22 (d, lH, NH), 
10.80 (s, lH, COOH). HRMS (FAB) Calcd. for 
C31H40N50 8: 610.2877. Observed m/z 610.2870. Anal. 
Calcd. for C31H39N50 8.H20: C, S9.32; H, 6.S8; N, 11.16. 5 
Found: C, S9.49; H, 6.32; N, 11.36. 
2H, NH), 10.80 (b, 2H. COOH). HRMS (FAB) Calcd. for 
C37H49N60 13 : 78S.33S8. Observed m/z 78S.3401. Anal. 
Calcd. for C37H48N60 13 .2H20: C, S4.l4; H, 6.39; N, 10.24. 
Found: C, S3.26; H, 6.12; N, 9.90. 
Example 12L 
Example 12H 
(2S,3 S)-2-(Dibenzy lcarbamoy l)-3-(N2 -(3-pheny lpro-
panoy lvalylalany 1)-N 1-carboxymethylhydrazinocarbony l) 
oxirane (PhPr-Val-Ala-AAsp-(2S,3S)-EP- CON(CH2Ph)2). 1H NMR (DMSO-d6): 0.7S (m, 6H, Val CH3), 1.08 (m, 3H, 
Ala CH3), 1.90 (m, lH, Val CH), 2.42 (m, 2H, PhCH2), 2.77 
(t, 2H, PhCH2CH2CO), 3.40 (d, 2H, AAsp CH2COOH), 
3.80 (s, 2H, epoxy), 4.lS (m, 2H, a-H), 4.SS (d, 4H, 
PhCH2N), 7.13-7.40 (m, llH, Ph and NH), 7.8S (m, lH, 
NH), 8.lS (m, lH, NH), 10.80 (s, lH, COOH). HRMS 
(FAB) Calcd. for C37H44N50 8: 686.3190. Observed m/z 
686.3238. Anal. Calcd. for C37H43N50 8.0.SH20: C, 63.98; 





(2S,3S)-EP-CON(CH3)Bzl). 1H NMR (DMSO-d6): 0.83 (t, 
6H, Leu CH3), 1.04 (m, 3H, Thr CH3), 1.41 (m, 2H, Leu 
CH2), 1.60 (m, lH, Leu CH), l.7S and 1.90 (d ofm, 2H, Glu 
CH2), 2.24 (m, 2H, Glu CH2), 2.82 and 2.9S (d, 3H, NCH3), 
3.32 (s, 2H,AAsp CH2), 3.80-4.10 (m, SH, epoxy anda-H), 
4.2S (d, lH, Thr CH), 4.37 (m, 2H, CH2Ph), 4.99 (s, 2H, Z), 
7.lS-7.44 (m, llH, Ph and NH), 7.7S (b, lH, NH), 8.06 (b, 
2H, NH), 10.80 (b, 2H. COOH). Anal. Calcd. for 
C37H48N60 13 .2H20: C, S4.l4; H, 6.39; N, 10.24. Found: C, 





CON(Bzl)2). 1H NMR (DMSO-d6): 0.84 (t, 6H, Leu CH3), 
1.03 (m, 3H, Thr CH3), 1.42 (m, 2H, Leu CH2), 1.60 (m, lH, 
Leu CH), 1.76 and 1.92 (d ofm, 2H, Glu CH2), 2.24 (m, 2H, 
Glu, CH2), 3.32 (s, 2H, AAsp CH2), 3.76 (s, 2H, epoxy), 
4.03 (b, 2H, a-H), 4.11 (s, lH, a-H), 4.28-4.SS (m, SH, Thr 
CH and CH2Ph), S.00 (s, 2H, Z), 7.18-7.43 (m, 16H, Ph and 
NH), 7.78 (b, lH, NH), 8.07 (b, 2H, NH), 10.8S (b, 2H. 
COOH). HRMS (FAB) Calcd. for C43H53N60 13 : 861.3671. 
Observed m/z 861.3649. Anal. Calcd. for 
C43H52N60 13 .H20: C, S8.76; H, 6.19; N, 9.S6. Found: C, 
S8.87; H, 6.01; N, 9.37. 
Example 12K 
(2S,3S)-2-(N-Methyl-N-benzylcarbamoyl)-3-(N2 -(N-
benzyloxycarbonylisoleucy lglutamy lthreonyl )-N1 -car-
boxymethylhydrazinocarbony l)oxirane (Cbz-Ile-Glu-Thr-
AAsp-(2S,3S)-EP-CO-N(CH3)Bzl). 1H NMR (DMSO-
d6): 0.79 (t, 6H, Ile CH3), 1.09 (m, SH, Thr CH3 and Ile 
CH2), 1.40 (m, lH, Ile CH), 1.71and1.92 (d ofm, 2H, Glu 
CH2), 2.2S (m, 2H, Glu CH2), 2.79 and 2.98 (d, 3H, NCH3), 
3.32 (s, 2H,AAsp CH2), 3.80-4.10 (m, SH, epoxy anda-H), 
4.27 (d, lH, Thr CH), 4.39 (m, 2H, CH2Ph), S.00 (s, 2H, Z), 
7.lS-7.40 (m, llH, Ph and NH), 7.80 (b, lH, NH), 8.07 (b, 
(2S,3S )-2-(Dibenzy lcarbamoyl )-3-(N2 -(N-benzy loxycar-
bony lisoleucy lglutamy lthreony l)-N1 -carboxymethy lhy-
10 drazinocarbonyl)oxirane (Cbz-Ile-Glu-Thr-AAsp-(2S,3S)-
EP-CO-N(Bzl)2). 1H NMR (DMSO-d6): 0.82 (m, 6H,Ile 
CH3), 1.02 (m, 3H, Thr CH3), 1.10 (m, 2H, Ile CH2), 1.40 
(m, lH, Ile CH), l.7S and 1.8S (d ofm, 2H, Glu CH2), 2.24 
(m, 2H, Glu CH2), 3.32 (s, 2H, AAsp CH2), 3.61 and 3.76 
15 (d, 2H, epoxy), 3.88 (b, 2H, a-H), 4.00 (m, lH, a-H), 
4.30--4.SS (m, SH, Thr CH and CH2Ph), S.00 (s, 2H, Z), 
7.lS-7.4S (m, 17H, Ph and NH), 7.8S (d, lH, NH), 9.SS (s, 
lH, NH), 10.8S (b, 2H. COOH). HRMS (FAB) Calcd. for 
C43H53N60 13 : 861.36706. Observed m/z 861.36964. Anal. 
20 Calcd. for C43H52N60 13 .2H20: C, S7.S8; H, 6.29; N, 9.37. 
Found: C, S7.62; H, S.9S; N, 9.24. 
Example 13 
25 cis-3-(N-(N-Benzy loxycarbony leucy 1 )-N1 -pheny lethy l-
hydrazinocarbony l)oxirane-2-carboxylic Acid Ethyl Ester 
(Cbz-Leu-AHph-cis-EP-COOEt). This compound was 
obtained using the EDC/HOBt coupling method and purified 
by chromatography on a silica gel colunm using 1:29: 10 
30 MeOH:CH2Cl2:EtOAc as the eluting solvent system; white 
solid, yield 20%. 1H NMR (CDC13): 0.9S (t, 6H, Leu), l.2S 
(t, 3H, OCH2CH3), 1.40--1.90 (m, 3H, Leu), 2.80--2.90 (m, 
2H, CH2Ph), 3.SO and 3.SS (d, 2H, epoxy), 3.60 (m, 2H, 
NCH2CH2Ph), 4.00 (m, lH, a-H), 4.20 (q, 2H, OCH2CH3), 
35 S.20 (m, 2H, Cbz), S.30 (m, lH, NH), 7.16-7.37 (m, 101H, 
Ph), 8.1 (m, lH, NH). HRMS (FAB) Calcd. for 




ethylhydrazinocarbonyl)oxirane-2-carboxylic Acid Ethyl 
Ester (Cbz-Leu-AHph-(2S,3S)-EP-COOEt). This com-
pound was obtained using the EDC/HOBt coupling method 
45 and purified by chromatography on a silica gel colunm using 
1 :32:7 MeOH:CH2Cl2:EtOAc as the eluting solvent system; 
white solid, yield 48%. 1 H NMR (CDC13): 0.9S (t, 6H, Leu), 
l.2S (t, 3H, OCH2CH3), 1.40-1.90 (m, 3H, Leu), 2.80-2.90 
(m, 2H, CH2Ph), 3.S6 and3.76 (d, 2H, epoxy), 3.60 and 3.90 
50 (m, 2H, NCH2CH2Ph), 4.00 (m, lH, a-H), 4.20 (q, 2H, 
OCH2CH3), S.00 (d, lH, NH), S.20 (m, 2H, Cbz), 7.16-7.37 
(m, lOH, Ph), 8.1 (m, lH, NH). HRMS (FAB) Calcd. for 
C28H36N30 7: S26.2SS3. Observed m/z S26.2Sl6. 
55 Example lS 
(2R,3R)-3-(N2 -(N-Benzyloxycarbonyleucyl)-N1-phenyl-
ethylhydrazinocarbonyl)oxirane-2-carboxylic Acid Ethyl 
Ester (Cbz-Leu-AHph-(2R,3R)-EP-COOEt). This com-
60 pound was obtained using the EDC/HOBt coupling method 
and purified by chromatography on a silica gel colunm using 
1:29:10 MeOH:CH2Cl2:EtOAc as the eluting solvent sys-
tem; white solid, yield 64%. 1H NMR (CDC13): 0.9S (t, 6H, 
Leu), l.2S (t, 3H, OCH2CH3), 1.40--1.90 (m, 3H, Leu), 
65 2.80--2.90 (m, 2H, CH2Ph), 3.S8 and 3.80 (d, 2H, epoxy), 
3.60 and 3.90 (m, 2H, NCH2CH2Ph), 4.00 (m, lH, a-H), 
4.20 (q, 2H, OCH2CH3), 4.80 (d, lH, NH), S.20 (m, 2H, 
US 7,056,947 B2 
59 
Cbz), 7.16-7.37 (m, lOH, Ph), 7.90 (m, lH, NH). HRMS 




640.2982S. Observed m/z 640.298S4. Anal. Calcd. for 
C32H41N5 0 9 .0.SH20: C, S9.26; H, 6.48; N, 10.8. Found: C, 
S9.47; H, 6.48; N, 10.SO. 
Example 20 
(2S,3S)-3-(N2-(N-Benzyloxycarbonyleucyl)-N1-phenyl-
ethy lhydrazinocarbony l)oxirane-2-carboxylic Acid ( Cbz-
Leu-AHph-(2S,3 S)-EP-COO H). This compound was 
recrystallized using (1: 19 MeOH:CH2Cl2)/hexane to yield a 10 
white solid, yield 92%. 1H NMR (DMSO-d6): 0.9S (t, 6H, 
Leu), 1.40-1.90 (m, 3H, Leu), 2.80-2.90 (m, 2H, CH2Ph), 
3.S6 and 3.80 (d, 2H, epoxy), 3.60 and 3.90 (m, 2H, 
NCH2CH2Ph), 4.00 (m, lH, a-H), S.00 (d, lH, NH), S.20 
(m, 2H, Cbz), 7.16-7.37 (m, SH, Ph), 8.1 (m, lH, NH), 15 
11.00 (s, lH, COOH). HRMS (FAB) Calcd. for 
C26H32N30 7 : 498.2240. Observed m/z 498.22S2. 
(2S,3S)-3-(N2-(N-Benzyloxycarbonylleucylpheny-
lalanyl )-N 1 -carbamoylethy lhydrazinocarbony l)oxirane-2-
carboxylic Acid Ethyl Ester (Cbz-Leu-Phe-AG!n-(2S,3S)-
EP-COOEt). This compound was obtained using the EDC/ 
HOBt coupling method and purified by chromatography on 
a silica gel colunm using 1:13 MeOH:CH2Cl2 as the eluting 
solvent system; white solid, yield 72%. 1H NMR (DMSO-
d6): 0.8 (t, 6H, CH3), 1.18 (t, 3H, OCH2CH3), 1.2-1.4 (m, 
2H, Leu CH2), l.42-1.SS (m, lH, Leu CH(CH3)2), 2.0S-2.3 
(m, 2H, NCH2CH2CO), 2.8-3.0 (m, 2H, Phe CH2), 3.4-3.6 
and 3.7 (m, 2H, NCH2CH2CO), 3.S (m, lH, epoxy), 4.0 (m, 
lH, a-CH), 4.0S-4.2 (m, 3H, epoxy and OCH2CH3), Example 17 
(2R,3R)-3-(N2-(N-Benzyloxycarbonyleucyl)-N1-isobu-
tylhydrazinocarbonyl)oxirane-2-carboxylic Acid Ethyl Ester 
(Cbz-Leu-ALeu-(2R,3R)-EP-COOEt). This compound was 
obtained using the EDC/HOBt coupling method and purified 
20 4.3S-4.S3 (m, 2H, a-H and NH), S.O (s, 2H, Cbz), 6.9 (m, 
lH, NH), 7.18-7.42 (m, lOH, Ph), 8.3 (m, lH, NH). MS 
(FAB) m/z 640 [(M+lt]. HRMS (FAB) Calcd. for 
C32H42N5 0 9 : 640.2982S. Observed m/z 640.2963S. Anal. 
Calcd. forC32H41N50 9 : C, 60.08; H, 6.46; N, l0.9S. Found: by chromatography on a silica gel colunm using 1:29:10 
MeOH:CH2Cl2:EtOAc as the eluting solvent system; white 
solid, yield Sl %. 1H NMR (CDC13): 0.9S (m, 12H, Leu and 
ALeu), l.2S (t, 3H, OCH2CH3), 1.40--1.90 (m, 4H, Leu and 
ALeu), 3.20 and 3.SO (m, 2H, NCH2CH), 3.60 and 3.90 (d, 
2H, epoxy), 4.10 (m, lH, a-H), 4.20 (q, 2H, OCH2CH3), 30 
4.90 (d, lH, NH), S.10 (m, 2H, Cbz), 7.16-7.37 (m, SH, Ph), 
8.40 (m, lH, NH). HRMS (FAB) Calcd. for C24H36N30 7 : 
478.2SS3 Observed m/z 478.2SSO. 
25 C, 60.12; H, 6.46; N, 10.72. 
Example 21 
(2R,3 R )-3-(N1 -(N-Benzy loxycarbony lleucy lpheny-
lalanyl )-N 1 -carbamoylethy lhydrazinocarbony l)oxirane-2-
carboxylic Acid Ethyl Ester (Cbz-Leu-Phe-AG!n-(2R,3R)-
EP-COOEt). This compound was obtained using the EDC/ 
HOBt coupling method and purified by chromatography on 
Example 18 
cis-3-(N2 -(N-Benzyloxycarbonyleucyl)-N1-isobutylhy-
drazinocarbonyl)oxirane-2-carboxylic Acid Ethyl Ester 
(Cbz-Leu-ALeu-cis-EP-COOEt). This compound was 
obtained using the EDC/HOBt coupling method and purified 
by chromatography on a silica gel colunm using 1 :2 EtOAc: 
CH
2 
Cl2 as the eluting solvent system; white solid, yield 40%. 1H NMR (CDC13): 0.9S (m, 12H, Leu and ALeu), l.2S (t, 
3H, OCH2CH3), 1.40-1.90 (m, 4H, Leu andALeu), 3.20 and 
3.SO (m, 2H, NCH2CH), 3.SO and 3.SS (d, 2H, epoxy), 4.10 
(m, lH, a-H), 4.20 (q, 2H, OCH2CH3), S.10 (m, lH, NH), 
S.20 (m, 2H, Cbz), 7.16-7.37 (m, SH, Ph), 8.1 (m, lH, NH). 
HRMS (FAB) Calcd. for C24H36N30 7 : 478.2SS3. Observed 
m/z 478.2S73. 
Example 19 
trans-3-(N2 -(N-Benzy loxycarbony lleucylphenylalany l)-
N1-carbamoy lethylhydrazinocarbony l)oxirane-2-carboxylic 
Acid Ethyl Ester (Cbz-Leu-Phe-AG!n-trans-EP-COOEt). 
This compound was obtained using the EDC/HOBt coupling 
method and purified by chromatography on a silica gel 
colunm using 1:19 MeOH:CH2Cl2 as the eluting solvent 
system; white solid, yield 30%. 1H NMR (DMSO-d6): 0.8 (t, 
6H, CH3), 1.1-1.2 (m, 3H, OCH2CH3), 1.2-1.4 (m, 2H, Leu 
CH2), l.S (m, lH, Leu CH(CH3)2), 2-2.4 (m, 2H, 
NCH2CH2CO), 2.8-3.0 (m, 2H, Phe CH2), 3.2-3.4 (m, 2H, 
NCH2CH2CO), 3.S (s, lH, epoxy), 3.8 (m, lH, a-CH), 
4.0-4.2 (m, 3H, epoxy and OCH2CH3), 4.2S-4.3S (m, 2H, 
a-Hand NH), S.O (s, 2H, Cbz), 6.8S (m, lH, NH), 7.2-7.4 
(m, lOH, Ph), 8.2S (m, lH, NH). MS (FAB) m/z 640 
[(M+ltJ. HRMS (FAB) Calcd. for C32H42N50 9 : 
35 a silica gel colunm using 1:13 MeOH:CH2Cl2 as the eluting 
solvent system; white solid, yield 3S%. 1H NMR (DMSO-
d6): 0.8 (t, 6H, CH3), 1.18 (t, 3H, OCH2CH3), 1.3-1.4 (m, 
2H, Leu CH2), 1.42-1.6 (m, lH, Leu CH(CH3)2), 2-2.3 (m, 
2H, NCH2CH2CO), 2.8-3.1 (m, 2H, Phe CH2), 3.3-3.4 and 
40 3.SS-3.6S (m, 2H, NCH2CH2CO), 3.4S (s, lH, epoxy), 3.83 
(m, lH, a-CH), 4.0-4.2 (m, 3H, epoxy and OCH2CH3), 
4.3-4.S (m, 2H, a-Hand NH), S.O (s, 2H, Cbz), 6.8S (m, lH, 
NH), 7.2-7.4 (m, lOH, Ph), 8.3 (m, lH, NH). MS (FAB) m/z 
45 
640 [(M+lt]. HRMS (FAB) Calcd. for C32H42N50 9 : 
640.2982S. Observed m/z 640.30011. Anal. Calcd. for 
C32H41N5 0 9 : C, 60.08; H, 6.46; N, l0.9S. Found: C, 60.21; 
H, 6.49; N, 10.74. 
50 Example 22 
trans-3-(N2-(N-Benzyloxycarbonylalanylalanyl)-N1-
ethoxycarbonylmethylhydrazinocarbonyl)oxirane-2-car-
boxylic Acid Ethyl Ester (Cbz-Ala-Ala-AAsp(OEt)-trans-
55 EP-COOEt). This compound was obtained using the EDC/ 
HOBt coupling method and purified by chromatography on 
silica gel column using 1 :9 MeOH:CH2Cl2 as the eluting 
solvent system; recrystallized from EtOAc/hexane; white 
solid, yield 19%. 1H NMR (CDC13): 1.2-1.4 (m, 12H, 
60 CH3),3.4- 3.6 (m, 2H, NCH2CO), 3.6 (s, lH, epoxy), 3.92 
(s, lH, epoxy), 4.1-4.3 (m, SH, a-Hand 2xOCH2CH3), 4.4 
(m, lH, a-H), S.13 (m, 2H, Cbz), 6.S (m, lH, NH), 7.2 (m, 
lH, NH), 7.3S (s, SH, Ph), 9.0 (m, lH, NH). MS (FAB) m/z 
S37 [(M+ltJ. HRMS (FAB) Calcd. for C24H33N40 10 : 
65 S37.21967. Observed m/z S37.22012. Anal. Calcd. for 
C24H32N40 10.0.7SH20: C, S2.4l; H, 6.096; N, 10.19. 
Found: C, S2.6l; H, S.93; N, 9.98. 




bamoy lmethy lhydrazinocarbonyl )oxirane-2-carboxy lie 
Acid Benzyl Ester (Cbz-Ala-Ala-AAsn-trans-EP-COOBzl). 
This compound was obtained using the EDC/HOBt coupling 
method and purified by chromatography on a silica gel 
colunm using 1:7 MeOH:CH2Cl2 as the eluting solvent 
system; recrystallized from EtOAc/hexane; white solid, 
yield 4%. 1H NMR (DMSO-d6): 1-1.3 (m, 6H, CH3), 
3.2S-3.4 and 3.S-3.7 (m, 3H, epoxy and NCH2CO), 3.98 (d, 
lH, epoxy), 4.0--4.1 (m, lH, a-H), 4.2 (m, lH, a-H), S.O and 
S.2 (m, 4H, OCH2Ph), 7.2-7.S (m, llH, NH and Ph), 7.SS 
(m, lH, NH), 8.2 (m, lH, NH). HRMS (FAB) Calcd. for 
C27H32N50 9 : S70.22000. Observed m/z S70.21623. Anal. 
Calcd. for C27H31N50 9 .0.6H20: C, SS.88; H, S.SS; N, 
12.07. Found: C, S6.2l; H, S.68; N, 11.69. 
Example 24 
trans-3-(N2 -(N-tert-Butoxycarbonyl-2-naphthy lalanyl )-
N1-iso butylhydrazinocarbony l)oxirane-2-carboxy lic Acid 
Ethyl Ester (Boc-Np2-ALeu-trans-EP-COOEt). This com-
pound was obtained using the EDC/HOBt coupling method 
and purified by chromatography on a silica gel colunm using 
1 :2 Et0Ac:CH2Cl2 as the eluting solvent system; 78% yield. 
1H NMR (CDC13): 0.6-0.9 (m, 6H, Leu CH3), 1.3-1.S (m, 
4H, Leu CH and OCH2CH3), 2.2-2.S (m, 4H, Sue CH2), 
3.0-3.4 (m, 4H, Np2 CH2 andNCH2CO), 3.S (s, lH, epoxy), 
4.03-4.2 (m, 3H, OCH2CH3 and epoxy), 4.4-4.6 (m, lH, 
a-H), 4.6-4.7 (m, lH, NH), 7.4-7.S and 7.7-7.9 (m, 7H, 
Ph), 8.S (m, lH, NH), HRMS (FAB) Calcd. for 
C28H38N30 7 : S28.27098. Observed rn/z S28.27138. 
Example 2S 
trans-3-(N2-2-Naphthylalanyl)-N1-isobutylhydrazinocar-
bonyl)oxirane-2-carboxylic Acid Ethyl Ester Trifluoracetate 
Salt (Np2-ALeu-trans-EP-COOEt-TFA). The blocked 
epoxysuccinyl peptide Boc-Np2-ALeu-trans-EP-COOEt 




nocarbonyl)oxirane-2-carboxylic Acid Ethyl Ester (Cbz-
5 ALeu-trans-EP-COOEt). This compound was obtained 
using the EDC/HOBt coupling method and purified by 
chromatography on a silica gel colunm using 1 :4 EtOAc: 
CH
2
Cl2 as the eluting solvent system; 19% yield. 
1H NMR 
(CDC13): 0.9 (d, 6H, CH3), 1.3 (t, 3H, OCH2CH3), 1.7 (m, 
10 lH, CH(CH3)2), 2.6-2.7 (m, 2H, N--CH2), 3.SS (d, lH, 
epoxy), 4.2-4.3 (q, 2H, OCH2CH3), 4.S (d, lH, epoxy), S.3 
(m, 2H, Cbz), 7.3-7.S (m, SH, Ph). HRMS (FAB) Calcd. for 
C18H25N20 6: 36S.17126. Observed rn/z 36S.1731S. Anal. 
Calcd. for C18H24N20 6: C, S9.33; H, 6.64; N, 7.69. Found: 
15 C, S9.3l; H, 6.S8; N, 7.66. 
Example 28 
trans-3-(N2 -(N-Benzyloxycarbonyl)-N1-phenylethylhy-
20 drazinocarbonyl)oxirane-2-carboxylic Acid Ethyl Ester 
(Cbz-AHph-trans-EP-COOEt). This compound was 
obtained using the EDC/HOBt coupling method and purified 
by chromatography on a silica gel colunm using 1 :4 EtOAc: 
CH
2
Cl2 as the eluting solvent system; 6% yield. 
1H NMR 
25 (CDC13): 1.3-1.4 (t, 3H, OCH2CH3), 2.8 (t, 2H, CH2), 3.lS 
(t, 2H, CH2), 3.SS (d, lH, epoxy), 4.3 (q, 2H, OCH2CH3), 
4.4S (d, lH, epoxy), S.3 (m, 2H, Cbz), 7.1 (m, lH, NH), 
7.2-7.4 (m, !OH, Ph). HRMS (FAB) Calcd. for 
C22H25N20 6: 413.17126. Observed rn/z 413.172Sl. Anal. 
3° Calcd. for C22H24N20 6.l.04H20: C, 61.29; H, 6.0S; N, 




nyl)oxirane-2-carboxylic Acid Ethyl Ester (Ac-AHph-trans-
EP-COOEt). This compound was obtained using the EDC/ 
HOBt coupling method and purified by chromatography on 
40 a silica gel colunm using 1:19 MeOH:CH2Cl2 as the eluting 
solvent system; 46% yield. 1H NMR (CDC13): l.2S-l.3S (t, 
3H, OCH2CH3), 1.82 (s, 3H, CH3), 2.82-3.0 (m, 2H, CH2), 
3.SS-3.7 (m, 2H, CH2), 3.63 (d, lH, epoxy), 3.77 (d, lH, 
minutes, the excess TFA was removed under vacuum. MS 45 
(FAW) m/z 428 (M-TFA+l, 60%). 
epoxy), 4.2-4.3 (q, 2H, OCH2CH3), 6.9 (m, lH, NH), 
7.lS-7.4 (m, SH, Ph). HRMS (EI) Calcd. for C16H20N20 5: 
320.13722. Observed rn/z 320.1313S. Anal. Calcd. for 
Example 26 
trans-3-(N2-(N-Succinyl-2-naphthylalanyl)-N1-isobutyl- 50 
hydrazinocarbonyl)oxirane-2-carboxylic Acid Ethyl Ester 
(Suc-Np2-ALeu-trans-EP-COOEt). To a stirred solution of 
Np2-ALeu-trans-EP-COOEt-TFA (1 eq) in DMF at -10° C. 
was added succinic anhydride (1.1 eq), followed by NMM 
(1 eq). The reaction was left to stir at room temperature for 55 
16 hours, and purified by chromatography on a silica gel 
colunm using 1:9 MeOH:CH2Cl2 as the eluting solvent 
system; 34% yield. 1H NMR (DMSO-d6): 0.2--0.9 (m, 6H, 
Leu CH3), 1.1-1.3 (m, 4H, Leu CH and OCH2CH3), 2.2-2.S 
(m, 4H, Sue CH2), 3.0-3.4 (m, 4H, Np2 CH2 and NCH2CO), 60 
3.S (s, lH, epoxy), 4.03-4.2 (m, 3H, OCH2CH3 and epoxy), 
4.4-4.6 (m, lH, a-H), 4.6-4.7 (m, lH, NH), 7.4-7.S and 
7.7-7.9 (m, 7H, Ph), 8.S (m, lH, NH), 10.8 (m, COOH). 
HRMS (FAB) Calcd. for C27H34N30 8: S28.234S9. 
Observed m/z S28.23471. Anal. Calcd. for 65 
C27H33N30 3 1.SH20: C, S8.S; H, 6.SO; N, 7.S8. Found: C, 
S8.77; H, 6.26; N, 7.27. 
C16H20N20 5.0.1H20: C, S9.66; H, 6.28; N, 8.70. Found: C, 
S9.40; H, 6.46; N, 9.11. 
Example 30 
trans-3-(N2-(N-Acetylleucyl)-N1-isobutylhydrazinocar-
bonyl)oxirane-2-carboxylic Acid Ethyl Ester (Ac-Leu-
ALeu-trans-EP-COOEt). This compound was obtained 
using the EDC/HOBt coupling method and purified by 
colunm chromatography using 1:19 MeOH:CH2Cl2 as an 
eluent, and was then rechromatographed using 4: 1 EtOAc: 
CH
2
Cl2 as the eluent; white solid, 3S% yield. 
1H NMR 
(CDC13): 0.8-1.0 (m, 12H, CH3), 1.2-1.4 (m, 3H, 
OCH2CH3), 1.S-1.9 (m, 3H, Leu CH2 and CH(CH3)2), 2.0S 
(d, 3H, CH3CO), 3.2-3.3 and3.4-3.S (m, 2H, N--CH2), 3.6 
(d, lH, epoxy), 3.8S (d, lH, epoxy), 4.2-4.3 (m, 2H, 
OCH2CH3), 4.4-4.SS (m, lH, a-H), 6.1 (m, lH, NH), 9.1 
(m, lH, NH). HRMS (FAB) Calcd. for C22H32N30 6: 
434.22911. Observed rn/z 434.23111. Anal. Calcd. for 
C18H31N30 6: C, S6.09; H, 8.11; N, 10.90. Found: C, SS.99; 
H, 8.12; N, 10.61. 




nocarbonyl)oxirane-2-carboxylic Acid Ethyl Ester (Ac-Leu-
AHph-trans-EP-COOEt). This compound was obtained 5 
using the EDC/HOBt coupling method and purified by 
chromatography on a silica gel colunm using 1:19 MeOH: 
CH Cl2 as the eluting solvent system; white solid, 23% yield. 
1 2 
H NMR (CDCl3): 0.8S-1.0 (m, 6H, CH3), 1.22-1.32 (m, 
3H, OCH2CH3), 1.42-1.7 (m, 3H, Leu CH2 andCH(CH3)2), 10 
2.03 (d, 3H, CH3CO), 2.8-3.0 (m, 2H, CH2), 3.S8 (d, lH, 
epoxy), 3.78 (d, lH, epoxy), 3.7-3.8 and 3.8-4.0 (m, 2H, 
CH2), 4.2-4.4 (m, 3H, OCH2CH3 and a-H), S.8 (m, lH, 
NH), 7.18-7.4 (m, SH, Ph), 8.SS (m, lH, NH). HRMS (FAB) 
Calcd. for C22H32N30 6 : 434.22911. Observed rn/z 15 
434.23111.Anal. Calcd. forC22H31N30 6 : C, 60.9S; H, 7.21; 
N, 9.69. Found: C, 60.72; H, 7.29; N, 9.S6. 
Example 32 
64 
EDC (1.1 eq), and the reaction mixture was stirred at room 
temperature for 16 hours. The DMF was evaporated in 
vacuo and the residue was dissolved in EtOAc (20 ml), and 
washed with 1 N HCI, 4% NaHC03, and brine, dried over 
MgS04, and concentrated. The residue was purified by 
colunm chromatography and the product was eluted with 
1 :49 MeOH:CH2Cl2; white solid, yield 33%; TLC Rf=0.4 
(1:49 MeOH:CH2Cl2); 
1H-NMR (CDCl3): 0.9-1.0 (t, 3H), 
1.2-1.4 (m, SH), 1.4 (s, 9H), 1.S-1.8 (m, 2H), 2.8-3.0 (m, 
2H), 3.6 (s, lH), 3.7-3.9 (2s, lH), 3.9-4.0 (m, lH), 4.2-4.3 
(m, 2H), 4.7-4.8 (m, lH), 7.2-7.4 (m, SH), 8.3-8.4 (2s, lH). 
MS (FAW) 424 (M-tBu+l, 40%), 378 (M-Boc+l, 3S%). 
Example 3S 
trans-3-(N2-(N-tert-Butoxycarbonylnorleucyl)-N1-phe-
nylethylhydrazinocarbonyl)oxirane-2-carboxylic Acid Ethyl 
Ester (Boc-Nle-AHph-trans-EP-COOEt). This compound 
was prepared by the EDC/HOBt coupling method. It was 
20 purified by colunm chromatography using 1 :49 MeOH: 
(2S,3S)-3-(N2-(N-Benzyloxycarbonylisoleucyl- CH
2 
Cl2 as an eluent, and was then rechromatographed using 
Et0Ac:CH2Cl2=1:1 as the eluent; white solid, yield 22%; 
TLC Rf=0.7 (1:1 EtOAc:CH2Cl2); 
1H-NMR (CDCl3): 
0.8-1.0 (t, 3H), 1.2-1.4 (m, 4H), 1.4 (s, 9H), 1.4-1.8 (m, 
glutamy lthreonyl )-N 1 -carboxymethy lhydrazinocarbonyl) 
oxirane-2-carboxylic Acid Ethyl Ester (Cbz-Ile-Glu-Thr-
AAsp-(2S,3S)-EP-COOEt). This compound was obtained 
using the mixed anhydride coupling method and the t-butyl 
esters were deblocked using the procedure previously 
described. 1H NMR (DMSO-d6 ): 0.8 (m, 6H, Ile CH3), 
1-1.2 (m, 4H, Thr CH3 and Ile CH2), 1.2 (t, 3H, OCH2CH3), 
25 2H), 2.8-3.0 (m, 2H), 3.6 (s, lH), 3.8-3.9 (2s, lH), 3.8-4.0 
(m, 2H), 4.2-4.3 (m, 2H), 4.7-4.8 (m, lH), 7.2-7.4 (m, SH), 
8.3 (b, lH), 8.S (b, lH). MS (FAB+) 492 (M+l, 80%), 436 
(M-tBu+l, 100%). 
1.4 (m, lH, Ile CH2), 1.6-1.8 (m, 2H, CH Ile and Glu CH2), 
1.8-1.9 (m, lH, Glu CH2), 2.1-2.3 (m, 2H, Glu CH2), 3.S (d, 30 
lH, epoxy), 3.8S-4.0S (m, 3H, NCH2COOH and CH-OH), 
4.1 (d, lH, epoxy), 4.1-4.3 (m, 3H, OCH2CH3 and a-H), 
4.3-4.4S (m, 2H, a-H), 4.6 (m, lH, NH), 4.9 (m, lH, NH), 
S.OS (m, 2H, Cbz), 7.30-7.40 (m, SH, Ph), 7.80 (m, lH, 
NH), 8.1 (m, lH, NH), 11.00 (m, COOH). HRMS (FAB) 35 
Calcd. for C31H44N5 0 14: 710.28848. Observed rn/z 
710.2920S. Anal. Calcd. for C31 H43N50w2H20: C, 49.93; 
H, 6.31; N, 9.40. Found: C, 49.71; H, 6.12; N, 9.42. 
Example 36 
trans-3-(N2 -(N-tert-Butoxycarbony lnorvaly 1)-N 1 -phenyl-
ethylhydrazinocarbony l)-2-(2-phenylethyl )oxirane (Boc-
Nva-AHph-trans-EP-CH2CH2Ph). This compound was pre-
pared by the EDC/HOBt coupling method. It was purified by 
colunm chromatography using 1 :49 MeOH:CH2Cl2 as an 
eluent, and was then rechromatographed using 1: 1 EtOAc: 
CH
2
Cl2 as the eluent; white solid, yield 38%; TLC Rf=0.7S 
(1:1 Et0Ac:CH2Cl2); 
1H-NMR (CDCl3): 0.9-1.0 (t, 3H), 
Example 33 
(2R,3R)-3-(N2-(N-Benzyloxycarbonylisoleucyl-
40 1.2-1.4 (m, 2H), 1.4 (2s, 9H), 1.6-1.9 (m, 2H), 2.7-2.9 (m, 
4H), 3.1 (s, lH), 3.3 &3.4 (2s, lH), 3.6-3.8 (m, lH), 3.8-4.0 
(m, 2H), 4.7-4.8 (m, lH), 7.1-7.4 (m, !OH), 7.9, 8.1 (s, lH). 
MS (FAB+) SlO (M+l, 20%), 4S4 (M-tBu+l, 100%). glutamy lthreonyl )-N 1 -carboxymethy lhydrazinocarbonyl) 
oxirane-2-carboxylic Acid Ethyl Ester (Cbz-Ile-Glu-Thr-
AAsp-(2R,3R)-EP-COOEt). This compound was obtained 45 
using the mixed anhydride coupling method and the t-butyl 
esters were deblocked using the procedure previously 
described. 1H NMR (D.MSO-d6): 0.8 (m, 6H, Ile CH3), 1.0 
( d, 3H, Thr CH3), 1-1.2 and 1.4 (m, 2H, Ile CH2), 1.2 (t, 3H, 
OCH2CH3), 1.6S-1.8 (m, 2H, CH Ile and Glu CH2), 1.8-2.0 50 
(m, lH, Glu CH2), 2.1-2.3 (m, 2H, Glu CH2), 3.S (d, lH, 
epoxy), 3.8-4.0 (m, 3H, NCH2COOH and CH-OH), 4.0S 
(d, lH, epoxy), 4.1-4.23 (m, 3H, OCH2CH3 and a-H), 
4.3-4.4S (m, 2H, a-H), S.OS (m, 2H, Cbz), 7.30--7.40 (m, 
SH, Ph), 7.80 (m, lH, NH), 8.1 (m, lH, NH), 11.00 (m, 55 
COOH). HRMS (FAB) Calcd. for C31 H44N5 0 14: 
710.28848. Observed rn/z 710.28779. Anal. Calcd. for 
C31H43N50wlH20: C, Sl.17; H, 6.19; N, 9.63. Found: C, 




trans-3-(N2 -(N-tert-Butoxycarbony I-a-amino butanoyl )-
N 1-phenylethylhydrazinocarbony1)-2-(2-phenylethyl )ox-
irane (Boc-Abu-AHph-trans-EP-CH2CH2Ph). This com-
pound was obtained using the EDC/HOBt coupling method 
and purified by chromatography on a silica gel colunm using 
1 :9 MeOH:CH2Cl2 as the eluting solvent system; white 
solid, yield 39%. 1H NMR (CDCl3): 1.00 (t, 3H, Abu), 1.4 
(2s, 9H), 1.6 (m, 2H, EP-CH2), 1.7-1.9 (m, 2H, Abu), 
2.7-2.9 (m, 4H, CH2Ph), 3.1 (s, lH, epoxide), 3.3 and 3.4 
(2s, lH, epoxide), 3.6-3.8 (m, 2H NCH2CH2), 4.1 (m, lH, 
aH), 7.1-7.4 (m, 10 H), 7.9 and 8.1 (s, lH, NH). MS (FAB+) 
496 (M+l, 80%), 440 (M-tBu+l, 60%). HRMS (FAB) 





ethy lhydrazinocarbony l)oxirane-2-carboxylic Acid Ethy I 
Ester (Boc-Nva-AHph-trans-EP-COOEt). To a stirred solu-
tion of ethyl trans-epoxysuccinate (1 eq), HOBt (1 eq) and 
Boc-Nva-NHNH--CH2CH2Ph (1 eq) in DMF was added 
65 Ala-AHph trans-EP-CH2CH2Ph). This compound was 
obtained using the EDC/HOBt coupling method and purified 
by chromatography on a silica gel colunm using 1 :4 EtOAc: 
US 7,056,947 B2 
65 
CH2Cl2 as the eluting solvent system; white solid, yield 
73%. 1H NMR (CDC13): 1.10 (d, 3H, Ala), 1.4 (2s, 9H), 1.6 
(m, 2H, EP-CH2), 2.7-2.9 (m, 4H, CH2Ph), 3.1 (s, lH, 
epoxide), 3.3 &3.4 (2s, lH, epoxide), 3.6-3.8 (m, 2H, 
NCH2CH2), 4.1 (m, lH, aH), 4.7-4.8 (s, lH, NH), 7.1-7.4 5 
(m, 10 H), 7.9 and 8.1 (s, lH, NH). MS (FAB+) 481 (M+l, 
20%), 426 (M-tBu+l, 100%). HRMS (FAB) Calcd. for 
C27H36N30 5: 482.26SS. Observed m/z 482.2676 
Example 39 10 
66 
1H NMR (CDC13): l.2S (t, 3H, OCH2CH3), 3.48 and 4.4S 
(d, 2H, epoxy), 3.9S (d 2H, CH2-Ph) 4.30 (q, 2H, 
OCH2CH3), S.10 (m, lH, NH), S.20 (m, 2H, Cbz). HRMS 
(FAB) Calcd. for C21H23N20 6: 399.1S96. Observed m/z 
399.1S83. Anal. Calcd. for C21 H22N20 6: C, 63.31; H, S.S7; 




EP-CH2CH2Ph). This compound was obtained using the 
EDC/HOBt coupling method and purified by chromatogra-
phy on a silica gel column using 1 :4 Et0Ac:CH2Cl2 as the 
15 eluting solvent system; white solid, yield 22%. 1H NMR 
(CDC13): 1.8S (m, 2H, CH2CH2Ph), 2.80 (m, 2H EPCH2), 
3.00 and 4.10 (d, 2H, epoxy), 3.9S (d 2H, NHCH2Ph), S.10 
(m, lH, NH), S.20 (m, 2H, Cbz). HRMS (FAB) Calcd. for 
C26H27N20 4: 431.1970. Observed m/z 431.1961. 
trans-3-(N2-Norvalyl)-N1-phenylethylhydrazinocarbo-
nyl)-1-(2-phenylethyl)oxirane Trifluoroacetate Salt (Nva-
AHph-trans-EP-CH2CH2Ph.TFA). The blocked epoxysucci-
nyl peptide was dissolved in a small amount ofTFA at 0° C. 
After IS minutes, the excess TFA was removed under 
vacuum. The residue was purified by colunm chromatogra-
phy and the product eluted with 1:49 MeOH:CH2Cl2; white 
solid, yield 48%. TLC Rf=0.6 (9:1 CH2Cl2:MeOH); 
1H-NMR (DMSO-d6): 0.7-0.9 (m, 3H), 1.2-1.4 (m, 2H), 20 
1.6-1.8 (m, 2H), 2.6-2.8 (m, 4H), 2.9-3.0 (m, lH), 3.6 (s, 
lH), 4.0 (m, lH), 7.1-7.4 (m, !OH), 8.1-8.2 (m, lH); MS 
(FAW) m/z 392 (M-TFA+l, 100%); HRMS Calcd. for 




ty lhydrazinocarbony l)oxirane-2-carboxy lie Acid Ethy 1 Ester 
25 (Cbz-Leu-ALeu-(2S,3S)-EP-COOEt). This compound was 
obtained using the EDC/HOBt coupling method and purified 
by chromatography on a silica gel colunm using 1:34: 12 
trans-3-(N2-Norleucyl)-N1-phenylethylhydrazinocarbo- MeOH:CH2Cl2:EtOAc as the eluting solvent system; white 
nyl)oxirane-2-carboxylic Acid Ethyl Ester Trifluoroacetate solid, yield 4S%. 1H NMR (CDC13): 0.9S (m, 6H, Leu), l.2S 
Salt (Nle-AHph-trans-EP-COOEt-TFA). The blocked 30 (t, 3H, OCH2CH3), l.4S-l.90 (m, 3H, Leu), 3.20 and 3.SS 
epoxysuccinyl peptide was dissolved in a small amount of (m, 2H, NCH2CH), 3.60 and 3.80 (d, 2H, epoxy), 4.lS-4.2S 
TFAat 0° C. After IS minutes, the excess TFA was removed (m, 3H, OCH2CH3 and a-H), S.10 (m, 2H, Cbz), S.lS (m, 
under vacuum. The residue was purified by colunm chro- lH, NH), 7.16-7.37 (m, SH, Ph), 8.80 (m, lH, NH). HRMS 
matography and the product eluted with 1:49 MeOH: (FAB) Calcd. for. C24H36N30 7 : 478.2SS3. Observed m/z 
CH2Cl2; white solid, yield S2%; TLC Rf=O.S (1:9 MeOH: 35 478.2S63. Anal. Calcd. for C24H35N50 7 .0.6SH20: C, 
CH2Cl2); 
1H-NMR (DMSO-d6): 0.8-1.0 (m, 3H), 1.2-1.3 (t, S8.92H, 7.47; N, 8.S8. Found: C, S9.43; H, 7.02; N, 8.11. 
3H), 1.3-1.4 (m, 4H), 1.6-1.8 (m, 2H), 2.7-2.9 (m, 2H), 3.6 
(s, lH), 3.8-4.0 (m, 2H), 4.1-4.2 (q, 2H), 7.1-7.4 (m, SH), 
8.2-8.4 (b, 2H); MS (FAB+) m/z 392 (M-TFA+l, 100%); 





drazinocarbonyl)oxirane-2-carboxylic Acid Ethyl Ester 
(Cbz-Leu-ALeu-trans-EP-COOEt). This compound was 
obtained using the EDC/HOBt coupling method and purified 
by chromatography on a silica gel colunm using 1:34: 12 
45 MeOH:CH2Cl2:EtOAc as the eluting solvent system; white 
solid, yield 4S%. 1H NMR (CDC13): 0.9S (m, 12H, Leu and 
ALeu), l.2S (t, 3H, OCH2CH3), l.4S-l.90 (m, 4H, Leu and 
ALeu), 3.20 and 3.SS (m, 2H, NCH2CH), 3.60 and 3.80 (d, 
2H, epoxy), 4.lS-4.2S (m, 3H, OCH2CH3 and a-H), S.10 
trans-3-(N2-Alanyl)-N1-phenylethylhydrazinocarbonyl)-
2-(2-phenylethyl)oxirane Trifluoroacetate Salt (Ala-AHph-
trans-EP-CH2CH2Ph.TFA). The blocked epoxysuccinyl 
peptide was dissolved in a small amount of TFA at 0° C. 
After IS minutes, the excess TFA was removed under 
vacuum. The residue was purified by colunm chromatogra-
phy and the product eluted with 1:9 MeOH:CH2Cl2; white 
solid, yield 8S%. TLC Rf=O.S8 (1 :9 MeOH:CH2Cl2); 
1H-NMR (DMSO-d6): 0.8 (d, 3H, Ala), 1.6 (m, 2H, EP-
CH2), 2.7-2.9 (m, 4H, CH2Ph), 3.1 (s, lH, epoxide), 3.3 and 
3.4 (2s, lH, epoxide), 3.6-3.8 (m, 2H, NCH2CH2), 4.1 (m, 55 
lH, a-H), 4.7-4.8 (s, lH, NH), 7.1-7.4 (m, !OH), 8.1 (s, lH, 
NH). MS (FAB+) m/z 382 (M+l, 100%); HRMS Calcd. for 
C22H28N30 3: 382.2130. Observed m/z 382.2133. 
Example 42 
trans-3-(N2 -Benzyl-N1 -benzyloxycarbonylhydrazi-
nocarbonyl)oxirane-2-carboxylic Acid Ethyl Ester (Cbz-
APhe-(trans)-EP-COOEt). This compound was obtained 
using the EDC/HOBt coupling method and purified by 
chromatography on a silica gel colunm using 1 :4 EtOAc: 
CH
2 
Cl2 as the eluting solvent system; white solid, yield 19%. 
50 (m, 2H, Cbz), S.lS (m, lH, NH), 7.16-7.37 (m, SH, Ph), 
8.80 (m, lH, NH). HRMS (FAB) Calcd. for C24H36N30 7 : 
478.2SS3. Observed m/z 478.2S61. 
Example 46 
trans-3-(N2-(N-3-Benzyloxyphenylalanyl)-N1-isobutyl-
hydrazinocarbonyl)oxirane-2-carboxylic Acid Ethyl Ester 
(Cbz-Phe-ALeu-trans-EP-COOEt). This compound was 
obtained using the EDC/HOBt coupling method and purified 
60 by chromatography on a silica gel colunm using 1: 1 EtOAc: 
CH Cl2 as the eluting solvent system; white solid, yield 2S%. 1 2 
H NMR (CDC13): 0.78 (m, 6H, Leu), l.2S(m, 3H 
OCH2CH3), l.4S (m, lH, Leu), 2.9-3.1 (m, 2H, NCH2CH), 
3.60 and 3.83 (d, 2H, epoxy), 4.2 (m, 2H, OCH2CH3), 4.3S 
65 (m, lH, a-H), S.20 (m, 2H, Cbz), 7.16-7,26 (m, SH, Ph), 8.4 
(m, lH, NH). HRMS (FAB) Calcd. for C27H34N30 7 : 
Sl2.2396. Observed m/z S12.2394. 
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Example 47 Example SI 
trans-3-(N2-(N-3-Benzyloxyphenylalanyl)-N1-isobutyl-
hydrazinocarbonyl)-2-(2-phenylethyl)oxirane (Cbz-Phe-
ALeu-trans-EP-CH2CH2Ph). This compound was obtained 5 
using the EDC/HOBt coupling method. It was purified by 
colunm chromatography using 1:19 MeOH:CH2Cl2 as an 
eluent, and was then rechromatographed using 1 :4 EtOAc: 
(2S,3S)-3-(N2 -(N-Benzyloxycarbonylleucylleucyl)-N1-
iso buty lhydrazinocarbony l)oxirane-2-carboxy lie Acid ( Cbz-
Leu-Leu-ALeu-(2S,3 S )-EP-COO H). This compound was 
obtained by saponification of the ethyl ester with KOH/ 
EtOH and recrystallized from ether/hexane; white solid, 
yield 37%. 1H NMR (CDC13): 0.90 (m, 18H, Leu), 1.21 (t, 
3H, OCH2CH3), 1.40-1.90 (m, 7H, Leu), 3.20-3.4S (m, 2H, 
ALeu), 3.60 and 3.70 (d, 2H, epoxy), 4.lS (m, lH, a-H), 
4.4S (m, lH, a-H) S.20 (m, 2H, Cbz), S.30 (m, lH, NH), 
6.41 (m, lH, NH), 7.16-7.37 (m, SH, Ph), 9.00 (m, lH, NH). 




Cl2 as the eluent; white solid, yield 47%. 
1H NMR 
(DMSO-d6): 0.78 (m, 6H, Leu), 1.6-1.9(m, 3H, CHCH2 and 10 
CH2-EP) 2.62 (m, 2H, PhCH2CH), 2.80 (m, 2H, 
PhCH2CH2-EP), 3.20 and 3.4S (m, 2H, NCH2CH), 3.60 and 
3.80 (m, 2H, epoxy), 4.2 (m, lH, a-H) S.20 (m, 2H, Cbz), 
7.16-7,26 (m, !SH, Ph), 8.10 (m, lH, NH). HRMS (FAB) 
Calcd. for C30H38N40 7: S44.281S. Observed rn/z S44.2803. 15 
Anal. Calcd. for C32H37N30 5.0.SH20: C, 69.S6; H, 6.88; N, 
7.61. Found: C, 69.S2; H, 6.82; N, 7.64. 
Example S2 
(2S,3S )-3-(N2 -(N-Benzyloxycarbonylglutamylvalyl )-N1-




APhe-trans-EP-CH2CH2Ph). This compound was obtained 
using the EDC/HOBt coupling method. It was purified by 
colunm chromatography using 1 :3 Et0Ac:CH2Cl2 as an 
eluent, and was then rechromatographed using 1 :2 EtOAc: 
20 Acid Ethyl Ester (Cbz-Glu-Val-AAsp-(2S,3S)-EP-COOEt). 
This compound was obtained using the mixed anhydride 
coupling method and the t-butyl esters were deblocked using 
the procedure previously described. 1H NMR (DMSO-d6): 
0.84 (d, 6H, Val), 1.20, 1.21 (t, 3H, OCH2CH3), 1.7-2.1 (m, 
25 3H, Val, Glu), 2.21 (m, 2H, Glu), 3.60 and 4.10 (d, 2H, 
epoxy), 3.09-4.20 (m, 4H, NCH2COOH, and OCH2CH3), 
4.20--4.40 (m, 2H, a-H), S.OS (m, 2H, Cbz), 7.20--7.40 (m, 
SH, Ph), 8.00 (m, lH, NH), 11.00 (m, COOH). HRMS 
(FAB) Calcd. for C26H35N40 12: S9S.22Sl. Observed rn/z 
30 S9S2268. Anal. Calcd. for C26H35N40 12.0.SH20: C, Sl.74; 




Cl2 as the eluent; recrystallized from ether/hexane; 
white solid, yield 36%. 1H NMR (CDC13). 1.7-1.9 (m, 2H, 
CH2-EP), 2.S0-2.60 (m, 2H, PhCH2CH), 2.80-3.10 (m, 2H, 
PhCH2CH2-EP), 3.60 and 3.80 (m, 2H, epoxy), 4.0 (m, 2H, 
NHCH2), 4.2 (m, lH, a-H) S.20 (m, 2H, Cbz), 7.16-7,26 
(m, 20H, Ph), 8.10 (m, lH, NH). HRMS (FAB) Calcd. for 
C35H36N30 5: S77.2S762. Observed rn/z S77.2S4l. Anal. 
Calcd. for C35H35N30s-0.6SH20: C, 71.32; H, 6.21; N, 
7.13. Found: C, 71.74; H, 6.68; N, 6.73. 35 
trans-2-(N2 -(N-Benzy loxycarbony lalanylalany l)-N1 -car-
bamoy lmethy lhydrazinocarbonyl )-3-( 4-chlorophenyl )ox-
irane (Cbz-Ala-Ala-AAsn-trans-EP-Ph-4-Cl) was obtained 
using the EDC/HOBt coupling method, purified by colunm 
chromatography on silica gel using 1:9 MeOH:CH2Cl2 as 
the eluent, and then recrystallized from Et0Ac/CH2Cl2; 
Example 49 
trans-3-(N2 -(N-Benzy loxycarbony leucy 1)-N 1 -ethy lhy-
drazinocarbony l)oxirane-2-carboxy lic Acid Ethyl Ester 
(Cbz-Leu-AAbu-trans-EP-COOEt). This compound was 
obtained using the EDC/HOBt coupling method and purified 
by chromatography on a silica gel colunm using 1:34: 12 
MeOH:CH2Cl2:EtOAc as the eluting solvent system; white 
solid, yield 62%. 1H NMR (CDC13): 0.93 (m, 6H, Leu), l.lS 
40 white powder, yield SO%. 1H NMR(DMSO-d6): 1.02-1.03 
(d, 3H, CH3), 1.14-1.18 (d, 3H, CH3), 3.29-3.31 (d, 2H, 
NCH2CO), 3.94-4.16 (m, 4H, epoxy and 2xa-H), 4.99 (m, 
2H, Cbz), 7.20 (s, lH, NH), 7.32 (m, 9H, Ph and Ph-Cl), 
8.07-8.09 (d, lH, NH), 10.64 (s, lH, NH). HRMS (ESI) 
45 Calcd. for C25H29N50 7Cl : S46.17S8. Observed rn/z 
S46.l 7SSSl. Anal. Calcd. for C25H28N50 7Cl.0.2H20: C, 
S4.63; H, S.21; N, 12.74. Found: C, S4.6S; H, S.2S; N, 12.47. 
(q, 3H, NHCH2CH3), l.2S (t, 3H, OCH2CH3), 1.4S-1.80 
(m, 3H, Leu andAAbu), 3.S6 (m, 2H, NCH2CH3), 3.60 and 
3.8S(d, 2H, epoxy), 4.lS-4.2S (m, 3H, OCH2CH3 anda-H), 
S.10 (m, 2H, Cbz), S.30 (m, lH, NH), 7.16-7.37 (m, SH, 50 
Ph), 8.80 (m, lH, NH). HRMS (FAB) Calcd. for 
C22H32N30 7: 4S0.2240. Observed rn/z 4S0.22S6. Anal. 
Calcd. for C22H31N30 7.0.SSH20: C, S7.SO; H, 7.04; N, 
9.14. Found: C, S7.S8; H, 6.98; N, 9.07. 
Example S4 
trans-3-(N2 -(N-Benzy loxycarbony lalanylalany 1)-N 1 -car-
bamoy lmethy lhydrazinocarbonyl )-2-(2-phenethy l)oxirane 
(Cbz-Ala-Ala-AAsn-trans-EP-CH2CH2Ph) was obtained 




AAbu-trans-EP-COOH). This compound was obtained by 
saponification of the ethyl ester with KOH/EtOH; white 
solid, yield 63%. 1H NMR (CDC13): 0.93 (m, 6H, Leu), l.lS 
(q, 3H NHCH2CH3), 1.4S-1.80 (m, 3H, Leu andAAbu), 3.0 
(d, 2H, epoxy), 3.S6 (m, 2H, NCH2CH3), 4.2S (m, lH, a-H), 
S.10 (m, 2H, Cbz), S.30(m, lH, NH), 7.16-7.37 (m, SH, Ph), 
8.10 (m, lH, NH). HRMS (FAB) Calcd. for C20H33N30 7: 
422.1927. Observed rn/z 422.1949. 
55 chromatography on silica gel using 1:9 MeOH:CH2Cl2 as 
the eluent, and then recrystallized from EtOAc/hexane; 
white powder, yield 40%. 1H NMR (DMSO-d6): 1.lS-1.17 
(d, 3H, CH3), l.23-l.2S (d, 3H, CH3), 1.67 (m, 2H, 
CH2CH2Ph), 2.6S (m, 2H, CH2CH2Ph), 2.86 (m, lH, 
60 epoxy), 3.28-3.31 (d, 2H, NCH2CO), 3.63 (s, lH, epoxy), 
4.01 (m, lH, a-H), 4.24 (m, lH, a-H), 4.99 (m, 2H, Cbz), 
7.13 (s, lH, NH), 7.17-7.41 (m, !OH, 2xPh), 7.48 (s, lH, 
NH), 8.17 (d, lH, NH), 10.67 (s, lH, NH). MS (ESI) rn/z 
S40 [(M+ltJ. HRMS (ESI) Calcd. for C27H34N50 7: 
65 S40.2392. Observed rn/z S40.24S8. Anal. Calcd. for 
C27H33N50 7.0.2H20: C, S9.70; H, 6.20; N, 12.89. Found: 
C, S9.46; H, 6.lS; N, 12.76. 




bony lalanylalany 1)-N 1 -carbamoy lmethy lhydrazinocar-
bony l)oxirane (Cbz-Ala-Ala-AAsn-(2S,3S)-EP-CON(nBu) 5 
2) was obtained using the EDC/HOBt coupling method, 
purified by column chromatography on silica gel using 1:9 
MeOH:CH2Cl2 as the eluent, and then recrystallized from 
EtOAc/hexane; white powder, yield 26%. 1H NMR 
(DMSO-d6): 0.84-0.90 (m, 6H, 2xNCH2CH2CH2CH3), 10 
1.17-1.27 (m, !OH, 2xAla-CH3 and 2xNCH2CH2CH2CH3), 
1.41 (t, 2H, NCH2CH2CH2CH3), l.Sl (t, 2H, 
NCH2CH2CH2CH3), 3.20-3.32 (m, 7H, NCH2CO and 
CH
2
NCH2 and epoxy), 3.63 (s, lH, epoxy), 4.04 (m, lH, 
a-H), 4.26 (m, lH, a-H), 4.99 (m, 2H, Cbz), 7.21 (s, lH, 15 
NH), 7.33 (m, SH, Ph), 7.49 (s, lH, NH), 8.lS (d, lH, NH), 
10.62 (s, lH, NH). MS (ESI) m/z S9l [(M+ltJ. HRMS 
(ESI) Calcd. for C28H43N60 8: S9l.30S9. Observed m/z 
S91.314238. Anal. Calcd. for C28H42N60 8.1H20: C, SS.2S; 
70 
column using 1:13 MeOH:CH2Cl2 as the eluent, rechro-
matographed using 1:19 MeOH:CH2Cl2 as the eluent, and 
then recrystallized from EtOAc/hexane; white solid, yield 
8%. HRMS (FAB) Calcd. for C28H35N60 8: S83.2S164. 
Observed m/z S83.2S393. 1H NMR (DMSO-d6 ): 1.1-1.3 
(m, 6H, CH3), 2.7-2.8 (m, 2H, NHCH2CH2Ph), 3.2-3.4 (m, 
2H, NHCH2CH2Ph), 3.8-4.0 (d, lH, epoxy), 4.0-4.1 (m, 
3H, epoxy and NCH2CO), 4.3S-4.S (m, 2H, a-H), 4.9-S.l 
(m, 3H, NH and OCH2Ph), 6.S (d, lH, NH), 7.1-7.4 (m, 
llH, NH and Ph), 8.0S (m, lH, NH), 8.1 (m, lH, NH). Anal. 
Calcd. for C28H34N60 8.0.7SH20: C, S6.42; H, S.96; N, 
14.10. Found: C, S6.81; H, S.92; N, 13.66. 
Example S9 
(2R,3 R )-2-(1-Benzy lcarbamoy lethy lcarbamoy l)-3-(N2 -
(N-benzyloxycarbonylalany lalany 1)-N1 -carbamoy lmethy 1-
hydrazinocarbony l)oxirane ( Cbz-Ala-Ala-AAsn-(2R,3R )-
EP-CO-Ala-NHBzl) was obtained using the EDC/HOBt 
H, 7.29; N, 13.81. Found: C, SS.32; H, 7.10; N, 13.80. 
Example S6 
20 coupling method, purified by chromatography on a silica gel 
column using 1:13 MeOH:CH2Cl2 as the eluent, rechro-
matographed using 1 :7 MeOH:CH2Cl2 as the eluent, and 
then recrystallized from EtOAc/hexane; white solid, yield 
4%. HRMS (FAB)Calcd. for C30H38N70 9 :640.273101. (2S,3S)-3-(N
2 -N-Benzyloxycarbonylalanylalanyl)-N1-
carbamoy lmethy lhydrazinocarbony 1 )oxirane-2-carboxylic 
Acid Phenethyl Ester (Cbz-Ala-Ala-AAsn-(2S,3S)-EP-
COOCH2CH2Ph) was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel using 1:9 MeOH:CH2Cl2 as the eluent, and then recrys-
tallized from EtOAc/hexane; white powder, yield 9%. 1H 
NMR ((CD3)2CO): 1.34 (m, 6H, 2xAla-CH3), 2.87 (s, 2H, 
NCH2CO), 2.98 (t, 2H, CH2Ph), 3.48 (s, lH, epoxy), 4.04 
(m, lH, a-H), 4.17 (m, lH, a-H), 4.28-4.43 (m, 3H, 
CH2CH2Ph and epoxy), S.10 (m, 2H, Cbz), 6.S7 (s, lH, 
NH), 6.6S (s, lH, NH), 7.19-7.38 (m, !OH, 2xPh), 7.77 (s, 35 
lH, NH), 9.89 (s, lH, NH). MS (ESI) m/z S84 [(M+ltJ. 
HRMS (ESI) Calcd. for C28H34N50 9 : S84.233. Observed 
n/z S84.23S6S3. Anal. Calcd. for 
C28H33N50 9 .0.1H200_5Et0Ac: C, S7.18; H, 6.06; N, 11.11. 
Found: C, S6.96; H, S.88; N, 11.08. 
Example S7 
(2S,3S)-2-(N-Methyl-N-benzylcarbamoyl)-3-(N2 -(N 
25 Observed m/z 640.2717. 1 H NMR (DMSO-d6): 1.1-1.4 (m, 
9H, CH3), 3.9-4.2 (m, 4H, epoxy and NCH2CO), 4.2-4.4 
(m, 4H, a-Hand NCH2Ph), 4.4S (m, lH, a-H), 4.9-S.OS (m, 
2H, OCH2Ph), S.OS (s, lH, NH), 6.7 (m, lH, NH), 7.lS-7.S 
(m, !OH, Ph), 8.1-8.2 (m, 2H, NH), 8.4S (m, lH, NH). Anal. 
30 Calcd. for C30H37N70 9 .Et0Ac: C, S6.l2; H, 6.19; N, 13.48. 
Found: C, S6.l9; H, 6.21; N, 13.S6. 
Example 60 
(2S,3S)-2-(2-Benzylcarbamoyl)-3-(N2-(N-benzyloxycar-
bony lalanylalany 1)-N 1 -carbamoy lmethy lhydrazinocar-
bony l)oxirane (Cbz-Ala-Ala-AAsn-(2S,3S)-EP-
CONHCH2Ph) was obtained using the EDC/HOBt coupling 
method, purified by chromatography on a silica gel column 
40 using 1:13 MeOH:CH2Cl2 as the eluent, and then recrystal-
lized from EtOAc/hexane; white solid, yield 1 S%. MS (ESI) 
m/z S69 [(M+lt]. 1H NMR (DMSO-d6 ): l.lS-l.2S (m, 6H, 
CH3), 3.9 (m, lH, epoxy), 4.0-4.1 (m, 3H, epoxy and 
NCH2CO), 4.2-4.3 and 4.3-4.S (m, 3H, a-Hand NCH2Ph), 
45 4.S (m, lH, a-H), 4.9-S.OS (m, 2H, OCH2Ph), S.OS (s, lH, 
NH), 6.S (d, lH, NH), 7.lS-7.3 (m, llH, NH and Ph), 8.0S 
(m, lH, NH), 8.S (m, lH, NH). Anal. Calcd. for 
C27H32N60 8: C, S7.04; H, S.67; N, 14.78. Found: C, S7.ll; 
H, S.83; N, l4.S2. 
-benzy loxycarbony lalanylalany l)-N1 -carbamoy lmethy lhy-
drazinocarbony l)oxirane (Cbz-Ala-Ala-AAsn-(2S,3S)-EP-
CON(CH3)Bzl) was obtained using the EDC/HOBt cou-
pling method, purified by colunm chromatography on silica 
gel using 1:9 MeOH:CH2Cl2 as the eluent, and then recrys-
tallized from EtOAc/hexane; white powder, yield 10%. 1 H 50 
NMR (DMSO-d6 ): 1.11-1.27 (m, 6H, 2xAla-CH3), 2.9S (d, 
3H, N--CH3), 3.20-3.32 ( d, 3H, NCH2CO and epoxy), 3.34 
Example 61 
(s, lH, epoxy), 4.04-4.61 (m, 4H, 2xa-H, CH2Ph), S.02 (m, 
2H, Cbz), 7.21 (s, lH, NH), 7.33 (m, SH, Ph), 7.42 (d, lH, 
NH), 8.20 (d, lH, NH), 10.73 (s, lH, NH). MS (ESI) m/z 55 
S83 [(M+lt]. HRMS (ESI) Calcd. for C28H35N60 8: 
(2S,3S)-3-(N2 -(N-Benzyloxycarbonylalanylalanyl)-N1-
carbamoylmethylhydrazinocarbonyl)oxirane-2-carboxylic 
Acid Benzyl Ester (Cbz-Ala-Ala-AAsn-(2S,3S)-EP-
COOBzl) was obtained using the EDC/HOBt coupling 
S83.2S67. Observed m/z S83.2S1638. Anal. Calcd. for 
C28H34N60 8.l.3H20: C, SS.49; H, 6.09; N, 13.87. Found: 
C, SSAS; H, S.89; N, 13.8S. 
Example S8 
(2S,3S)-2-(2-Phenethylcarbamoyl)-3-(N2-(N -benzyloxy-
carbony lalany lalany 1)-N 1 -carbamoylmethylhydrazinocar-
bony l)oxirane (Cbz-Ala-Ala-AAsn-(2S,3S)-EP-
CONHCH2CH2Ph) was obtained using the EDC/HOBt 
coupling method, purified by chromatography on a silica gel 
method, purified by chromatography on a silica gel column 
using 1:13 MeOH:CH2Cl2 as the eluent, and then recrystal-
lized from EtOAc/hexane; white solid, yield 1 S%. HRMS 
60 (FAB) Calcd. for C27H32N50 9 : S70.22000. Observed m/z 
S70.21949. 1H NMR(DMSO-d6): 1.1-1.3 (m, 6H, CH3), 
3.2S-3.4 and 3.S-3.7 (m, 3H, epoxy and NCH2CO), 4.0S 
(m, 2H, epoxy and a-H), 4.2 (m, lH, a-H), 4.9S and S.2 (m, 
4H, OCH2Ph), 7.2-7.S (m, llH, NH and Ph), 7.S (s, lH, 
65 NH), 8.lS (m, lH, NH). Anal. Calcd. forC27H31N50 9 .H20: 
C, SS.20; H, S.62; N, 11.92. Found: C, SS.SS; H, S.61; N, 
11.49. 
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Example 62 
trans-2-(N2 -(N-Benzy loxycarbony lvaly 1)-N 1 -carboxym-
ethy lhydrazinocarbony 1)-3-( 4-chlorophenyl )oxirane ( Cbz-
Val-AAsp-trans-EP-Ph-4-Cl). 1 H NMR (DMSO-d6): 5 
0.75--0.88 (d, 6H, Val), 1.80 (m, lH, Val), 3.58 (s, lH, 
epoxy), 4.11 (s, lH, NHCH2COOH), 4.35 (s, lH, a-H), 5.02 
(s, 2H, Cbz), 6.18 (d, lH, NH), 7.15-7.53(m, 9H, Ph), 7.92 
(d, lH, NH). HRMS (ESI) Calcd. for C24H26N30 7Cl: 
503.1543. Observed m/z 503.1537. Anal. Calcd. for 10 
C24H26N30 7Cl.1.5H20: C, 54.29; H, 4.93; N, 7.91. Found: 
C, 54.12; H, 5.00; N, 7.68. 
Example 63 
72 
(m, 2H, Benzyl), 7.15-7.37 (m, llH, Ph and NH), 7.84 (m, 
lH, NH), 8.24 (m, lH, NH), 10.90 (b, lH, COOH). HRMS 
(FAB) Calcd. for C30H37N40 9: 597.25605. Observed m/z 
597.25875. Anal. Calcd. for C30H36N40 9.0.5H20: C, 59.49; 





COOCH2CH2Ph). 1H NMR (DMSO-d6): 0.77 (m, 6H, Val 
CH3), 1.18 (m, 3H, Ala CH3), 1.86 (m, lH, Val CH), 2.41 
(m, 2H, PhCH2), 2.76 (t, 2H, PhCH2CH2CO), 2.90 (t, 2H, 
15 PhCH2), 3.32 (s, 2H, AAsp CH2COOH), 3.53 and 3.69 (d, 
2H, epoxy), 4.16 (m, 2H, a-H), 4.27 (m, 2H, OCH2), 
7.12-7.30 (m, llH, Ph and NH), 7.80 (m, lH, NH), 8.24 (d, 
lH, NH), 10.85 (s, lH, COOH). HRMS (FAB) Calcd. for 
C31 H39N40 9: 611.27170. Observed m/z 611.27640. Anal. 
(2S,3S)-3-(N2-(3-Phenylpropanoylvalylalanyl)-N1-car-
boxymethylhydrazinocarbonyl)oxirane-2-carboxylic Acid 
Ethyl Ester (PhPr-Val-Ala-AAsp-(2S,3S)-EP-COOEt). 1H 
NMR (DMSO-d6): 0.75 (m, 6H, Val CH3), 1.17 (m, 6H, Ala 
CH3 and OEt), 1.85 (m, lH, Val CH), 2.42 (m, 2H, PhCH2), 
2.76 (t, 2H, PhCH2CH2CO), 3.32 (s, 2H,AAsp CH2COOH), 
3.59 (d, 2H, epoxy), 4.15 (m, 4H, a-Hand OEt), 7.16-7.24 
(m, 6H, Ph and NH), 7.80 (m, lH, NH), 8.15 (d, lH, NH), 
10.85 (s, lH, COOH). HRMS (FAB) Calcd. for 
C25H35N40 9: 535.24040. Observed m/z 535.24220. Anal. 25 
Calcd. for C25H34N40 9: C, 56.17; H, 6.41; N, 10.48. Found: 
C, 55.90; H, 6.12; N, 10.16. 
Example 64 
20 Calcd. for C31H38N40 9.H20: C, 59.23; H, 6.41; N, 8.91. 
Found: C, 59.19; H, 6.25; N, 9.26. 
Example 68 
(2S,3S )-2-(2-Ethy lcarbamoy l)-3-(N2 -(3-pheny lpro-
panoylvalylalany l)-N1-carboxymethy lhydrazinocarbony l) 
oxirane (PhPr-Val-Ala-AAsp-(2S,3S)-EP-CONHCH2CH3). 1H NMR (DMSO-d6): 0.76 (m, 6H, Val CH3), 1.02 (t, 3H, 
CH3), 1.19 (d, 3H, Ala CH3), 1.90 (m, lH, Val CH), 2.45 (m, 
30 2H, PhCH2), 2.77 (t, 2H, PhCH2CH2CO), 3.09 (m, 2H, 
CH2N), 3.37 (s, 2H, AAsp CH2COOH), 3.41 (s, 2H, epoxy), 
4.17 (m, 2H, a-H), 7.11-7.25 (m, 6H, Ph and NH), 7.82 (d, 
lH, NH), 8.23 (s, lH, NH), 8.36 (t, lH, NH), 10.85 (s, lH, 
COOH). HRMS (FAB) Calcd. for C25H36N50 8: 534.2564. 
(2R,3R)-3-N2 -(3-Phenylpropanoylvalylalanyl)-N1-car-
boxymethylhydrazinocarbonyl)oxirane-2-carboxylic Acid 
Ethyl Ester (PhPr-Val-Ala-AAsp-(2R,3R)-EP-COOEt). 1H 
NMR (DMSO-d6): 0.77 (m, 6H, Val CH3), 1.19 (m, 6H, Ala 
CH3 and OEt), 1.87 (m, lH, Val CH), 2.42 (m, 2H, PhCH2), 
2.76 (m, 2H, PhCH2CH2CO), 3.32 (s, 2H, AAsp 
CH2COOH), 3.45 (s, 2H, epoxy), 4.15 (m, 4H, a-H and 
OEt), 7.11-7.24 (m, 6H, Ph and NH), 7.84 (m, lH, NH), 
8.26 (d, lH, NH), 10.85 (s, lH, COOH). HRMS (FAB) 
Calcd. for C25H35N40 9: 535.24040. Observed m/z 40 
535.24153. Anal. Calcd. for C25H34N40 9.0.5H20 C., 55.25; 
35 Observedm/z 534.2535. Anal. Calcd. for C25H35N50 8.H20: 
C, 54.44; H, 6.76; N, 12.70. Found: C, 54.53; H, 6.65; N, 
12.90. 
Example 69 
(2S,3S )-2-(2-Benzy lcarbamoyl )-3-(N2 -(3-pheny lpro-
panoylvalylalany l)-N1-carboxymethy lhydrazinocarbony l) 
oxirane (PhPr-Val-Ala-AAsp-(2S,3S)-EP-CONHBzl). 1H 
NMR (DMSO-d6): 0.75 (m, 6H, Val CH3), 1.13 (m, 3H, Ala 
H, 6.44; N, 10.31. Found: C, 55.04; H, 6.36; N, 10.26. 
Example 65 
45 CH3), 1.87 (m, lH, Val CH), 2.43 (m, 2H, PhCH2), 2.77 (m, 
2H, PhCH2CH2CO), 3.37 (m, 2H, AAsp CH2COOH), 3.50 
(s, 2H, epoxy), 4.15 (m, 2H, a-H), 4.31 (t, 2H, PhCH2N), 
7.13-7.31 (m, llH, Ph and NH), 7.83 (m, lH, NH), 8.10 (m, 




COOCH2Ph). 1 H NMR (DMSO-d6): 0.77 (m, 6H, Val CH3), 
1.13 (m, 3H, Ala CH3), 1.87 (m, lH, Val CH), 2.42 (m, 2H, 
PhCH2), 2.77 (m, 2H, PhCH2CH2CO), 3.32 (s, 2H, AAsp 
CH2COOH), 3.61 (d, 2H, epoxy), 4.15 (m, 2H, a-H), 5.17 
(m, 2H, Benzyl), 7.15-7.37 (m, llH, Ph and NH), 7.80 (m, 
lH, NH), 8.15 (m, lH, NH), 10.90 (s, lH, COOH). HRMS 
(FAB) Calcd. for C30H37N40 9: 597.25605. Observed m/z 55 
597.26012. Anal. Calcd. for C30H36N40 9.0.5H20: C, 59.49; 
50 (FAB) Calcd. for C30H38N50 8: 596.27204. Observed m/z 
596.27178. Anal. Calcd. for C30H37N50 8.0.7H20: C, 59.22; 




oxirane (PhPr-Val-Ala-AAsp-(2R,3R)-EP-CONHBzl). 1 H 
NMR (DMSO-d6): 0.75 (m, 6H, Val CH3), 1.13 (m, 3H, Ala 





COOCH2Ph). 1 H NMR (DMSO-d6): 0.77 (m, 6H, Val CH3), 
1.13 (m, 3H, Ala CH3), 1.87 (m, lH, Val CH), 2.42 (m, 2H, 
PhCH2), 2.77 (t, 2H, PhCH2CH2CO), 3.32 (s, 2H, AAsp 
CH2COOH), 3.61 (d, 2H, epoxy), 4.15 (m, 2H, a-H), 5.17 
60 CH3), 1.87 (m, lH, Val CH), 2.42 (m, 2H, PhCH2), 2.77 (m, 
2H, PhCH2CH2CO), 3.37 (m, 2H, AAsp CH2COOH), 3.55 
(d, 2H, epoxy), 4.15 (m, 2H, a-H), 4.28 (t, 2H, PhCH2N), 
7.14-7.30 (m, llH, Ph and NH), 7.85 (m, lH, NH), 8.24 (m, 
lH, NH), 8.90 (t, lH, NH), 10.94 (s, lH, COOH). HRMS 
65 (FAB) Calcd. for C30H38N50 8: 596.27204. Observed m/z 
596.27030. Anal. Calcd. for C30H37N50 8.H20: C, 58.72; H, 
6.41; N, 11.41. Found: C, 58.42; H, 6.05; N, 11.62. 






CONHCH2CH2Ph). 1HNMR(DMSO-d6 ): 0.75 (m, 6H, Val 
CH3), 1.18 (m, 3H, Ala CH3), 1.88 (m, lH, Val CH), 2.43 
(m, 2H, PhCH2), 2.47-2.80 (m, 4H, PhCH2CH2CO and 
PhCH2CH2N), 3.32 (m, 4H, NCH2CH2Ph and AAsp 
CH2COOH), 3.43 (s, 2H, epoxy), 4.16 (m, 2H, a-H), 
7.13-7.31 (m, llH, Ph and NH), 7.82 (m, lH, NH), 8.25 (m, 
lH, NH), 8.48 (t, lH, NH), 10.85 (s, lH, COOH). HRMS 
(FAB) Calcd. for C31 H40N5 0 8 : 610.28769. Observed m/z 
610.28714. Anal. Calcd. for C31 H39N50 8 .0.8H20: C, 59.65; 





CONHCH2CH2Ph). 1HNMR(DMSO-d6 ): 0.75 (m, 6H, Val 
CH3), 1.12 (m, 3H, Ala CH3), 1.86 (m, lH, Val CH), 2.40 
(m, 2H, PhCH2), 2.76 (m, 4H, PhCH2CH2CO and 
PhCH2CH2N)), 3.33 (m, 4H, NCH2CH2Ph and AAsp 
CH2COOH), 3.67(s, 2H, epoxy), 4.15 (m, 2H, a-H), 
7.13-7.31 (m, llH, Ph and NH), 7.83 (m, lH, NH), 8.15 (m, 
lH, NH), 8.24 (t, lH, NH), 10.93 (s, lH, COOH). HRMS 
(FAB) Calcd. for C31 H40N5 0 8 : 610.28769. Observed m/z 
610.29073. Anal. Calcd. for C31H39N5 0 8 : C, 59.32 H, 6.58; 
N, 11.16. Found: C, 59.49; H, 6.45; N, 11.59. 
Example 73 
(2S,3S)-2-(2-Hydroxy-2-phenylethylcarbamoyl)-3-(N2-
(3-pheny lpropanoy lvaly lalany 1)-N1 -carboxymethy lhydrazi-
74 
Example 75 
(2S,3S )-2-( 1-Benzy lcarbamoylethylcarbamoyl )-3-(N2 -
(3-pheny lpropanoy lvaly lalany 1)-N 1 -carboxymethylhydrazi-
5 nocarbonyl)oxirane (PhPr-Val-Ala-AAsp-(2S,3S)-EP-CO-
Ala-NHBzl). 1H NMR (DMSO-d6 ): 0.76 (m, 6H, Val CH3), 
1.16 ( d, 3H, Ala CH3), 1.26 ( d, 3H, Ala CH3), 1.88 (m, lH, 
Val CH), 2.43 (m, 2H, PhCH2), 2.78 (t, 2H, PhCH2CH2CO), 
3.33 (d, 2H, AAsp CH2COOH), 3.60 (s, 2H, epoxy), 4.15 
10 (m, 3H, a-H), 4.27 (d, 2H, PhCH2N), 7.13-7.30 (m, llH, Ph 
and NH), 7.80 (d, lH, NH), 8.25 (d, lH, NH), 8.45 (s, lH, 
NH), 8.70 (b, lH, NH), 10.85 (s, lH, COOH). HRMS (FAB) 
Calcd. for C33H43N60 9: 667.30915. Observed m/z 
667.31344. Anal. Calcd. for C33H42N60 9.0.5H20: C, 58.67; 
15 H, 6.37; N, 12.44. Found: C, 58.11; H, 6.31; N, 12.30. 
Example 76 
(2R,3 R )-2-(1-Benzy lcarbamoy lethy lcarbamoy l)-3-(N2 -
20 (3-pheny lpropanoy lvaly lalany l)-N1 -carboxymethylhydrazi-
nocarbony l)oxirane (PhPr-Val-Ala-AAsp-(2R,3R)-EP-CO-
Ala-NHBzl). 1H NMR (DMSO-d6 ): 0.77 (m, 6H, Val CH3), 
1.13 (m, 3H, Ala CH3), 1.25 (d, 3H, Ala CH3), 1.88 (m, lH, 
Val CH), 2.43 (m, 2H, PhCH2), 2.78 (m, 2H, 
25 PhCH2CH2CO), 3.36 (d, 2H, AAsp CH2COOH), 3.50 (s, 
2H, epoxy), 4.15 (m, 3H, a-H),), 4.26 (m, 2H, PhCH2N), 
7.13-7.30 (m, llH, Ph and NH), 7.85 (d, lH, NH), 8.25 (d, 
lH, NH), 8.45 (s, lH, NH), 8.70 (b, lH, NH), 10.93 (s, lH, 
COOH). HRMS (FAB) Calcd. forC33H43N60 9: 667.30915. 
30 Observed m/z 667.31059. Anal. Calcd. for 
35 
C33H42N60 9.H20: C, 57.88; H, 6.48; N, 12.27. Found: C, 






1H NMR (DMSO-d6 ): 0.76 (m, 6H, 
Val CH3), 1.18 (m, 3H, Ala CH3), 1.85 (m, lH, Val CH), 
2.43 (m, 2H, PhCH2), 2.77 (m, 2H, PhCH2CH2), 3.37 (m, 
4H, NCH2 andAAsp CH2COOH), 3.53 (s, 2H, epoxy), 4.16 
(m, 2H, a-H), 4.60 (b, lH, CH), 7.14-7.39 (m, llH, Ph and 45 
NH), 7.80 (m, lH, NH), 8.20 (m, lH, NH), 8.50 (t, lH, NH), 
10.90 (s, lH, COOH). HRMS (FAB) Calcd. for 
C31H40N5 0 9: 626.28260. Observed m/z 626.28608. Anal. 
Calcd. for C31 H39N50 9.H20: C, 57.84; H, 6.42; N, 10.88. 
Found: C, 58.03; H, 6.35; N, 10.65. 
phenylpropanoy lvaly lalanyl )-N 1 -carboxymethy lhydrazi-
nocarbony l)oxirane (PhPr-Val-Ala-AAsp-(2S,3S)-EP-CO-
Leu-NH2). 1H NMR (DMSO-d6 ): 0.74-0.87 (m, 12H, Val 
and Leu CH3), 1.17 ( d, 3H, Ala CH3), 1.45 (m, 2H, Leu 
Example 74 
(2R,3 R )-2-(2-Hydroxy-2-phenylethylcarbamoyl )-3-(N2 -
(3-pheny lpropanoy lvaly lalany 1)-N1 -carboxymethy lhydrazi-
nocarbony l)oxirane (PhPr-Val-Ala-AAsp-(2R,3R)-EP-
CONHCH2CH(OH)Ph). 1 H NMR (DMSO-d6 ): 0.77 (m, 6H, 
Val CH3), 1.17 (m, 3H, Ala CH3), 1.85 (m, lH, Val CH), 
2.43 (m, 2H, PhCH2), 2.77 (m, 2H, PhCH2CH2), 3.32 (m, 
4H, NCH2 andAAsp CH2COOH), 3.40 (s, 2H, epoxy), 4.16 
(m, 2H, a-H), 4.60 (b, lH, CH), 7.13-7.39 (m, llH, Ph and 
NH), 7.80 (m, lH, NH), 8.21 (m, lH, NH), 8.50 (t, lH, NH), 
10.90 (s, lH, COOH). HRMS (FAB) Calcd. for 
C31H40N5 0 9: 626.28260. Observed m/z 626.28250. Anal. 
Calcd. for C31 H39N50 9.H20: C, 57.84; H, 6.42; N, 10.88. 
Found: C, 57.92; H, 6.40; N, 10.76. 
CH2), 1.54 (m, lH, Leu CH), 1.88 (m, lH, Val CH), 2.40 (m, 
2H, PhCH2), 2.78 (t, 2H, PhCH2CH2CO), 3.32 (s, 2H, AAsp 
CH2COOH), 3.56 (s, 2H, epoxy), 4.16 (m, 2H, a-H), 4.26 
(m, lH, a-H), 7.00 (s, lH, NH), 7.15-7.23 (m, 6H, Ph and 
NH), 7.42 (s, lH, NH), 7.85 (d, lH, NH), 8.25 (s, lH, NH), 
8.55 (b, lH, NH), 10.85 (b, lH, COOH). HRMS (FAB) 
Calcd. for C29H43N60 9: 619.30915. Observed m/z 
619.3129. Anal. Calcd. for C29H42N60 9.H20: C, 54.71; H, 
50 6.97; N, 13.20. Found: C, 54.40; H, 6.89; N, 13.18. 
Example 78 
(2R,3R)-2-(3-Methyl-1-amido-butylcarbamoyl)-3-(N2-
55 (3-pheny lpropanoy lvaly lalany 1)-N 1 -carboxymethylhydrazi-
nocarbony l)oxirane (PhPr-Val-Ala-AAsp-(2R,3R)-EP-CO-
Leu-NH2). 1H NMR (DMSO-d6 ): 0.73-0.87 (m, 12H, Val 
and Leu CH3), 1.17 ( d, 3H, Ala CH3), 1.43 (m, 2H, Leu 
CH2), 1.53 (m, lH, Leu CH), 1.87 (m, lH, Val CH), 2.40 (m, 
60 2H, PhCH2), 2.77 (t, 2H, PhCH2CH2CO), 3.32 (s, 2H, AAsp 
CH2COOH), 3.48 (s, 2H, epoxy), 4.20 (m, 3H, a-H), 6.97(s, 
lH, NH), 7.15-7.24 (m, 6H, Ph and NH), 7.42 (s, lH, NH), 
7.85 (d, lH, NH), 8.25 (s, lH, NH), 8.55 (d, lH, NH), 10.85 
(b, lH, COOH). HRMS (FAB) Calcd. for C29H43N60 9: 
65 619.30915. Observed m/z 619.31200. Anal. Calcd. for 
C29H42N60 9.0.7H20: C, 55.18; H, 6.88, N, 13.32. Found: 
C, 55.34; H, 6.81; N, 13.31. 
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Example 79 Example 83 
(2S,3S)-2-(1-Amido-phenethy lcarbamoy l)-3-(N2 -(3-phe-
ny lpropanoylvaly lalany 1)-N 1 -carboxymethy lhydrazinocar-
bony l)oxirane (PhPr-Val-Ala-AAsp-(2S,3S)-EP-CO-Phe- 5 
NH2). 
1HNMR(DMSO-d6): 0.76 (m, 6H, Val CH3), 1.15 (d, 
3H, Ala CH3), 1.90 (m, lH, Val CH), 2.42 (m, 2H, PhCH2), 
2.80 (m, 3H, Phe PhCH2 and PhCH2CH2CO), 3.00 (m, lH, 
Phe PhCH2), 3.32 (s, 2H, AAsp CH2COOH), 3.56 (s, 2H, 
epoxy), 4.16 (m, 2H, a-H), 4.50 (m, lH, Phe a-H), 10 
7.13-7.30 (m, 12H, Ph and NH), 7.54 (s, lH, NH), 7.84 (d, 
lH, NH), 8.25 (s, lH, NH), 8.70 (d, lH, NH), 10.85 (b, lH, 
COOH). HRMS (FAB) Calcd. for C32H41 N60 9: 653.29350. 
Observed m/z 653.29936. Anal. Calcd. for 
C32H40N60 9.H20: C, 57.30; H, 6.31; N, 12.53. Found: C, 15 
57.53; H, 6.14; N, 12.16. 
(2S,3S )-2-(2-Benzy lcarbamoyl )-3-(N2 -(N-benzy loxycar-
bony laspartylglutamylvaly l )-N1-carboxymethy lhydrazi-
nocarbonyl)oxirane (Cbz-Asp-Glu-Val-AAsp-(2S,3S)-EP-
CONHCH2Ph). 1H NMR (CDC13): 0.97 (m, 6H, Val), 
1.9-2.3 (m, 3H, Val and Glu), 2.41 (m, 2H, Glu), 2.80-2.95 
(m, 2H, Asp), 3.63 and 3.97 (d, 2H, epoxy), 4.05-4.22 (m, 
4H, NCH2COOH), 4.20--4.55 (m, 3H, a-H), 4.45 (m, 2H, 
NHCH2Ph), 5.05 (m, 2H, Cbz), 7.20-7.40 (m, !OH, Ph), 
6.15 (m, lH, NH), 6.60 (lH, NH), 7.85 (m, 2H, NH). HRMS 
(ESI) Calcd. for C35H43N60 14: 771.3. Observed m/z 771.4. 
Anal. Calcd. for C35H42N60w2.2H20: C, 51.86; H, 5.77; 
N, 10.36. Found: C, 51.92; H, 5.66; N, 10.39. 
Example 80 
(2R,3R)-2-(1-Amido-phenethylcarbamoyl)-3-(N2-(3-
pheny lpropanoylvaly lalany 1)-N 1 -carboxymethy lhydrazi-
nocarbony l)oxirane (PhPr-Val-Ala-AAsp-(2R,3 R )-EP-CO-
Phe-NH2). 1H NMR (DMSO-d6): 0.77 (m, 6H, Val CH3), 
1.15 (d, 3H, Ala CH3), 1.88 (m, lH, Val CH), 2.43 (m, 2H, 
PhCH2), 2.80 (m, 3H, Phe PhCH2 and PhCH2CH2CO), 2.95 
(m, lH, Phe PhCH2), 3.32 (s, 2H, AAsp CH2COOH), 3.47 
(s, 2H, epoxy), 4.15 (m, 2H, a-H), 4.45 (m, lH, Phe a-H), 
7.13-7.30 (m, llH, Ph and NH), 7.45 (s, lH, NH), 7.83 (d, 
lH, NH), 8.00 (d, lH, NH), 8.15 (b, lH, NH), 8.30 (s, lH, 
NH), 10.88 (s, lH, COOH). HRMS (FAB) Calcd. for 
C32H41N60 9: 653.29350. Observed m/z 653.29525. Anal. 
Calcd. for C32H40N60 9.0.5H20: C, 58.09; H, 6.20; N, 
12.70. Found: C, 57.83; H, 6.31; N, 12.84. 
Example 81 
(2S,3S)-2-(2-Amido-pheny1( 4-hydroxy )ethy lcarbamoyl )-
3-(N2 -(3-phenylpropanoylvalylalanyl)-N1-carboxymethyl-
hydrazinocarbonyl)oxirane (PhPr-Val-Ala-AAsp-(2S,3S)-
EP-CO-Tyr-NH2). 1H NMR (DMSO-d6): 0.78 (m, 6H, Val 
CH3), 1.08 ( d, 3H, Ala CH3), 1.90 (m, lH, Val CH), 2.42 (m, 
2H, PhCH2), 2.77 (m, 3H, Tyr PhCH2 and PhCH2CH2CO), 
2.88 (m, lH, Tyr PhCH2), 3.32 (s, 2H, AAsp CH2COOH), 
3.65 (d, 2H, epoxy), 4.16 (t, lH, a-H), 4.32 (m, 2H, a-H), 
6.59 (d, 2H, Tyr Ph), 6.95 (d, 2H, Tyr Ph), 7.10-7.22 (m, 6H, 
Ph and NH), 7.38 (s, lH, NH), 7.50 (d, lH, NH), 7.85 (d, lH, 
NH), 8.23 (s, lH, NH), 9.13 (d, lH, NH), 10.80 (b, lH, 
COOH). HRMS (FAB) Calcd. for C32H41N60 10 : 669.2884. 
Observed m/z 669.2879. 
Anal. Calcd. forC32H40N60 10.H20: C, 55.97; H, 6.16; N, 
12.24. Found: C, 55.72; H, 6.04; N, 11.98. 
Example 82 
(2S,3S)-3-(N2-(N-Benzyloxycarbonylaspartyl-
glutamy lvaly 1)-N 1 -carboxymethy lhydrazinocarbony l)ox-
irane-2-carboxy lic Acid Benzyl Ester (Cbz-Asp-Glu-Val-
AAsp-(2S,3S)-EP-COOCH2Ph). 1H NMR (DMSO-d6): 
0.85 (m, 6H, Val), 1.80-2.24 (m, 3H, Val, Glu), 2.41 (m, 2H, 
Glu), 2.65-2.90 (m, 2H, Asp), 3.60 and 4.00 (d, 2H, epoxy), 
4.05-4.12 (m, 2H, NCH2COOH), 4.10-4.40 (m, 3H, a-H), 
5.05 (m, 4H, Cbz), 6.05 (m, lH, NH), 7.20-7.40 (m, !OH, 
Ph), 7.85 (m, 2H, NH), 9.05 (m, lH, NH). HRMS (ESI) 
Calcd. for C47H66N50 15: 940.5. Observed m/z 940.5. Anal. 
Calcd. forC35H41N50 15 .l.5H20: C, 52.60; H, 5.55; N, 8.76. 
Found: C, 52.59; H, 5.37; N, 8.76. 
Example 84 
20 (2S,3S)-2-(2-Phenethylcarbamoyl)-3-(N2-(N-benzyloxy-
carbonylglutamy lvalyl )-N 1 -carboxymethy lhydrazinocarbo-
nyl )oxirane (Cbz-Glu-Val-AAsp-(2S,3S)-EP-
CONHCH2CH2Ph). 1H NMR (DMSO-d6): 0.95 (d, 6H, 
25 
Val), 1.20 (t, 3H, OCH2CH3), 1.60-2.10 (m, 3H, Val and 
Glu), 2.21 (m, 2H, Glu), 3.60 and 4.10 (d, 2H, epoxy), 
3.90--4.20 (m, 4H, NCH2COOH, andOCH2CH3), 4.20-4.30 
(m, 2H, a-H), 5.05 (m, 2H, Cbz), 7.20-7.40 (m, SH, Ph), 
8.00 (m, lH, NH), 11.00 (m, COOH). HRMS (FAB) Calcd. 
30 for C32H40N50 11 : 670.2724. Observed m/z 670.2822. Anal. 
35 
40 
Calcd. for C32H39N50 11 .H20: C, 55.88; H, 6.00; N, 10.19. 
Found: C, 55.91; H, 5.89; N, 10.32. 
Example 85 
(2R,3R)-2-(1-Amido-phenethylcarbamoyl)-3-(N2-(N-
benzyloxycarbonylasparty lglutamy lvaly 1)-N 1 -carboxym-
ethylhydrazinocarbony l)oxirane (Cbz-Glu-Val-AAsp-(2R, 
3R)-EP-CO-Phe-NH2). 
1H NMR (DMSO-d6): 0.94 (m, 6H, 
Val), 1.62-2.00 (m, 3H, Val and Glu), 2.20 (m, 2H, Glu), 
2.80 and 3.00 (m, 2H, Phe), 3.60 and 4.05 (d, 2H, epoxy), 
4.05 (m, 2H, NCH2COOH), 4.05-4.40 (m, 3H, a-H), 5.10 
(m, 2H, Cbz), 7.0 (s, 2H, NH2), 7.10-7.40 (m, !OH, Ph), 
45 8.00 (m, 2H, NH). HRMS Calcd. for C33H41N60 12: 
713.2782 Observed m/z 713.2811. Anal. Calcd. for 
C33H40N60 12 .1.0H20: C, 54.21; H, 5.68; N, 11.34. Found: 
C, 54.24; H, 5.79; N, 10.50. 
50 Example 86 
(2S,3S)-3-(N2 -(N-Benzyloxycarbonylleucyl-
glutamy lthreonyl )-N1 -carboxymethy lhydrazinocarbonyl) 
oxirane-2-carboxylic Acid Benzyl Ester (Cbz-Leu-Glu-Thr-
55 AAsp-(2S,3S)-EP-COOCH2Ph). 
1H NMR (DMSO-d6): 
0.7--0.9 (t, 6H, Leu CH3), 0.9-1.1 (d, 3H, Thr CH3), 1.3-1.5 
(m, 2H, Leu CH2), 1.6-1.7 (m, lH, CH Leu), 1.7-1.8 (m, 
lH, Glu CH2), 1.8-2.0 (m, lH, Glu CH2), 2.2-2.35 (m, 2H, 
60 
Glu CH2), 3.6 (s, lH, epoxy), 3.9-4.1 (m, 4H, NCH2COOH, 
epoxy, a-H), 4.1-4.3 (m, lH, CH-OH), 4.3-4.4 (m, 2H, 
a-H), 4.95 (m, H, NH), 4.95-5.05 and 5.1-5.3 (m, 4H, Cbz), 
7.20--7.50 (m, !OH, Ph), 7.78 (m, lH, NH), 8.05 (m, lH, 
NH), 11.00 (m, COOH). HRMS (FAB) Calcd. for 
65 C36H46N50 14: 772.30413. Observed m/z 772.30610. Anal. 
Calcd. for C36H46N50wH20: C, 54.75; H, 5.96; N, 8.87. 
Found: C, 54.78; H, 5.94; N, 8.87. 
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Example 87 
(2S,3 S)-2-(2-Phenethylcarbamoyl )-3-(N2 -(N -benzyloxy-
carbony lleucy lglutamy lthreony 1)-N 1 -carboxymethylhy-
drazinocarbony l)oxirane (Cbz-Leu-Glu-Thr-AAsp-(2S,3S)- 5 
EP-CONHCH2CH2Ph). 
1H NMR (DMSO-d6): 0.83 (t, 6H, 
Leu CH3), 1.00 (m, 3H, Thr CH3), 1.40 (m, 2H, Leu CH2), 
1.60 (m, 1 H, Leu CH), 1. 75 and 1.90 ( d of m, 2H, Glu CH2), 
2.23 (m, 2H, Glu CH2), 2.71 (t, 2H, CH2Ph), 3.32 (s, 2H, 
AAsp CH2), 3.43 and3.52 (d, 2H, epoxy), 3.92 (b, 2H, a-H), 10 
4.02 (b, lH, a-H), 4.19 (m, lH, Thr CH), 4.34 (m, 2H, 
NCH2), 4.99 (s, 2H, Z), 7.15-7.35 (m, !OH, Ph), 7.40 (d, lH, 
NH), 7.78 (b, lH, NH), 8.00 (b, lH, NH), 8.15 (s, lH, NH), 
8.20 (b, lH, NH), 10.80 (b, 2H. COOH). HRMS (FAB) 
Calcd. for C37H49N60 13 : 785.3358. Observed m/z 15 
785.3400. Anal. Calcd. for C37H48N60 13 .H20: C, 55.35; H, 
6.28; N, 10.47. Found: C, 54.96; H, 6.13; N, 10.21. 
Example 88 
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Calcd. for C36H46N50 14: 772.30413. Observed m/z 
772.30837. Anal. Calcd. for C36H45N50wH20: C, 54.75; 
H, 5.96; N, 8.87. Found: C, 54.51; H, 5.82; N, 8.82. 
Example 91 
(2R,3R)-2-(2-Benzylcarbamoyl)-3-(N2-(N-benzyloxycar-
bony lisoleucy lglutamy lthreony 1)-N 1 -carboxymethy lhy-
drazinocarbony l)oxirane (Cbz-Ile-Glu-Thr-AAsp-(2R,3R)-
EP-CONHCH2Ph). 1H NMR (DMSO-d6): 0.7-0.9 (m, 6H, 
Ile CH3), 0.9-1.15 (m, 4H, Thr CH3 and Ile CH2), 1.4 (m, 
lH, Ile CH2), 1.65-1.8 (m, 2H, CH Ile and-Glu CH2), 
1.8-2.0 (m, lH, Glu CH2), 2.2-2.3 (m, 2H, Glu CH2), 3.5 ( d, 
lH, epoxy), 3.8-4.0 (m, 3H, NCH2COOH and CH-OH), 
4.03 (d, lH, epoxy), 4.1-4.2 (m, lH, a-H), 4.3-4.4 (m, 2H, 
NHCH2Ph), 4.4 (m, 2H, a-H), 4.9-5.1 (m, 2H, Cbz), 
7.15-7.40 (m, !OH, Ph), 7.85 (m, lH, NH), 8.05 (m, lH, 
NH), 11.00 (m, COOH). HRMS (FAB) Calcd. for 
C36H47N60 13 : 771.32011. Observed m/z 771.33322. Anal. 
Calcd. for C36H46N60 13 .l.25H20: C, 54.51; H, 6.12; N, 
(2S,3S)-2-(1-Benzylcarbamoyl-ethylcarbamoyl)-3-(N2 -
(N-benzyloxycarbonylleucy lglutamy lthreony l)-N1 -car-
boxymethylhydrazinocarbony l)oxirane ( Cbz-Leu-Glu-Thr-
AAsp-(2S,3 S )-EP-CO-Ala-NHBzl ). 1H NMR (DMSO-d6): 
0.83 (t, 6H, Leu CH3), 0.99 (d, 3H, Thr CH3), 1.25 (d, 3H, 
20 10.60. Found: C, 54.30; H, 6.04; N, 10.36. 
25 
Ala CH3), 1.39 (m, 2H, Leu CH2), 1.60 (m, lH, Leu CH), 
1.75 and 1.90 (d of m, 2H, Glu CH2), 2.24 (m, 2H, Glu 
CH2), 3.32 (s, 2H,AAsp CH2), 3.56 and 3.64 (d, 2H, epoxy), 
3.95 (b, lH, a-H), 4.02 (b, 2H, a-H), 4.19 (m, lH, a-H), 
4.26 (d, lH, Thr CH), 4.35 (m, 2H, CH2Ph), 4.99 (s, 2H, Z), 30 
7.15-7.35 (m, llH, Ph and NH), 7.40 (d, lH, NH), 7.75 (b, 
lH, NH), 8.05 (d, lH, NH), 8.45 (m, 2H, NH), 10.85 (b, 2H. 
COOH). HRMS (FAB) Calcd. for C39H52N70 14: 842.3572. 
Observed m/z 842.3336. Anal. Calcd. for 
C39H51N70wH20: C, 54.48; H, 6.21; N, 11.40. Found: C, 35 
53.83; H, 5.96; N, 11.10. 
Example 89 
(2S,3S)-3-(N1 -(N-Benzyloxycarbonylisoleucyl-
40 glutamy lthreonyl )-N1 -carboxymethy lhydrazinocarbonyl) 
oxirane-2-carboxylic Acid Benzyl Ester (Cbz-Ile-Glu-Thr-
AAsp-( 2S13S)-EP-COOCH2Ph). 
1 H NMR (DMSO-d6): 0.8 
(m, 6H, Ile CH3), 0.9-1.2 (m, 4H, Thr CH3 and Ile CH2), 
1.3-1.5 (m, lH, Ile CH2), 1.6-1.8 (m, 2H, CH Ile and Glu 
CH2), 1.8-2.0 (m, lH, Glu CH2), 2.2-2.3 (m, 2H, Glu CH2), 45 
3.55 (d, lH, epoxy), 3.9-4.0 (m, 3H, NCH2COOH and 
CH-OH), 4.05 (d, lH, epoxy), 4.2 (m, lH, a-H), 4.4 (m, 
2H, a-H), 4.95 (m, lH, NH), 5-5.05 and 5.1-5.2 (m, 4H, 
Cbz), 7.20-7.40 (m, !OH, Ph), 7.80 (m, lH, NH), 8.1 (m, 
lH, NH), 11.00 (m, COOH). HRMS (FAB) Calcd. for 50 
C36H46N50 14: 772.30413. Observed m/z 772.30898. Anal. 
Calcd. for C36H45N50wH20: C, 54.75; H, 5.96; N, 8.87. 




boxymethylhydrazinocarbony l)oxirane ( Cbz-Ile-Glu-Thr-
AAsp-(2S,3 S )-EP-CO-Ala-NHBzl ). 1H NMR (DMSO-d6): 
0.79 (m, 6H, Ile CH3), 1.01 (d, 3H, Thr CH3), 1.10 (m, 2H, 
Ile CH2), 1.25 (d, 3H, Ala CH3), 1.39 (m, lH, Ile CH), 1.70 
and 1.90 (d of m, 2H, Glu CH2), 2.24 (m, 2H, Glu CH2), 
3.32 (s, 2H, AAsp CH2), 3.57 (s, 2H, epoxy), 3.88 (t, lH, 
a-H), 3.95 (b, 2H, a-H), 4.20 (m, lH, a-H), 4.28 (d, lH, Thr 
CH), 4.36 (m, 2H, CH2Ph), 4.99 (s, 2H, Z), 7.15-7.35 (m, 
llH, Ph and NH), 7.40 (d, lH, NH), 7.75 (b, lH, NH), 8.05 
(d, lH, NH), 8.45 (m, 3H, NH), 10.85 (b, 2H, COOH). 
HRMS (FAB) Calcd. for C39H52N70 14: 842.35722. 
Observed m/z 842.36598. Anal. Calcd. for 
C39H51N70w2H20: C, 53.42; H, 6.31; N, 11.18. Found: C, 
53.06; H, 6.25; N, 10.97. 
Example 93 
(2S,3S)-3-(N2 -(N-Morpholinylcarbonyl)-N1-phenethyl-
hydrazinocarbonyl)oxirane-2-carboxylic Acid Ethyl Ester 
(Morph-CO-AHph-( 2S,3S)-EP-COOEt) was obtained 
using the EDC/HOBt coupling method. The crude product 
was purified by colunm chromatography using 1: 13 MeOH: 
CH
2 
Cl2 as an eluent, then rechromatographed using 1: 19 
MeOH:CH
2
Cl2 as an eluent, and was rechromatographed a 
final time using 50:50 (2:1 EtoAc:Hexane):(1:19 MeOH: 
CH2Cl2) as the eluent; oil (8% yield). HRMS (FAB) Calcd. 
for C19H26N306: 392.18216. Observed m/z 392.18454. 
1H 
NMR (DMSO-d6): 1.25 (t, 3H, OCH2CH3), 2.8 (m, 2H, 
CH2Ph), 3.3-3.4 (m, 2H, NCH2 morph), 3.4-3.6 (m, 6H, Example 90 
(2R,3R)-3-(N2-(N-Benzyloxycarbonylisoleucyl-
55 OCH2, OCH2 and NCH2 morph), 3.7 (m, lH, epoxy), 3.9 
(m, 2H, NCH2Cl2), 4.1-4.2 (m, 3H, epoxy and OCH2CH3), 
7.1-7.3 (m, SH, Ph), 9.4 (s, lH, NH). Anal. Calcd. for 
C19H25N30 6.0.25H20: C, 57.65; H, 6.45; N, 10.62. Found: 
glutamy lthreonyl )-N 1 -carboxymethy lhydrazinocarbonyl) 
oxirane-2-carboxylic Acid Benzyl Ester (Cbz-Ile-Glu-Thr-
AAsp-(2R,3R)-EP-COOCH2Ph). 1H NMR (DMSO-d6): 
0.7-0.9 (m, 6H, Ile CH3), 0.9-1.2 (m, 4H, Thr CH3 and Ile 
60 
CH2), 1.4 (m, lH, Ile CH2), 1.6-1.8 (m, 2H, CH Ile and Glu 
CH2), 1.8-2.0 (m, lH, Glu CH2), 2.2-2.35 (m, 2H, Glu 
CH2), 3.55-3.6 (d, lH, epoxy), 3.8-4.0 (m, 3H, 
NCH2COOH and CH-OH), 4.05 (d, lH, epoxy), 4.15 (m, 
lH, a-H), 4.3-4.5 (m, 2H, a-H), 4.9-5.1 and 5.1-5.3 (m, 
4H, Cbz), 7.20-7.50 (m, !OH, Ph), 7.7-7.9 (m, lH, NH), 
8-8.15 (m, lH, NH), 11.00 (m, COOH). HRMS (FAB) 
C, 57.78; H, 6.69; N, 10.34. 
The above specification and Examples fully disclose how 
to make and use the compounds of the present invention. 
However, the present invention is not limited to the particu-
lar embodiments described hereinabove, but includes all 
modifications thereof within the scope of the following 
65 claims. The various references to journals, patents, and other 
publications which are cited herein comprise the state of the 
art and are incorporated herein by reference. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 4 
<210> SEQ ID NO 
<211> LENGTH: 5 
<212> TYPE: PRT 
<213> ORGANISM: Artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: consenus active site motif for caspases 
<220> FEATURE: 
<221> NAME/KEY: MISC_FEATURE 
<222> LOCATION: (4) .. (4) 
<223> OTHER INFORMATION: X ~ R, Q, OR G 
<400> SEQUENCE: 
Gln Ala Cys Xaa Gly 
1 5 
<210> SEQ ID NO 2 
<211> LENGTH: 4 
<212> TYPE: PRT 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: 
<400> SEQUENCE: 2 
Trp Glu His Asp 
1 
<210> SEQ ID NO 
<2 11 > LENGTH : 4 
<212> TYPE: PRT 
<213> ORGANISM: artificial 
<220> FEATURE: 
caspase recognition sequence 
<223> OTHER INFORMATION: caspase group II recognition sequence 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (3) .. (3) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE: 
Asp Glu Xaa Asp 
1 
<210> SEQ ID NO 
<2 11 > LENGTH : 4 
<212> TYPE: PRT 
<213> ORGANISM: artificial 
<220> FEATURE: 
<223> OTHER INFORMATION: caspase group III recognition sequence 
<220> FEATURE: 
<221> NAME/KEY: MISC_FEATURE 
<222> LOCATION: (1) .. (1) 
<223> OTHER INFORMATION: X ~ V OR L 
<220> FEATURE: 
<221> NAME/KEY: misc_feature 
<222> LOCATION: (3) .. (3) 
<223> OTHER INFORMATION: Xaa can be any naturally occurring amino acid 
<400> SEQUENCE: 
Xaa Glu Xaa Asp 
80 
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What is claimed is: 
1. A compound of the formula: 
wherein, 
R1 is selected from the group consisting ofM1, M2-AA1, 
M2-AA2-AA1, and M2-AA3-AA2-AA1; 
10 
M1 is selected from the group consisting ofNH2--CO-, 15 
NH2--CS-, NH2-S02-, X-NH--CO-, X2N-
CO-, X-NH--CS-, X2N--CS-, X-NH-
S02-, X2N-S02-, X-CO-, X-CS-, 
Y-S02-, Y-0---CO-, Y---0-CS-, phenyl sub-
stituted with K, phenyl disubstituted with K, and mor- 20 
pholine-CO-; 
M2 is selected from the group consisting of H, NH2-
CO-, NH2--CS-, NH2-S02-, X-NH--CO-, 
X2N--CO-, X-NH--CS-, X2N-CS-, 
X-NH-S02-, X2N-S02-, X-CO-, X-CS-, 
25 
Y-S02-, Y---0-CO-, Y---0-CS-, phenyl, 
phenyl substituted with K, phenyl disubstituted with K, 
and morpholine-CO-; 
Xis selected from the group consisting ofH, C1_10 alkyl, 30 
c3-15 cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl sub-
stituted with J, cl-10 fluoroalkyl substituted with J, 
1-admantyl, 9-fluorenyl, phenyl, phenyl substituted 
with K, phenyl disubstituted with K, phenyl trisubsti-
tuted with K, naphthyl, naphthyl substituted with K, 
35 
naphthyl disubstituted with K, naphthyl trisubstituted 
with K, C1_10 fluoroalkyl with an attached phenyl 
group, cl-10 alkyl with an attached phenyl group, cl-10 
alkyl with two attached phenyl groups, cl-10 alkyl with 
an attached phenyl group substituted with K, C1_10 40 
alkyl with two attached phenyl groups substituted with 
K, C1_10 alkyl with an attached naphthyl group, C1_10 
alkyl with an attached naphthyl group substituted with 
K, C1_10 alkyl with an attached phenoxy group, bioti-
nyl, and C1_10 alkyl with an attached phenoxy group 45 
substituted with K on the phenoxy group; 
Y is selected from the group consisting of C1_10 alkyl, 
c315 cyclized alkyl, cl-10 fluoroalkyl, cl-10 alkyl sub-
stituted with J, cl-10 fluoroalkyl substituted with J, 
1-admantyl, 9-fluorenyl, phenyl, phenyl substituted 50 
with K, phenyl disubstituted with K, phenyl trisubsti-
tuted with K, naphthyl, naphthyl substituted with K, 
naphthyl disubstituted with K, naphthyl trisubstituted 
with K, C1_10 fluoroalkyl with an attached phenyl 
group, cl-10 alkyl with an attached phenyl group, cl-10 55 
alkyl with two attached phenyl groups, cl-10 alkyl with 
an attached phenyl group substituted with K, C1_10 
alkyl with two attached phenyl groups substituted with 
K, C1_10 alkyl with an attached naphthyl group, C1_10 
alkyl with an attached naphthyl group substituted with 60 
K, C1_10 alkyl with an attached phenoxy group, bioti-
nyl, and C1_10 alkyl with an attached phenoxy group 
substituted with K on the phenoxy group; 
J is selected from the group consisting of halogen, C02H, 
OH, CN, N02, NH2, C1_10 alkoxy, C1_10 alkylamino, 65 
C212 dialkylamino, C1_10 alkyl-0-CO-, C1_10 alkyl-
0---CO-NH-, and C1_10 alkyl-S-; 
82 
K is selected from the group consisting of halogen, C1_10 
alkyl, cl-10 perfluoroalkyl, cl-10 alkoxy, phenoxy, 
N02, CN, OH, C02H, amino, C1_0 alkylamino, C2_12 
dialkylamino, C1_10 acyl, and C1_10 alkoxy-CO-, and 
C1_10 alkyl-S-; 
AA1, AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pra-
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, beta-
alanine, norleucine, norvaline, alpha-aminobutanoic 
acid, epsilon-aminocaproic acid, citrulline, hydrox-
yproline, omithine, homoarginine, sarcosine, indoline 
2-carboxylic acid, 2-azetidinecarboxylic acid, pipe-
colinic acid (2-piperidine carboxylic acid), 0-meth-
ylserine, 0-ethylserine, S-methylcysteine, S-ethylcys-
teine, S-benzylcysteine, NH2-CH(CH2CHEt2)-




C02H, NH2--CH(CH2-cyclopropyl)-C02H , trifluoro-
leucine, 4-fluorophenylalanine, lysine substituted on 
the epsilon nitrogen with a biotinyl group, and 
hexafluoroleucine; 
R2 is selected from the group consisting of C1_10 alkyl, 
cl 10 alkyl substituted with Q, cl-10 alkyl substituted 
with phenyl, C1_10 alkyl with an attached phenyl sub-
stituted with K, C1_10 alkyl substituted with naphthyl, 
C110 alkyl with an attached naphthyl substituted with K, 
phenyl, phenyl substituted with K, naphthyl, naphthyl 
substituted with K, C1_10 alkyl substituted with 
CONH2, C1_10 alkyl substituted with CONHR4 , C1_10 
alkyl substituted with C02H, C1_10 alkyl substituted 
with C02R4 , cH2CH2SCH3, CH2-3-indolyl, CH2-2-
thienyl, CH2-2-furyl, CH2-3-furyl, CH2-2-imidazyl, 
C110 alkyl substituted with G, C1_10 alkyl with an 
attached phenyl substituted with G, C1_10 alkyl with an 
attached naphthyl substituted with G, phenyl substi-
tuted with G, and naphthyl substituted with G; 
R4 is selected from the group consisting ofC1_10 alkyl and 
cl-10 alkyl substituted with phenyl; 
Q is selected independently from the group consisting of 
C1_10 alkoxy, C1_10 alkyl-S-, C1_10 alkoxy substituted 
with phenyl, and C1_10 alkyl-S- substituted with phe-
nyl; 
G is selected independently from the group consisting of 
amidino (--C(=NH)NH2), guanidino (-NHC(=NH) 
NH2), isothiureido (-S-C(=NH)NH2), amino, C1_6 
alkylamino, c2-12 dialkylamino, and imidazyl; 
R3 is selected independently from the group consisting of 
R5, C02H, C02R5, CONHR6 , CONR6R7 , CO-AA4 -T, 







R5 is selected independently from the group consisting of 20 
cl-10 alkyl, c3-15 cyclized alkyl, cl-10 alkyl with a 
phenyl group attached to the cl-10 alkyl, c3-15 cyclized 
alkyl with an attached phenyl group, C1_10 alkyl with an 
attached phenyl group substituted with K, C1_10 alkyl 
with an attached phenyl group disubstituted with K, 25 
cl 10 alkyl with an attached phenyl group trisubstituted 
with K, C3_15 cyclized alkyl with an attached phenyl 
group substituted with K, C1_10 alkyl with a naphthyl 
group attached to the cl-10 alkyl, c3-15 cyclized alkyl 
with an attached naphthyl group, C1_10 alkyl with an 30 
attached naphthyl group substituted with K, C1_10 alkyl 
with an attached naphthyl group disubstituted with K, 
C1_10 alkyl with an attached naphthyl group trisubsti-
tuted with K, and C3_15 cyclized alkyl with an attached 
naphthyl group substituted with K; 35 
T is selected independently from the group consisting of 
OH, OR8 , NHR9 , and NR8R9 ; 
AA4 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of 40 
alanine, valine, leucine, isoleucine, praline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, phenylglycine, beta-alanine, norleu- 45 
cine, norvaline, alpha-aminobutanoic acid, epsilon-
aminocaproic acid, citrulline, hydroxyproline, orni-
thine, homoarginine, sarcosine, indoline 2-carboxylic 
acid, 2-azetidinecarboxylic acid, pipecolinic acid (2-pi-
peridine carboxylic acid), 0-methylserine, 0-eth- 50 
ylserine, S-methylcysteine, S-ethylcysteine, S-benzyl-
cysteine, NH2---CH(CH2CHEt2)-C02H, alpha-
aminoheptanoic acid, NH2-CH(CH2-l-naphthyl)-
C02H, NH2---CH(CH2-2-naphthyl)-C02H, NH2---CH 
(CH2-cyclohexyl)-C02H, NH2-CH(CH2- 55 
cyclopentyl)-C02H, NH2---CH(CH2-cyclobutyl)-
C02H, NH2---CH(CH2-cyclopropyl)-C02H, 
trifluoroleucine, 4-fluorophenylalanine, lysine substi-
tuted on the epsilon nitrogen with a biotinyl group, and 
hexafluoroleucine; 60 
R6 and R7 are selected independently from the group 
consisting ofH, C1_10 alkyl, C3_20 cyclized alkyl, C1_10 
alkyl with a phenyl group attached to the cl-10 alkyl, 
cl 10 alkyl with two phenyl groups attached to the cl-10 
alkyl, C3_20 cyclized alkyl with an attached phenyl 65 
group, phenyl, phenyl substituted with K, C1_10 alkyl 
with an attached phenyl group substituted with K, C1_10 
84 
alkyl with an attached phenyl group disubstituted with 
K, C1_10 alkyl with an attached phenyl group trisubsti-
tuted with K, C1_10 alkyl with two phenyl groups 
attached to the C1_10 alkyl and substituted with Kon the 
phenyl group, cl-10 alkyl with two phenyl groups 
attached to the C1_10 alkyl and disubstituted with K on 
the phenyl groups, c3-20 cyclized alkyl with an attached 
phenyl group substituted with K, C1_10 alkyl with a 
morpholine [-N(CH2CH2)0] ring attached through 
nitrogen to the alkyl, cl-10 alkyl with a piperidine ring 
attached through nitrogen to the alkyl, cl-10 alkyl with 
a pyrrolidine ring attached through nitrogen to the 
alkyl, C1_20 alkyl with an OH group attached to the 
alkyl, ---CH2CH2CH20CH3, C1_10 alkyl with an 
attached 4-pyridyl group, C1_10 alkyl with an attached 
3-pyridyl group, cl-10 alkyl with an attached 2-pyridyl 
group, C1_10 alkyl with an attached cyclohexyl group, 
-NH-CH2CH2-( 4-hydroxyphenyl), -NH-
CH2CH2-(3-indolyl), C1_10 alkyl with an attached 2-fu-
ryl group, cl-10 alkyl with an attached 3-furyl group, 
and C1_5 alkyl with an attached phenyl and a hydroxyl 
attached to the cl-5 alkyl; 
R8 and R9 are selected independently from the group 
consisting of H, C1_10 alkyl, phenyl, nitrophenyl, and 
C
110 
alkyl substituted with phenyl; or a pharmaceuti-
cally acceptable salt, pharmaceutically derivative, 
hydrate or solvate thereof. 
2. A compound according to claim 1 wherein: 
R1 is selected from the group consisting of M2-AA1, 
M2-AA2-AA1, and M2-AA3-AA2-AA1; 
M2 is selected from the group consisting of H, X---CO-, 
X-NH-CO-, Y-S02-, and Y---0---CO-; 
Xis selected from the group consisting ofH, C1_10 alkyl, 
C1_10 alkyl substituted with J, phenyl, phenyl substi-
tuted with K, naphthyl, naphthyl substituted with K, 
cl 10 alkyl with an attached phenyl group, cl-10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with an attached naphthyl group, C1_10 alkyl with 
an attached naphthyl group substituted with K, C1_10 
alkyl with an attached phenoxy group, and C1_10 alkyl 
with an attached phenoxy group substituted with K on 
the phenoxy group; 
Y is selected from the group consisting of C1_10 alkyl, 
C
110 
alkyl substituted with J, phenyl, phenyl substituted 
with K, naphthyl, naphthyl substituted with K, C1_10 
alkyl with an attached phenyl group, C1_10 alkyl with an 
attached phenyl group substituted with K, C1_10 alkyl 
with an attached naphthyl group, C1_10 alkyl with an 
attached naphthyl group substituted with K, C1_10 alkyl 
with an attached phenoxy group, and C1_10 alkyl with 
an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of C02H, OH, 
NH2, C1_10 alkoxy, C1_10 alkylamino, and C1_10 alkyl-
0---CO-; 





perfluoroalkyl, C1_10 alkoxy, N02, CN, OH, C02H, 
amino, cl-10 alkylamino; 
AA1, AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pro 
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid, epsilon-
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cyclopentyl)-C02H, NH2---CH(CH2-cyclobutyl)- 5 
C02H, and NH2-CH(CH2-cyclopropyl)-C02H; 
R2 is selected from the group consisting of C1 _10 alkyl 
substituted with CONH2, C1_10 alkyl substituted with 
C02H, and C1_10 alkyl substituted with C02R4 ; 
R4 is selected from the group consisting ofC1 _10 alkyl and 10 
cl-10 alkyl substituted with phenyl; 
R3 is selected independently from the group consisting of 
Rs, C02H, C02Rs, CONHR6 , CONR6R7 , and 
CO-AA4 -T; 
Rs is selected independently from the group consisting of 15 
cl-10 alkyl, cl-10 alkyl with a phenyl group attached to 
the cl-10 alkyl, cl-10 alkyl with an attached phenyl 
group substituted with K, C1 _10 alkyl with a naphthyl 
group attached to the cl-10 alkyl, and cl-10 alkyl with 
an attached naphthyl group substituted with K. 20 
AA4 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, praline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, 25 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, phenylglycine, norleucine, norval-
ine, alpha-aminobutanoic acid, epsilon-aminocaproic 
acid, omithine, homoarginine, sarcosine, alpha-amino- 30 
heptanoic acid, NH2-CH(CH2-l-naphthyl) -C02H, 
NH2---CH(CH2-2-naphthyl)-C02H, NH2-CH(CH2-
cyclohexyl)-C02H, NH2---CH(CH2-cyclopentyl)-
C02H, NH2---CH(CH2-cyclobutyl)-C02H, and NH2-
CH(CH2-cyclopropyl)-C02H; 35 
R6 and R7 are selected independently from the group 
consisting ofH, C1_10 alkyl, C3 _20 cyclized alkyl, C1_10 
alkyl with a phenyl group attached to the cl-10 alkyl, 
cl 10 alkyl with two phenyl groups attached to the cl-10 
alkyl, C3 _20 cyclized alkyl with an attached phenyl 40 
group, phenyl, phenyl substituted with K, C1 _10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with an attached phenyl group disubstituted with 
K, C1_10 alkyl with an attached phenyl group trisubsti-
tuted with K, C1_10 alkyl with two phenyl groups 45 
attached to the cl-10 alkyl, cl-10 alkyl with two phenyl 
groups attached to the C1 _10 alkyl and substituted with 
K on the phenyl group, C1_10 alkyl with two phenyl 
groups attached to the cl-10 alkyl and disubstituted 
with Kon the phenyl groups, C3 _20 cyclized alkyl with 50 
an attached phenyl group substituted with K, C1_20 
alkyl with an OH group attached to the alkyl, 
---CH2CH2CH20CH3 , C1_10 alkyl with an attached 
4-pyridyl group, cl-10 alkyl with an attached 3-pyridyl 
group, cl-10 alkyl with an attached 2-pyridyl group, 55 
C
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alkyl with an attached cyclohexyl group, -NH-
CH2CH2-( 4-hydroxyphenyl), -NH---CH2CH2CH2-
(3-indolyl), cl-10 alkyl with an attached 2-furyl group, 
cl-10 alkyl with an attached 3-furyl group, and cl-S 
alkyl with an attached phenyl and a hydroxyl attached 60 
to the cl-S alkyl; 
R8 and R9 are selected independently from the group 
consisting of H, C1_10 alkyl, phenyl, nitrophenyl, and 
cl 10 alkyl substituted with phenyl. 
3. A compound according to claim 2 wherein 65 
Xis selected from the group consisting ofH, C1_10 alkyl, 
phenyl, naphthyl, C1 _10 alkyl with an attached phenyl 
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group, C1_10 alkyl with an attached naphthyl group, and 
C1_10 alkyl substituted with C02H; 
AA1 , AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pra-
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid, epsilon-
aminocaproic acid, ornithine, homoarginine, sarcosine, 
NH2-CH(CH2-l-naphthyl)-C02H, and NH2---CH 
(CH2-2-naphthyl)-C02H; 
Rs is selected independently from the group consisting of 
cl-10 alkyl and cl-10 alkyl with a phenyl group attached 
to the cl-10 alkyl; 
AA4 are side chain blocked or unblocked amino acids 
with the L configuration, D configuration, or no chiral-
ity at the a-carbon selected from the group consisting 
of alanine, valine, leucine, isoleucine, praline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, phenylglycine, norleucine, norval-
ine, alpha-aminobutanoic acid, epsilon-aminocaproic 
acid, citrulline, homoarginine, sarcosine, NH2---CH 
(CH2-l-naphthyl)-C02H, and NH2---CH(CH2-2-naph-
thyl)-C02H; 
R6 and R7 are selected independently from the group 
consisting of H, C1 _10 alkyl, C1_10 alkyl with a phenyl 
group attached to the cl-10 alkyl, cl-10 alkyl with two 
phenyl groups attached to the cl-10 alkyl, phenyl sub-
stituted with K, C1 _10 alkyl with an attached phenyl 
group substituted with K, C1_10 alkyl with an attached 
phenyl group disubstituted with K, C1 _10 alkyl with two 
phenyl groups attached to the cl-10 alkyl, cl-10 alkyl 
with two phenyl groups attached to the cl-10 alkyl and 
substituted with Kon the phenyl group, C1_10 alkyl with 
two phenyl groups attached to the cl-10 alkyl and 
disubstituted with K on the phenyl groups, C3 _20 
cyclized alkyl with an attached phenyl group substi-
tuted with K, C1 _20 alkyl with an OH group attached to 
the alkyl, ---CH2CH2CH20CH3 , and C1 _s alkyl with an 
attached phenyl and a hydroxyl attached to the cl-S 
alkyl. 
4. A compound according to claim 1 wherein 
wherein, 
R1 is selected from the group consisting of M2-AA1 , 
M2-AA2-AA1 , and M2-AA3 -AA2-AA1 ; 
M2 is selected from the group consisting of H, X---CO-, 
X-NH-CO-, Y-S02-, and Y---0---CO-; 
Xis selected from the group consisting ofH, C1_10 alkyl, 
C1_10 alkyl substituted with J, phenyl, phenyl substi-
tuted with K, naphthyl, naphthyl substituted with K, 
cl 10 alkyl with an attached phenyl group, cl-10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with an attached naphthyl group, C1_10 alkyl with 
an attached naphthyl group substituted with K, C1_10 
alkyl with an attached phenoxy group, and C1_10 alkyl 
with an attached phenoxy group substituted with K on 
the phenoxy group; 
Y is selected from the group consisting of C1 _10 alkyl, 
C
110 
alkyl substituted with J, phenyl, phenyl substituted 
with K, naphthyl, naphthyl substituted with K, C1_10 
alkyl with an attached phenyl group, C1 _10 alkyl with an 
attached phenyl group substituted with K, C1_10 alkyl 
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with an attached naphthyl group, C1 _10 alkyl with an 
attached naphthyl group substituted with K, C1 _10 alkyl 
with an attached phenoxy group, and C1 _10 alkyl with 
an attached phenoxy group substituted with K on the 
phenoxy group; 
J is selected from the group consisting of C02H, OH, 
NH2, C1_10 alkoxy, C1 _10 alkylamino, and C1_10 alkyl-
0---CO-; 





perfluoroalkyl, C1 _10 alkoxy, N02, CN, OH, C02H, 10 
amino, cl-10 alkylamino; 
AAu AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pro- 15 
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid, epsilon- 20 




cyclopentyl)-C02H, NH2--CH(CH2-cyclobutyl)- 25 
C02H, and NH2-CH(CH2-cyclopropyl)-C02H; 
R2 is selected from the group consisting of C1_10 alkyl, 
cl 10 alkyl substituted with Q, cl-10 alkyl substituted 
with phenyl, C1_10 alkyl with an attached phenyl sub-
stituted with K, C1_10 alkyl substituted with naphthyl, 30 
C
110 
alkyl with an attached naphthyl substituted with K, 
and phenyl; 
R3 is selected independently from the group consisting of 
Rs, C02H, C02Rs, CONHR6 , CONR6R7 , and 
CO-AA4 -T; 35 
Rs is selected independently from the group consisting of 
cl-10 alkyl, cl-10 alkyl with a phenyl group attached to 
the cl-10 alkyl, cl-10 alkyl with an attached phenyl 
group substituted with K, C1 _10 alkyl with a naphthyl 
group attached to the cl-10 alkyl, and cl-10 alkyl with 40 
an attached naphthyl group substituted with K. 
AA4 is a side chain blocked or unblocked amino acid with 
the L configuration, D configuration, or no chirality at 
the a-carbon selected from the group consisting of 
alanine, valine, leucine, isoleucine, praline, methion- 45 
ine, methionine sulfoxide, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, phenylglycine, norleucine, norval-
ine, alpha-aminobutanoic acid, epsilon-aminocaproic 50 
acid, omithine, homoarginine, sarcosine, alpha-amino-
heptanoic acid, NH2-CH(CH2-l-naphthyl)-C02H, 
NH2--CH(CH2-2-naphthyl)-C02H, NH2-CH(CH2-
cyclohexyl)-C02H, NH2--CH(CH2-cyclopentyl)-
C02H, NH2--CH(CH2-cyclobutyl)-C02H, and NH2- 55 
CH(CH2-cyclopropyl)-C02H; 
R6 and R7 are selected independently from the group 
consisting ofH, C1_10 alkyl, C3 _20 cyclized alkyl, C1_10 
alkyl with a phenyl group attached to the cl-10 alkyl, 
cl 10 alkyl with two phenyl groups attached to the cl-10 60 
alkyl, C3 _20 cyclized alkyl with an attached phenyl 
group, phenyl, phenyl substituted with K, C1 _10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with an attached phenyl group disubstituted with 
K, C1_10 alkyl with an attached phenyl group trisubsti- 65 
tuted with K, C1_10 alkyl with two phenyl groups 
attached to the cl-10 alkyl, cl-10 alkyl with two phenyl 
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groups attached to the C1 _10 alkyl and substituted with 
K on the phenyl group, C1 _10 alkyl with two phenyl 
groups attached to the cl-10 alkyl and disubstituted 
with Kon the phenyl groups, C3 _20 cyclized alkyl with 
an attached phenyl group substituted with K, C1_20 
alkyl with an OH group attached to the alkyl, 
--CH2CH2CH20CH3 , C1 _10 alkyl with an attached 
4-pyridyl group, cl-10 alkyl with an attached 3-pyridyl 
group, cl-10 alkyl with an attached 2-pyridyl group, 
C
110 
alkyl with an attached cyclohexyl group, -NH-
CH2CH2-( 4-hydroxyphenyl), -NH--CH2CH2-(3-in-
dolyl), cl-10 alkyl with an attached 2-furyl group, cl-10 
alkyl with an attached 3-furyl group, and C1 _s alkyl 
with an attached phenyl and a hydroxyl attached to the 
cl-S alkyl; 
R8 and R9 are selected independently from the group 
consisting of H, C1_10 alkyl, phenyl, nitrophenyl, and 
cl 10 alkyl substituted with phenyl. 
5. A compound according to claim 4 wherein 
Xis selected from the group consisting ofH, C1_10 alkyl, 
phenyl, naphthyl, C1 _10 alkyl with an attached phenyl 
group, C1_10 alkyl with an attached naphthyl group, and 
C1_10 alkyl substituted with C02H; 
AA1 , AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pra-
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid, epsilon-
aminocaproic acid, ornithine, homoarginine, sarcosine, 
NH2-CH(CH2-l-naphthyl)-C02H, and NH2--CH 
(CH2-2-naphthyl)-C02H; 
Rs is selected independently from the group consisting of 
cl-10 alkyl and cl-10 alkyl with a phenyl group attached 
to the cl-10 alkyl; 
AA4 are side chain blocked or unblocked amino acids 
with the L configuration, D configuration, or no chiral-
ity at the a-carbon selected from the group consisting 
of alanine, valine, leucine, isoleucine, praline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, phenylglycine, norleucine, norval-
ine, alpha-aminobutanoic acid, epsilon-aminocaproic 
acid, ornithine, homoarginine, sarcosine, NH2--CH 
(CH2-l-naphthyl)-C02H, and NH2--CH(CH2-2-naph-
thyl)-C02H; 
R6 and R7 are selected independently from the group 
consisting of H, C1 _10 alkyl, C1_10 alkyl with a phenyl 
group attached to the cl-10 alkyl, cl-10 alkyl with two 
phenyl groups attached to the cl-10 alkyl, phenyl sub-
stituted with K, C1 _10 alkyl with an attached phenyl 
group substituted with K, C1_10 alkyl with an attached 
phenyl group disubstituted with K, C1 _10 alkyl with two 
phenyl groups attached to the cl-10 alkyl, cl-10 alkyl 
with two phenyl groups attached to the cl-10 alkyl and 
substituted with Kon the phenyl group, C1_10 alkyl with 
two phenyl groups attached to the cl-10 alkyl and 
disubstituted with K on the phenyl groups, C3 _20 
cyclized alkyl with an attached phenyl group substi-
tuted with K, C1 _20 alkyl with an OH group attached to 
the alkyl, --CH2CH2CH20CH3 , and C1 _s alkyl with an 
attached phenyl and a hydroxyl attached to the cl-S 
alkyl. 
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6. A compound according to claim 1 wherein 
R1 is selected from the group consisting of M 2-AA1 , 
M 2-AA2-AA1 , and M 2-AA3 -AA2-AA1 ; 
M 2 is selected from the group consisting ofH, X--CO-, 
X-NH-CO-, Y-S02-, and Y---0-CO-; 
Xis selected from the group consisting ofH, C1_10 alkyl, 
C1_10 alkyl substituted with J, phenyl, phenyl substi-
tuted with K, naphthyl, naphthyl substituted with K, 
cl 10 alkyl with an attached phenyl group, cl-10 alkyl 
with an attached phenyl group substituted with K, C1_10 10 
alkyl with an attached naphthyl group, C1_10 alkyl with 
an attached naphthyl group substituted with K, C1_10 
alkyl with an attached phenoxy group, and C1_10 alkyl 
with an attached phenoxy group substituted with K on 
the phenoxy group; 15 
Y is selected from the group consisting of C1 _10 alkyl, 
C
110 
alkyl substituted with J, phenyl, phenyl substituted 
with K, naphthyl, naphthyl substituted with K, C1_10 
alkyl with an attached phenyl group, C1 _10 alkyl with an 
attached phenyl group substituted with K, C1 _10 alkyl 20 
with an attached naphthyl group, C1 _10 alkyl with an 
attached naphthyl group substituted with K, C1 _10 alkyl 
with an attached phenoxy group, and C1 _10 alkyl with 
an attached phenoxy group substituted with K on the 
phenoxy group; 25 
J is selected from the group consisting of C02H, OH, 
NH2, C1_10 alkoxy, C1 _10 alkylamino, and C1_10 alkyl-
0---CO-; 





perfluoroalkyl, C1_10 alkoxy, N02, CN, OH, C02H, 30 
amino, cl-10 alkylamino; 
AAu AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pro- 35 
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid, epsilon- 40 




cyclopentyl)-C02H, NH2--CH(CH2-cyclobutyl)- 45 
C02H, and NH2-CH(CH2-cyclopropyl)-C02H; 
R2 is selected from the group consisting of C1 _10 alkyl 
substituted with G, C1_10 alkyl with an attached phenyl 
substituted with G, C1 _10 alkyl with an attached naph-
thyl substituted with G, phenyl substituted with G, and 50 
naphthyl substituted with G; 
G is selected independently from the group consisting of 
amidino (-C(=NH)NH2), guanidino (-NHC(=NH) 
NH2), isothiureido (-S-C(=NH)NH2), amino, and 
cl6 alkylamino; 55 
R3 is selected independently from the group consisting of 
Rs, C02H, C02Rs, CONHR6 , and CONR6R7 ; 
Rs is selected independently from the group consisting of 
cl-10 alkyl, cl-10 alkyl with a phenyl group attached to 
the cl-10 alkyl, cl-10 alkyl with an attached phenyl 60 
group substituted with K, C1 _10 alkyl with a naphthyl 
group attached to the cl-10 alkyl, and cl-10 alkyl with 
an attached naphthyl group substituted with K; 
R6 and R7 are selected independently from the group 
consisting ofH, C1_10 alkyl, C3 _20 cyclized alkyl, C1_10 65 
alkyl with a phenyl group attached to the cl-10 alkyl, 
cl 10 alkyl with two phenyl groups attached to the cl-10 
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alkyl, C3 _20 cyclized alkyl with an attached phenyl 
group, phenyl, phenyl substituted with K, C1 _10 alkyl 
with an attached phenyl group substituted with K, C1_10 
alkyl with an attached phenyl group disubstituted with 
K, C1_10 alkyl with an attached phenyl group trisubsti-
tuted with K, C1_10 alkyl with two phenyl groups 
attached to the cl-10 alkyl, cl-10 alkyl with two phenyl 
groups attached to the C1 _10 alkyl and substituted with 
K on the phenyl group, C1 _10 alkyl with two phenyl 
groups attached to the cl-10 alkyl and disubstituted 
with Kon the phenyl groups, C3 _20 cyclized alkyl with 
an attached phenyl group substituted with K, C1_20 
alkyl with an OH group attached to the alkyl, 
--CH2CH2CH20CH3 , C1 _10 alkyl with an attached 
4-pyridyl group, cl-10 alkyl with an attached 3-pyridyl 
group, cl-10 alkyl with an attached 2-pyridyl group, 
C
110 
alkyl with an attached cyclohexyl group, -NH-
CH2CH2-( 4-hydroxyphenyl), -NH--CH2CH2-(3-in-
dolyl), cl-10 alkyl with an attached 2-furyl group, cl-10 
alkyl with an attached 3-furyl group, and C1 _s alkyl 
with an attached phenyl and a hydroxyl attached to the 
cl-S alkyl; 
R8 and R9 are selected independently from the group 
consisting of H, C1_10 alkyl, phenyl, nitrophenyl, and 
cl 10 alkyl substituted with phenyl. 
7. A compound according to claim 5 wherein 
Xis selected from the group consisting ofH, C1_10 alkyl, 
phenyl, naphthyl, C1 _10 alkyl with an attached phenyl 
group, C1_10 alkyl with an attached naphthyl group, and 
C1_10 alkyl substituted with C02H; 
AA1 , AA2, and AA3 are side chain blocked or unblocked 
amino acids with the L configuration, D configuration, 
or no chirality at the a-carbon selected from the group 
consisting of alanine, valine, leucine, isoleucine, pra-
line, methionine, methionine sulfoxide, phenylalanine, 
tryptophan, glycine, serine, threonine, cysteine, 
tyrosine, asparagine, glutamine, aspartic acid, glutamic 
acid, lysine, arginine, histidine, phenylglycine, norleu-
cine, norvaline, alpha-aminobutanoic acid, epsilon-
aminocaproic acid, ornithine, homoarginine, sarcosine, 
NH2-CH(CH2-l-naphthyl)-C02H, and NH2--CH 
(CH2-2-naphthyl)-C02H; 
Rs is selected independently from the group consisting of 
cl-10 alkyl and cl-10 alkyl with a phenyl group attached 
to the cl-10 alkyl; 
AA4 are side chain blocked or unblocked amino acids 
with the L configuration, D configuration, or no chiral-
ity at the a-carbon selected from the group consisting 
of alanine, valine, leucine, isoleucine, praline, methion-
ine, methionine sulfoxide, phenylalanine, tryptophan, 
glycine, serine, threonine, cysteine, tyrosine, aspar-
agine, glutamine, aspartic acid, glutamic acid, lysine, 
arginine, histidine, phenylglycine, norleucine, norval-
ine, alpha-aminobutanoic acid, epsilon-aminocaproic 
acid, ornithine, homoarginine, sarcosine, NH2--CH 
(CH2-l-naphthyl)-C02H, and NH2--CH(CH2-2-naph-
thyl)-C02H; 
R6 and R7 are selected independently from the group 
consisting of H, C1 _10 alkyl, C1_10 alkyl with a phenyl 
group attached to the cl-10 alkyl, cl-10 alkyl with two 
phenyl groups attached to the cl-10 alkyl, phenyl sub-
stituted with K, C1 _10 alkyl with an attached phenyl 
group substituted with K, C1_10 alkyl with an attached 
phenyl group disubstituted with K, C1 _10 alkyl with two 
phenyl groups, attached to the cl-10 alkyl, cl-10 alkyl 
with two phenyl groups attached to the cl-10 alkyl and 
substituted with Kon the phenyl group, C1_10 alkyl with 
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two phenyl groups attached to the cl-10 alkyl and 
disubstituted with K on the phenyl groups, C3 _20 
cyclized alkyl with an attached phenyl group substi-
tuted with K, C 1 _20 alkyl with an OH group attached to 
the alkyl, --CH2CH2CH20CH3 , and C 1 _5 alkyl with an 5 
attached phenyl and a hydroxyl attached to the cl-5 
alkyl. 
8. The compound of claim 1 wherein epoxide carbons 2 
and 3 have stereochemistry selected from the group con-
sisting of cis; trans; R,R; S,S; R,S; and S,R. 10 
9. The composition of claim 1, wherein said composition 
is substantially optically pure. 
10. The composition of claim 1, wherein said composition . . 
1s racem1c. 
11. The composition of claim 9, wherein said composition 15 
substantially comprises a single optical isomer. 
12. A compound selected from the group consisting of: 
(a) APhe-(trans)-EP-COOEt, 
(b) Cbz-APhe-(trans)-EP-COOEt, 
(c) Cbz-APhe-(trans)-EP-CH2CH2Ph, 20 
(d) Cbz-ALeu-(trans)-EP-COOEt, 
( e) Cbz-AHph-(trans)-EP-COOEt, 
(f) Ac-AHph-(trans)-EP-COOEt, 
(g) Boc-Nva-AHph-(trans)-EP-COOEt, 
(h) Boc-Nle-AHph-(trans)-EP-COOEt, 25 
(i) Boc-Nle-AHph-(trans )-EP-CH2CH2Ph, 
G) Boc-Nva-AHph-(trans )-EP-CH2CH2Ph, 
(k) Boc-Abu-AHph-(trans)-EP-CH2CH2Ph, 
(I) Boc-Ala-AHph-(trans)-EP-CH2CH2Ph, 
(m) Boc-Np2-ALeu-(trans)-EP-COOEt, 30 














(bb) Cbz-Leu-AAbu-(trans)-EP-COOH, 45 
(cc) Cbz-Leu-AHph-(cis)-EP-COOEt, 
( dd) Cbz-Leu-AHph-(2S,3S)-EP-COOEt, 
(ee) Cbz-Leu-AHph-(2R,3R)-EP-COOEt, 
(ff) Cbz-Leu-AHph-(2S,3S)-EP-COOH, 





(ll) Cbz-Leu-Phe-AG!n-(2R,3R)-EP-COOEt, 55 
(mm) Cbz-Leu-Phe-AG!n-(trans)-EP-COOEt, 
(nn) Cbz-Ala-Ala-AAsn-(trans)-EP-COOEt, 
( oo) Cbz-Ala-Ala-AAsn-(2S,3S)-EP-COOEt, 
(pp) Cbz-Ala-Ala-AAsn-(2R,3R)-EP-COOEt, 


























(CH2CH2CH2CH3 ) 2, 




Cbz-Ile-Glu-Thr-AAsp-(2S,3 S)-EP-CON ( CH2Ph )2, 
(rrr) Cbz-Leu-Glu-Thr-AAsp-(2S,3S)-EP-CON(CH3 ) 
CH2Ph, 
(sss) PhPr-Val-Ala-AAsp-(2S,3S)-EP-CON(CH3)CH2Ph, 


























( 0000) PhPr-Val-Ala-AAsp-(S,S)-EP-CO-Phe-NH2, 
(pppp) PhPr-Val-Ala-AAsp-(R,R)-EP-CO-Phe-NH2, 











































and a pharmaceutically acceptable salt, pharmaceuti-
cally acceptable derivative, or combination thereof. 
13. A compound having the chemical formula of Cbz-
50 Asp-Glu-Val-AAsp-EP-COOCH2C6H5 . 
14. A compound according having the chemical formula 
Cbz-Ala-Ala-AAsn-EP-COOEt. 
15. A pharmaceutical composition, comprising an effec-
55 tive amount of a compound of claim 1 and a pharmaceuti-
cally acceptable carrier. 
16. A method of inhibiting a cysteine protease comprising 
the step of contacting said cysteine protease with a com-
60 pound according to claim 1. 
65 
17. The method of claim 16 wherein said contacting 
occurs m vivo. 
18. The method of claim 16 wherein said contacting 
occurs in vitro. 
19. The method according to claim 16 wherein said 
cysteine protease comprises a caspase. 
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20. The method according to claim 16 wherein said 
cysteine protease comprises legumain. 
21. The method according to claim 16 wherein said 
cysteine protease comprises a member of the clan CD of 
cysteine proteases. 
22. The method according to claim 16 wherein said 
cysteine protease comprises a member of the clan CA of 
cysteine proteases. 
23. A method of preparing a compound comprising of the 
step of coupling an epoxide with a substituted hydrazide. 
24. The method of claim 23 wherein said epoxide is an 
epoxysuccinate. 
25. The method of claim 23 wherein said epoxide is an 
oxirane carboxylic acid. 
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35. The compound of claim 29 containing an anionic side 
chain at said Pl site. 
36. The compound of claim 29 containing an aza-aspartic 
acid at the Pl site. 
37. The compound of claim 29 containing an aza-aspar-
agine at said Pl site. 
38. A compound comprising an aza-amino acid and an 
epoxide, wherein said compound specifically inhibits cys-
teine proteases selected from the group consisting of clan 
10 CD and clan CA cysteine proteases. 
39. The compound of claim 38, wherein said compound 
inhibits clan CD and clan CA cysteine proteases. 
40. A neuroprotective composition comprising an aza-
peptide epoxide. 
26. The method of claim 23 wherein said coupling com- 15 
prises the step of reacting the epoxide, substituted hydrazide, 
EDC, and HOBt. 
41. A method of treating a neurodegenerative disorder 
comprising: 
administering an effective amount of an aza-peptide 
epoxide to a patient having symptoms of a neurode-
generative disorder. 
27. The method of claim 23 wherein said coupling com-
prises the step of: reacting the epoxide, substituted 
hydrazide, NMM, and IBCF. 
28. A compound comprising an aza-amino acid and an 
epoxide, wherein said aza-amino acid does not have the 
formula: 
wherein, Rl is a quinolinyl and R2 is H. 
29. A compound comprising an aza-amino acid and an 
epoxide, wherein the compound comprises Pl and P2 resi-
dues. 
30. The compound of claim 29, wherein the Pl or P2 
residue comprises an aza-amino acid residue. 
20 42. The method of claim 41, wherein said aza-peptide 
epoxide inhibits a protease. 
43. The method of claim 42, wherein said protease 
comprises a cysteine protease. 
44. The method of claim 41, wherein said neurodegen-
25 erative disorder is selected from the group consisting of 
stroke, Alzheimer's disease, Parkinson's disease, multiple 
sclerosis, neuropathies, Huntington's disease, dentatorubro-
pallidoluysian atrophy, spinocerebellar atrophy type 3, spi-
nal bulbar muscular atrophy, and myotrophic lateral sclero-
30 SIS. 
45. A method of modulating a host's immune system 
comprising administering to said host a composition com-
prising an aza-peptide epoxide in an amount sufficient to 
inhibit cleavage of an antigen in the host and reduce antigen 
35 peptides displayed on cell surfaces. 
46. The method of claim 45, wherein said host is a 
mammal. 
31. The compound of claim 29, wherein the Pl residue 
comprises an aza-amino acid residue having a basic func-
40 
tional group. 
47. A method for treating inflammatory disease in a host 
comprising: 
administering to said host a composition comprising an 
aza-peptide epoxide in an amount sufficient to inhibit a 
cysteine protease. 32. The compound of claim 29, wherein the P2 residue 
comprises an amino acid residue having a hydrophobic 
functional group. 
33. The compound of claim 29, wherein the P2 residue 45 
comprises an amino acid residue having a hydrophobic alkyl 
functional group. 
34. A compound comprising an aza-amino acid and an 
epoxide, wherein said epoxide is coupled to said aza-amino 
acid. 
48. The compound of claim 28, wherein the compound 
comprises Pl, P2 and P3 residues. 
49. The compound of claim 28, wherein the compound 
comprises Pl, P2, P3, and P4 residues. 
50. The compound of claim 28, wherein the compound 
comprises Pl, P2, P3, P4, and Pl' residues. 
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